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ABSTRACT 
 A major challenge for effective gene therapy is systemic delivery of viruses carrying 
therapeutic genes into affected tissue. The immunogenic nature of human adenoviruses (Ads) 
limits their use for intratumoral (IT) injection in gene therapy. Ads transfection is further 
hampered by the fluctuating presence of Coxsackie and Adenovirus Receptor (CAR) and 
integrins on the cells’ surface. To circumvent these limitations we developed a novel approach 
wherein Ads are encapsulated inside the shell of lyophilized, lipid-encapsulated, perfluorocarbon 
microbubbles (MBs)/ultrasound (US) contrast agents, which act as delivery vehicles for a site-
specific gene transfer system.  
 We performed infection studies with Ad.GFP (Green Fluorescent Protein), Ad.mda-7 
(melanoma differentiation associated gene 7) and CTV.mda-7 on human DU145 and mouse 
prostate cancer cells as well as observed enhanced GFP expression when Ad.GFP was delivered 
by MBs and US. Our results show that US breaks open the MB/Ads complexes by undergoing 
cavitation at the sonoporated site, which allows Ads to transfer their transgene only to the 
sonoporated region. Cavitation collapse of the MBs creates small shockwaves that increase cell 
permeability by forming temporary micropores on the cell surface bypassing the receptor-
mediated dependence of Ads for transfection. Fetal bovine serum (FBS) containing complement 
did not allow the unprotected Ads to infect the cells; however, MBs complexed with Ad.GFP did 
infect DU145 and TRAMP-C2 cells in a FBS rich media.  
 We studied MB assisted gene delivery of reporter (GFP) and therapeutic genes (p53, Rb, 
Rb2 (p130) and Mda-7/IL-24) into prostate cancer (PC) xenografted in immune-compromised 
athymic mice. The results demonstrated that MBs protect the host from unspecific viral immune 
response thus protecting the viral payload and allowing for intravenous (IV) injection rather than 
xix 
IT injection. Additionally, Ad gene transfer was enhanced at the targeted/sonoporated mice 
tumor xenografts. This research demonstrated mda-7’s efficacy in reducing primary (treated) and 
untreated tumors that simulated the presence of metastasis in athymic mice xenograft models 
bearing human PC cells. Bystander anti-tumor activity of mda-7, a secreted cytokine was noted 
for non-targeted tumors.  
 Earlier in vitro studies on the combination of radiation and gene therapy (Ad.p53, Ad.Rb, 
and Ad.p130) demonstrated an increase in the percentage of cell death for DU145 cells. We also 
studied UTMD (ultrasound targeted microbubble destruction) gene therapy in combination with 
external beam radiation for radiation resistant PC. The results demonstrated an enhanced 
therapeutic benefit of tumor suppressor genes in radiation resistant PC. We also demonstrated an 
increase in the expression of tumor suppressor genes at the tumor site due to MBs and US.  
 These findings highlight the potential therapeutic benefit of this novel image guided gene 
transfer technology alone or in combination with external beam radiation for prostate cancer 
patients with therapy resistant disease. 
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CHAPTER I: PROSTATE CANCER AND TREATMENT STRATEGIES 
Prostate cancer 
 Prostate cancer (PC) is the most common malignancy in men and the second leading 
cause of cancer related deaths in the United States [1]. According to the American Cancer 
Society (ACS), PC represents 25% of newly diagnosed cancers every year [2]. There are more 
than 1,100,000 new cases of PC and 300,000 related deaths worldwide each year. In the United 
States about 240,000 new cases of PC are reported annually with a mortality rate >15% due to 
widespread implementation of prostate-specific antigen (PSA) testing and effective treatment of 
early stage PC disease [3-5]. 
 The disease is primarily diagnosed in men above the age of 40, with a median age above 
60 years [3]. The risk of incidence increases as one grows older. PC biology is heterogeneous as 
it ranges from indolent type where tumors progress slowly or not at all for several years to others 
that may progress more rapidly and be fatal after a few years. PC arises from different stresses 
such as chronic inflammation, oxidative stress, immune surveillance loss, and somatic 
alterations, which lead to genetic changes that transform the normal epithelium into pre-
neoplastic lesions to invasive carcinoma. Therapeutic options vary depending on the severity of 
the condition, age of the patient, staging, Gleason score and serum PSA level [6].  
 Organ confined disease staged T1/T2 with Gleason score ≤7 that lacks aggressive 
features [7] is suitable for radical prostatectomy (RP) and radiation therapy (RT) with external 
beam irradiation therapy (EBRT) or brachytherapy [8, 9]. This treatment option has shown 5 to 
10 year survival rate with significant morbidity, erectile dysfunction in 30-70% of cases and 
stress incontinence in up to 10% of the patients [6, 10]. In recent years, minimally invasive 
therapies have been developed for patients with localized prostate cancer such as three-
2 
dimensional conformal radiotherapy (3D-CRT), brachytherapy, intensity-modulated external 
beam radiotherapy (IMRT), cryosurgical ablation of the prostate and laparoscopic radical 
prostatectomy. These treatment strategies are for patients who are either not eligible for surgery 
or who do not want to risk the potential side-effects of surgery [6, 11-14]. 
 Cancer with a Gleason score ≥8 which exhibits aggressive features and found outside the 
prostate [7] and spread to other organs such as bladder, rectum and lymph nodes results in poor 
survival rate compared to localized PC. Approximately 30-35% is initially diagnosed as 
metastatic while 25% of patients develop metastases during follow up. Metastases are commonly 
found on the bone with an X-ray showing osteoblastic lesions or a bone scan as hot spots with 
areas of increased activity [15]. In such cases, RP followed by RT with hormone therapy (HT) 
can prolong survival but with negative quality of life [3]. HT with anti-androgens is the standard 
therapy for stage T4 PC that reduces serum levels of testosterone to castration levels, which 
eventually becomes non-responsive to androgen ablation. When these therapies fail and the 
cancer reoccurs there is a median survival of 2.5 years [15, 16]. Current therapy options for 
patients with hormone-refractory prostate cancer (HRPC) include RT and cytotoxic 
chemotherapeutic agents, such as mitoxantrone, estramustine and taxanes [15, 17]. These 
approaches only have a palliative benefit and show no consistent impact on survival [15]. No 
effective therapy exists for patients with metastases thus mandating the development of novel, 
more efficacious and innovative treatment approaches [18].  
 Different approaches have been tested with varying results. For example, gene therapy 
has been used to combat and cure a wide range of pathologies including locally advanced cancer 
but the major limiting factor has been the development of an effective delivery system. 
Metabolism of genetic materials by serum esterases prohibits intravenous administration. 
3 
Additionally, genes are macromolecules and their size greatly hinders passage across the 
capillary fenestrations of blood vessels without assistance. We and others have demonstrated 
viral vectors to be efficient delivery systems resulting in high levels of transgene expression. 
However, the antigenic nature of viruses leads to their rapid inactivation by the immune system. 
Additionally, the viruses are non-specific. This requires direct target organ injection with or 
without image guidance or operative bed injection. Current gene therapy technology is still in its 
infancy but the promise of molecular medicine is so immense that further research is needed.   
 
Treatment Strategies: 
Radiation Therapy 
 Ionizing radiation is primarily used to treat cancers by targeting critical cell components 
resulting in DNA damage directly by high radiation or indirectly by the action of free radicals 
formed as a result of ionization of water molecules by low radiation [19, 20]. The resulting DNA 
damage can result in double stranded breaks (DSB) that are difficult to repair and most toxic to 
the cancer cells [19]. Normal cells have intact mechanisms that repair the majority of DNA 
damage thus protecting the normal cells from harm. If the mechanism cannot repair the DNA, 
radiation induces apoptosis by either stimulating death receptors such as DR4 (death receptor 4) 
or CD95 (Fas) at the cell surface or halts cell cycle progression at distinct phases [19, 21]. The 
effect is most pronounced during M (mitosis) and G2 (Gap-2) phases of the cell cycle [22, 23]. 
Failure to undergo apoptosis may contribute to resistance of cancer cells to the therapeutic 
modalities. 
 Low dose rates of radiation can also be toxic as the oxygen reacts with the free radicals 
(reactive oxygen species (ROS)) formed during the ionization of water producing more toxic 
byproducts that make the cell sensitive to ionization radiation [23]. Solid tumors contain regions 
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with low blood supply resulting in reduced oxygen concentration (hypoxia) thus making these 
regions more resistant to ionization radiation [21]. Even though improvements in radiotherapy 
regimens are available the efficacy is still disappointing with regards to solid tumors.  
 Radiation can be delivered internally through radioactive seed implants called 
brachytherapy. Implants can be precisely placed into a body cavity, into the tissue, into the lungs 
and into blood vessels. The radiation sources deliver high doses of radiation to the specific tumor 
while the radiation dose drops off within the adjacent normal tissue [19]. Zelefsky et al. [12] 
reported the 8-year relapse free survival rate of 74% and 61% for low and intermediate risk 
groups respectively using Phoenix ASTRO (American Society for Therapeutic Radiology and 
Oncology) criteria for a multi-institutional study following brachytherapy [6].  
 The most common form of RT is delivered externally through a beam called EBRT. In 
most PC cases, RT is accompanied with RP or androgen deprivation therapy (ADT) [24]. 
Adjuvant RT has shown to benefit men with adverse pathologic features with Gleason scores ≥ 7 
at least in minimizing biochemical recurrence risk [25]. Thompson et al. from the Southwest 
Oncology Group (SWOG) showed an overall survival with adjuvant RT with 10 year estimates 
of 74% vs. 66% for patients with 60Gy to 64Gy and a metastasis free survival at 71% vs. 61% in 
adjuvant RT vs. no RT cohorts [25, 26]. Ten year survival rate following RT for well 
differentiated, moderately well differentiated and poorly differentiated PC is about 90%, 75% 
and 50% [27]. Along with the benefits seen with RT, complications such as rectal complications, 
urethral strictures and total urinary incontinence are common [25].  
 RT can be delivered in a fractionated dose of 1.8 - 2.0 Gy (Gray, unit of radiation) per 
day for 7-8 weeks (5 days per week) or until a total of 60 - 80Gy is delivered [28]. Pollark et al., 
showed that dosage has a direct impact on treatment effectiveness in a Phase III trial where they 
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compared 70Gy/2Gy versus 78Gy/2Gy, showing a significant difference (64% vs. 70% 
respectively) in the 6-year biochemical relapse free survival rate (bRFS) [29].  Similar results 
have been published in Phase III trial by Dearnaley et al., when comparing 64Gy/2Gy with 
74Gy/2Gy in a 10-year bRFS [30]. Additionally, treatment strategy that employs less frequent 
and larger fractions, termed hypofractionated radiation, may be more efficacious. Moderate (<5 
Gy/day) hypofractionated RT has shown similar efficacy with an improved side effect profile 
while extreme (≥5 Gy/day) hypofractionated RT is currently being evaluated but showing 
promising efficacy [28]. As dose is increased the risk of side effect increases as well.  
 Advances in imaging have raised the therapeutic ratio (the index between cytotoxic 
effects and normal tissue complications) and minimized damage to local tissue resulting in a 
decrease in the side effects seen due to RT. Advances in imaging has led to vast improvements in 
RT such as 3DCRT or IMRT and four dimensional RT (4D-RT) which splits the beam into 
several lower intensity beams sparing damage to surrounding normal tissue. With these advances 
more patients are being treated with doses exceeding 72Gy [31]. 
 In this study we treated human DU145 PC tumors with EBRT from a clinical linear 
particle accelerator (LINAC) model 21EX and model 6EX that produced 8Gy X-rays for the 
cancer treatment. These particle accelerators at the Tri-State Regional Cancer Center in Ashland, 
Kentucky offer bremsstrahlung x-ray energy of 6 MV, which was used in these investigations as 
well as a rapid dose delivery to the targeted tumor at a rate of 6 Gy/MU [32]. 
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High Intensity Focused Ultrasound 
  High Intensity Focused Ultrasound (HIFU) is used as a treatment for localized PC. It is a 
non-invasive and non-ionizing technique that induces coagulation, necrosis, cavitation and heat 
shock through intense US energy that thermally ablates a portion of the tissue situated at the 
focal point. US energy is delivered with a high-powered transducer, which is placed in the 
rectum to generate US waves that travel through the walls of the rectum and deposit energy to a 
focal zone in the prostate gland. There is no need for a surgical exposure or insertion of 
instruments into the lesion [6, 33].  
  The high powered US causes a rise in temperature up to 70 - 80ᴼC [34]. This elevation 
of tissue temperature leads to melting of the lipid membranes and protein denaturation (>43ᴼC) 
that results in irreversible tissue damage called coagulative necrosis [34, 35]. Similar tissue 
damage caused by a cavitation phenomenon can be achieved with bubble implosion and 
mechanical tissue disruption as a result of the interaction between US and MBs of water in the 
sonicated tissue enhancing tissue ablation [35]. 
 In the past 15 years there have been 30,000 prostate HIFU treatments, mainly in Europe 
[35].  In most clinical trials [6, 35, 36], patients had a localized PC (stage T1/T2) with Gleason 
scores ranging from 2 to 10 and received HIFU because the patients were either unsuitable for or 
unwilling to undergo RP. Uchida et al. [6] reported that after HIFU the biochemical disease free 
5 years rate was at 84%, 64% and 45% in low, intermediate and high-risk PC groups using 
Phoenix criteria. Pfeiffer et al. [36] also assessed the negative biopsy rates after HIFU at 84.2%, 
63.6% and 67.5% for the low, intermediate and high-risk PC groups. Similarly after HIFU, 5-
year biochemical free survival rates was reported to be 84.8%, 64.9% and 54.9% for 
aforementioned PC risk groups. Lastly, they also mentioned 5-year disease free survival rates as 
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81.7%, 53.2% and 51.2% for the respective PC risk groups [36].  
 HIFU has advantages over current treatment modalities as it is non-invasive and non-
ionizing allowing for repeated treatments of the affected tissue as well as the ability to affect a 
distant tissue [35, 37]. The disadvantages include the inability of US to travel through air 
preventing treatment within lung or lumen of most hollow organs within the body and long (1-
3hrs) exposure times depending on the size of the tumors [35]. Most common complications 
associated with HIFU are urinary retention, urinary tract infections, urinary incontinence and 
erectile dysfunction [35]. Presently, HIFU has some limitations and long-term clinical studies are 
needed to evaluate cancer specific and overall survival. Refinement of the HIFU and transducer 
technology will improve its therapeutic benefit making it an attractive treatment modality.  
 Currently, the cavitation phenomenon of microbubbles (MB) is being explored in relation 
to different US intensities as a potential drug delivery vehicle. The underlying mechanism is yet 
to be fully understood but there is growing evidence that suggest MB cavitation can elicit 
biological and mechanical changes that allow for the temporary uptake of drugs. Our lab has 
further explored this area of drug delivery with the intent to translate this technology from bench 
to bedside. 
 
Gene Therapy 
 Gene therapy is a therapeutic drug delivery and vaccination method that can be used to 
treat a large array of genetic and non-genetic diseases. It uses genetic materials such as DNA and 
RNA to rewrite or reverse the pathological conditions that account for the transformation of 
normal cells to a malignant or diseased phenotype. There have been significant improvements in 
the treatment of a variety of different malignancies including PC.  
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  Different strategies include the use of non-viral and viral vehicles that are suitable for 
integrating the genetic material into the host cell. There are distinct advantages and 
disadvantages for each delivery vehicle. Non-viral vehicles are suitable for their simplicity, 
packaging capacity, potential for large scale production and inducing fewer immunological 
responses. These vehicles have poor transfection and transduction efficiency to elicit a 
therapeutic benefit. Viral vehicles on the other hand can be engineered and finely tuned while 
retaining the capacity to deliver genetic material at a high transfection and transduction 
efficiency. However, our immunological system has evolved to counterattack against these viral 
pathogens by forming neutralizing antibodies that hamper its therapeutic potential. 
   Gene transfer can be done in vivo or ex-vivo. In vivo gene transfer is performed in the 
host via an intratumoral (IT) injection. It is cost effective and tailored to a class of patients rather 
than an individual. But the gene transfer efficiency is poor due to the mode of delivery and the 
stimulation of the hosts’ immune system. Ex-vivo gene transfer is performed on surgically 
harvested cells that are genetically engineered and re-introduced back  into the host [15]. Ex-
vivo gene transfer is typically done on clonal expansive cells such as dendritic cells, 
macrophages, monocytes, etc. for vaccination based gene therapy.   
 There have been several gene therapy clinical trials, which have shown potential towards 
treating prostate cancer. These therapies include vaccine therapy that uses various cytokines such 
as interleukin 2 (IL2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), suicide 
cytotoxic therapy such as HSV-thymidine kinase or certain toxins, transfection of suppressor 
genes such as p53 or retinoblastoma (Rb), oncolytic viruses such as CV787 or CN-706 that have 
been designed specifically to replicate preferentially in prostate cancer cells and anti-sense 
therapy such as bcl-2 and C-myc to block oncogenes [15, 38-40]. In this study we have 
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performed gene therapy with melanoma differentiated associated gene 7 or interleukin 24 (mda-
7/IL-24), p53, retinoblastoma (Rb), retinoblastoma like protein 2 (p130) on PC models. 
 
Adenoviruses 
 Adenoviridae are icosahedral non-enveloped viruses with a 30 to 40kb linear double 
stranded-DNA genome [41]. Ads have been isolated from a number of different species with 
over 100 reported serotypes [42].  Human adenoviruses (HAdVs) consist of more than 55 
serotypes that are divided according to haemagglutination and genome sequences into seven 
species, HAdV-A, B, C, D, E, F and G. Members of species C, serotypes 2 and 5 Ads, are 
commonly used as vectors for gene therapy [42-44].  
 
Figure 1. Life cycle of adenoviruses. Replication-defective adenoviral vectors express the 
proteins encoded on their DNA but do not enter the lytic phase. (Adapted from Vorburger and 
Hunt, The Oncologist, 2002 [42].) 
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 The life cycle of an adenovirus can be divided into several stages (Fig. 1). During the 
infection stage, virus surface proteins, such as hexon proteins, penton base proteins, and fiber 
proteins attach to cellular receptors such as the coxsackie adenovirus receptor (CAR), integrins 
αVβ1/2/3, membrane cofactor protein (CD46), desmoglein-2 (DSG2), coagulation factor IX and 
X (FIX/FX), heparan sulfate proteoglycan (HSPG), etc. [45]. After entry into the nucleus, genes 
from the early region 1 (E1a and E1b) are quickly transcribed (Fig. 1); these affect cellular 
proteins that modulate several cellular processes, such as preventing apoptosis or inducing cell 
cycle entry [46]. Four non-contiguous regions of the genome are expressed (E1 to E4) during the 
early phases of viral replication. These regions serve as master transcriptional regulators that 
start the process of viral gene expression leading unto genome replication. During genome 
replication, the major late genes (L1 to L5) drive the viral replication and code for proteins that 
make up components of the viral capsid or are involved in assembly of the capsid. Other viral 
elements (cis or trans genes) are responsible for the origin of replication or the packaging signal 
that condenses the DNA but these must be carried out by the virus itself [42].  
 The trans genes can be complemented or replaced by foreign or therapeutic DNA. At 
least three such regions of the viral genome can accept insertions or substitutions of DNA: a 
region in E1, E3, and between E4 and the end of the genome. The E1 deletion renders the 
recombinant virus replication-defective, and thus provides an important safety feature [47]. The 
first-generations of non-replicating ads are derived from E1/E3 deleted wild type (wt) Ads [41]. 
Newer generations of Ads have deleted or inactivated entire coding regions (E2, E3 or E4 
regions) to increase DNA capacity and to alleviate antiviral host adaptive immunity [41]. 
However, to achieve a significant antitumor response Ads needs to be administered multiple 
times, which can still provoke an immune response that mediates viral clearance [44, 48].  
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 Ad vectors have several advantages: first, they rapidly infect a broad range of human 
cells; second, they yield high levels of gene transfer; third, they have low pathogenicity in 
humans, fourth, they can accommodate relatively large (~7.5 kilobase (kb)) segments of DNA; 
fifth, they can transduce non-proliferating (quiescent) cells; sixth, the viral genome does not 
undergo rearrangement; seventh, they allow for the transmission of their genes into the host 
nucleus but do not insert them into the host chromosome; eighth they are easy to manipulate and 
finely retuned because the technology of Ad production at high titers is well established and the 
Ad structure, genome and replication cycle is well characterized [42, 48, 49].  Ads are the most 
commonly used vector in clinical trials (∼471 clinical trials or ∼23% of all clinical trials initiated 
until January 2015) and approximately 75% of the 471 clinical trials have been initiated to treat 
PC (51 clinical trials) [45, 50].  
 
Conditionally Replication-competent Adenoviruses (CRCAs) 
 Replicating Ads or oncolytic Ads have the ability to infect a small portion of the tumor 
and kill the tumor cells at the end of their lytic cycle. Their resulting progeny are now capable of 
infecting the neighboring tumor cells ensuring a significant increase in the efficacy of gene 
delivery coupled with cytolytic activity (Fig. 2). The replication competence of Ads can be made 
conditional on the biology of the cells being infected. These replicating viruses are called 
conditionally replicating Ads.  
 CRCAs can be made by modifying the adenoviral proteins to enable the virus to replicate 
only in cells that bear the cancer related phenotypes [51]. For example, Ads deficient in E1B 
(ONYX-015) contain a deletion of 827 base pairs (bp) in the E1B region that allows the virus to 
replicate only in tumor cells lacking functional p53 [52]. In normal adenovirus, E1B codes for a 
12 
55kDa protein that binds and inhibits p53 in normal cells which in turn blocks viral replication. 
The ONYX-015 infected normal cell would exhibit p53 mediated growth arrest or apoptosis. 
Thus functional ONYX-015 is restricted to p53 deficient cells, resulting in tumor selective 
destruction [51]. 
 CRCAs can also be made by placing key viral proteins under the regulatory control of 
cell-specific gene promoters that restrict the viral lytic cycle to only the target cells [51]. For 
example, Ad named CN706 contains a human PSA promoter gene that is cloned upstream of the 
E1A viral gene which starts the early viral replication phase. In this study, we used cancer 
terminator viruses (CTVs) that contained progression elevated gene-3 (PEG-3) promoter. This 
promoter drives the expression of E1A and E1B genes thus ensuring cancer specific replication. 
The CTV also contains cytomegalovirus (CMV) promoter that regulates the expression of 
melanoma differentiated associated gene 7 or interleukin 24 (mda-7/IL-24) [53]. 
 
Figure 2. Schematic diagram of the cancer-selective killing efficacy of oncolytic Ads. Oncolytic 
Ads specifically kill tumor cells at the end of their lytic cycle, while sparing normal cells. 
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Replicated viral progeny then spread throughout a tumor, infect, and lyse surrounding cancer 
cells, ultimately leading to improved antitumor efficacy over non-replicating Ads. Moreover, the 
amplification and propagation of therapeutic genes using replicating viruses in infected 
neighboring cancer cells highlights the potential of replicating virus-based therapy. (Adapted 
from Choi, et al. Advanced Drug Delivery Reviews, 2012 [54].) 
 
Barriers to Virotherapy 
 Gene therapy makes efficient use of targeting viruses for cancer therapy, but several 
barriers exist that limit the delivery of viruses from reaching and spreading throughout the tumor. 
These barriers forces an increase in dosage of the viral particles thus increasing the possibility of 
adverse events [55].    
 
Figure 3. Barriers to systemic delivery of oncolytic viruses. There are three main areas that must 
be addressed to enable systemic delivery of virus particles, namely (i) avoiding neutralization by 
components of the blood stream including complement, FactorX, leukocytes, erythrocytes and 
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antibodies, (ii) minimizing unwanted infection of irrelevant cells, notably hepatocytes, which are 
usually present in vast excess, and avoiding premature scavenging by phagocytes, such as 
hepatic Kupffer cells, (iii) maximizing extravasation within tumor vasculature and penetration to 
infect all viable tumor cells whilst avoiding other components of the interstitium. Polymer coated 
viruses present one promising approach to address these barriers, although several other 
technologies are also under development. Abbreviations: ECM: extracellularmatrix, IgA: 
ImmunoglobulinA, IgG: ImmunoglobulinG, IgM: ImmunoglobulinM, FX: FactorX. (Adapted 
from Tedcastle, et al. Drug Discovery Today, 2012 [56].)   
  
 Current clinical trials in gene therapy are limited to intratumoral injections. This delivery 
method has the advantage of delivering large payloads to the tumor site and minimizing 
interactions with other cells but the viral spread is often limited to the needle track due to 
pressure gradients, binding to extracellular matrix (ECM) components, and limited convection 
[57, 58]. For massive tumor regression, infection must spread to cover a large volume of the 
tumor mass. Poorly organized leaky vasculature (Fig. 3) increases the interstitial fluid pressure 
(IFP) resulting in the loss of convection throughout the tumor making macromolecular transport 
dependent on passive diffusion [55, 59]. However, in a solid tumor, the complicated structure of 
the ECM (Fig. 3), which is composed of proteoglycans formed by both neoplastic and normal 
stroma, acts as a physical barrier against the penetration of the viruses [54]. Thus passive 
diffusion is limited due to the composition and organization of the tumor microenvironment. In 
addition, both specific (e.g., neutralizing Abs or cytotoxic T cells) and nonspecific (e.g., 
phagocytes or anti-viral cytokines) immune response mechanisms may also limit spread of viral 
particles [57]. 
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 The other major hurdle is to successfully use systemic virotherapy to deliver viral 
particles into tumor nodules [56]. Virus arriving at the tumor site must extravasate into the 
tumor. Extravasation is dependent on the adequate blood supply, tissue perfusion and tumoral 
enhanced permeability and retention (EPR) for transvascular transport. Tumor vasculature is 
chaotic in terms of microvessel length, diameter, spatial distribution, blood flow velocity and 
direction causing heterogeneous blood perfusion throughout the tumor [55]. The tumor 
vasculature causes regions of low-oxygenation leading to hypoxic tumor environments that 
become inaccessible to the virus. These regions are important as they house tumor stem cell 
niches and treatment resistant cells that trigger relapses in patients [55, 60, 61]. On the contrary, 
leaky tumor-associated vasculature can sometimes enable limited extravasation of virus particles 
through passive diffusion [56]. The passive diffusion is mediated by EPR but it is not consistent 
because of the differences in pore size and the abrupt changes in blood perfusion [55, 62, 63], 
thus extravasation into the tumor site is a limiting factor of systemic delivery. Lastly, once 
injected into the vasculature, the viruses undergo various interactions with the immune system, 
thereby reducing viral efficiency.  
 Ads are regarded as pathogens by the body and are attacked by the host immune system. 
They mostly induce the innate arm of the immune system resulting in the inactivation of the Ads, 
the inflammation of the transduced tissue due to T- and B-cell targeting the transduced tissue[64] 
and efficient clearance of Ads by the immune cells [41].  In fact, within 24 hours after IV 
administration, 90% of the Ad vector is eliminated from the mouse liver [65]. Systemic delivery 
of Ads into the bloodstream also exposes the virus to plasma proteins and blood cells (Fig. 3) 
[58]. The resulting interactions include the neutralization and/or opsonization by antibodies and 
complement (C3a)[66], phagocytosis by neutrophils and macrophages, sequestration on 
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erythrocytes as well as others [56, 58]. The innate immune response also involves the induction 
of cytokines by the viral capsid proteins and interactions with leukocytes, epithelial and 
endothelial cells resulting in signal transduction via MAP (Mitogen-activated protein kinases) 
and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [41] as well as 
through Toll-like receptors and lectins in the plasma membrane and endosomes [44]. The 
adaptive arm of the immune response is seen in patients with pre-existing immunity. This 
immunity leads to a high prevalence of virus neutralization antibodies against Ads, preventing 
the vector from transducing cells efficiently and lowering the overall effect [67]. Lastly, non-
specific uptake by other tissues such as the lung, Kupffer cells in the liver, spleen and tissue 
resident macrophages all contribute to the rapid clearance of Ads. Thus these immune reactions 
severely limit the benefit of systemic delivery, intratumoral delivery, repeated administration and 
administration of high-titer Ads.  
 .  
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ABSTRACT 
 The field of ultrasound has expanded since the discovery of ultrasound contrast agents 
(UCAs) from diagnostics to therapeutic use. UCAs are known as microbubbles (MBs), which 
can be chemically and physically manipulated to improve their therapeutic potential. MBs can be 
tailored to bind to specific diseased tissues and act as carriers of different chemo-drugs and 
genetic materials. These engineered MBs can behave differently to ultrasound intensities 
resulting in different cavitation methods. Though the underlying mechanism is yet to be fully 
understood, there is evidence to suggest that mechanical pore formation of cellular membranes 
allows for the temporary uptake of drugs. The cavitation of MBs can induce temporary and 
reversible enhancement in the permeability of both individual cells as well as the endothelium 
including the blood brain barrier. There are too many side-effects and immune responses to 
current cancer and diseased treatments. MBs protect the immunogenic drugs from eliciting a 
detrimental response when delivered through the vasculature. They also help reduce the drug 
dosage by improving drug targeting and drug response. Thus, MBs can be used as vehicles for 
localized drug delivery and gene therapy allowing us to further develop the potential of curing 
cancer and other diseases.  
 
Keywords:  Microbubbles, ultrasound, ultrasound contrast agent, chemotherapy, adenovirus, 
Polyethylene glycol, perfluropentane, phospholipid, sonoporation, cavitation, Blood Brain 
Barrier (BBB), Gene Therapy, Chemotherapy, DNA, RNA, Protein, siRNA, miRNA, Drug 
delivery. 
  
19 
INTRODUCTION 
Historical Overview 
 Ultrasound (US) is the most widely used diagnostic imaging modality. This modality 
provides a safe, non-invasive, and portable real-time imaging at a low cost [68]. US sound waves 
have a frequency between 20 Hz to 20 kHz that is inaudible to the human ear [69]. Typically, in 
ultrasonography the diagnostic frequency ranges from 1-10 MHz [70]. To produce a US image a 
transducer that broadcasts the US wave pulses is placed on the skin or inside the body. These 
waves are reflected by the interfaces between different tissues or structures in the body. The 
imaging software system converts these reflected waves into electrical pulses and digitizes them 
[68]. Imaging is possible because the speed of sound in the tissue (~1500m/s) is known [71]. 
Biological tissues (except lung or bone) mainly consist of water, which has low compressibility, 
and sound waves propagate without significant scattering or reflection [71]. Thus the backscatter 
energy from tissue contains less or no harmonics [72]. Blood, a liquid phase material, has low 
compressibility and scatters US poorly, but the infusion of ultrasound contrast agents (UCAs) or 
microbubbles (MBs) can increase the scattering and reflection of the ultrasonic waves [68]. 
Thus, harmonics can be used to differentiate between blood flow with UCAs and the surrounding 
tissue [72].   
 The discovery of microbubble (MB) agents came from an accidental observation by Dr. 
Charles Joiner, a cardiologist in the late 1960s. Dr. Joiner performed an M-mode echocardiogram 
by injecting a patient with indocyanine green through the left ventricle to measure cardiac 
output. He observed a transient increase in the US signal from the ventricle after each injection 
[73, 74]. It was later shown that small bubbles forming at the catheter tip caused the increase in 
the signal, but subsequent research into duplicating the results was not successful [74]. In 1968, 
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Gramiak and colleagues observed a cloud of echoes after the injection of agitated saline in the 
aortic root [73]. They showed that the backscatter of the US for the blood pool can be increased 
by adding the gas bubbles that exist in agitated saline [72, 73]. Agitated saline is still used for the 
detection of right to left shunts in the heart [75]. These bubbles were large and unstable and had 
a short half-life and did not persist in the blood for long periods of time which limited their use 
[72]. Only right heart imaging was achieved because the first generation of UCAs that entrapped 
air and carbon dioxide in agitated saline and hydrogen peroxide could not pass through the 
pulmonary circulation [76]. 
 Mixing some of the patient’s blood with saline was found to markedly increase and 
prolong the stability of the bubbles [74]. Dr. Feinstein [77] found that albumin was the blood 
component improving MB stability [74].  Later on Feinstein developed the sonication method 
that produced more stable MBs, whose size could be controlled [78]. In 1994, Albunex 
(Molecular Biosystems, San Diego, CA) became the first commercially available contrast agent 
approved for human use in the United States. Albunex has a coating made of human serum 
albumin [72]. Coating of MBs resulted in the stabilization of MBs with different substances such 
as phospholipid, albumin, or polymers. Coated MBs formed the second generation UCAs that 
had a mean diameter less than 8 μm, which guarantees that the UCA could pass through the 
pulmonary circulation and reach various organs. MBs survived longer in the blood stream due to 
their lower solubility in water and had a strong harmonic response [76]. 
 The making of more stable, more effective UCAs revolutionized the pharmaceutical 
industry. The second commercially available contrast agent, Levovist, became available in 
Europe and Japan in 1996. Levovist like its forerunner Echovist [74] (Bayer Schering Pharma 
AG, Berlin, Germany) consists of galactose microcrystals whose surfaces provide absorption 
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sites on which air bubbles form when suspended in water [72]. Echovist performed poorly in the 
right heart because its intravenous (IV) injected MBs were not stable and failed to cross the lung 
capillaries [74]. Levovist MBs were further stabilized with a trace amount of palmitic acid [72], 
thus making it stable in the blood for 1-4 min, which increased the US signal by ~20 dB [74]. 
Levovist MBs formed in the blood flow while EchoGen® (Abbot Laboratories, Chicago, IL, 
USA) achieved MB formation through a totally different mechanism. EchoGen® consists 
essentially of a perfluoro-compound (perfluoropentane), which is liquid at room temperature but 
becomes a gas at body temperature. EchoGen® is prepared as an aqueous emulsion with 
surfactants that change to gas on injection, with the formation of MBs as small as 2–8 microns 
[74]. 
 Since 1997, contrast agents (CAs)  are further stabilized by replacing the air core with 
high-molecular-weight inert gases such as perfluorocarbons, which have a lower solubility and 
diffusivity in aqueous liquids compared with air [72].  Clinically proven agents based on this 
principle include SonoVue (SF6 gas), Definity/Luminity (C3F8), Imagent (C6H14), Sonazoid 
(C4F10) (these materials possess a lipid stabilizer shell), and Optison (C3F8 has a shell of 
denatured human serum albumin) [71]. These became the third generation of UCAs. 
 The history of UCA development has been long and difficult. Luck and astute 
observations helped develop and make US imaging the most cost effective technology available 
in the world. UCAs have opened up new opportunities in molecular imaging [71], drug delivery 
systems, high focused US (HIFU) surgery [79], and atherosclerosis [80]. 
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Ultrasound Contrast Agents or Microbubbles 
 Ultrasound contrast agents are also known as microbubbles (MBs). MBs enhance the 
quantification of perfusion and blood flow [81]. MBs are very echogenic and they resonate like a 
musical instrument [74]. The physical and chemical design of contrast agents (CAs)  are 
manipulated such that synthetic surfactant, tuning of size, composition, degradability, surface 
properties and bio-functionality make them very echogenic [81]. Typically, MBs are comprised 
of surfactant shell made from proteins, lipid and biodegradable polymers with an inner gas core, 
either of air or inert gases (Fig. 4). MBs have an average diameter of ~2 to 3µm, and the 
combined mass of the shell and gas core (Fig. 4) of each MB does not exceed a pictogram [71].        
 
 Figure 4. Schematic representation of a coated microbubble. 
 The particle size of MBs for intravenous injection plays a significant role and needs to be 
carefully controlled. MBs must be small enough to cross the capillary bed (7.5 micron). Indeed, 
large bubbles are unable to pass through the capillaries, whereas small bubbles are considerably 
less effective scatterers [81]. It is now accepted that the size must be in the range of 1-7µm, 
preferably around 3µm, with as narrow size distribution as possible. The critical resonance 
frequency required to destroy the bubble depends on the diameter [74]. The rigidity of the shell 
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determined by the thickness of the surfactant would also determine its resonating potency and its 
echogenicity. It has been determined that US reflectivity is proportional to the fourth power of a 
particle diameter, but also directly proportional to the concentration of the particles themselves. 
The resonance frequency of MBs 1–7µm in diameter lies within the 2–15 MHz range, which is 
the US frequency used for clinical diagnosis [74].  
 Echogenic liposomes and various nanoparticle (NP) dispersions are being evaluated as 
CAs. Most liposomes have a multi-lamellar structure with embedded air pockets that are 
responsible for acoustic backscatter signal [82, 83]. Without an enclosed gas core the US signal 
from these particles is low. NPs dispersions are mostly liquid perfluorocarbon-based emulsions 
[84]. These NPs are also characterized as contrast agents for MRI, optical imaging, and drug 
delivery. US imaging using these materials requires a high frequency (multi-MHz) or high 
degree of target surface coverage with a CA [71, 85].  
 MBs do not diffuse across the endothelium and thus there is no interstitial enhancement. 
Essentially, MBs act as blood pool markers, or markers of any other body space into which they 
have been injected and their behavior is, in many respects, similar to that of labeled red blood 
cells. Vascular enhancement usually lasts a few minutes and the MBs are then dissolved. 
However, this model is complicated by evidence that some MBs are taken up by the 
reticuloendothelial systems [74]. 
 Single-bubble detection is possible in vitro in normal saline or blood with older imaging 
equipment. However, echoes from normal tissue can be nonlinear with non-fundamental 
frequency. To reduce these signals from tissues multi-pulse techniques such as phase inversion 
and power modulation are applied [71]. However, to detect MB vibration current imaging 
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systems use harmonic imaging, both in free-flow conditions [86] and when attached to a solid 
target [71, 87]. MBs are known to emit US at different frequencies such as sub-harmonic, second 
and third harmonic frequencies. This large discrepancy in the echoes between MBs and tissue 
allows for enhanced imaging with quantification of perfusion, blood flow, tumor and tissue 
vascularization [81], thus MBs are essential for diagnosing modality. 
 MBs are used not only for diagnostic applications but also for molecular imaging and 
therapeutic applications [68, 88-90]. Molecular imaging targets the molecular changes associated 
with diseases and improves the efficiency of in vivo imaging [72]. However, in this chapter we 
will focus on its therapeutic applications in treating cancer. Initial applications of MBs depended 
on the rate of bubble collapse and their bio-effects such as inducing cell damage, vascular injury 
[91], and the lysis of thrombus [92]. Interestingly, oscillating MBs can increase membrane 
permeability and open up tight junctions in endothelial cells [93-97], thus the therapeutic 
potential of drug delivery and drug action is increased. Based on chemical and physical nature of 
drugs, some MBs are known to have drugs encapsulated in liposomes, polymeric micelles, 
hollow particles and emulsion droplets with the aim to reduce non-specific drug resistance and 
side-effects associated with traditional cancer therapies [81].  
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Types of Microbubbles 
 MBs can be divided into several categories depending on their physical and chemical 
properties which are crucial in the design of a contrast agent for US guided drug delivery [81]. 
There are a few characteristics that are important when designing an MB. First, the intensity of 
the backscatter or echo caused by the MB is determined by Rayleigh scattering regime [81, 98]. 
The intensity depends on the surface properties or shell material, gas content and colloidal 
properties of MBs [81, 99]. Shell and gas components (Fig. 4) should be biodegradable, i.e. 
readily metabolized and/or excreted with minimal side-effects [81]. Additionally, MBs shouldn’t 
aggregate into large clusters which could result in non-specific and undesired adhesion to cells 
[99]. MBs should be effective at low doses [81]; for instance, the typical US Food and Drug 
Administration (FDA) approved dose of MBs for a patient is approximately 109-1010 MBs given 
for a 1-2 mL bolus intravenous injection [99]. Additionally, pre-formed drug loaded MBs or 
MBs alone should be sterilizable and stable with a shelf-life of two years [81, 99]. Other 
requirements include backscattering proficiency, fragility and cavitation properties of MBs [81]. 
US or acoustic pressure required to cause cavitation is measured as mechanical index (MI), a 
relative quotient computed as a peak negative acoustic pressure divided by the square root of the 
frequency [71]. MBs behave differently at various acoustic pressures, for example, at MI >0.2 
MBs behave in a nonlinear manner that allows some systems to detect smaller MBs [71]. At 
higher pressures (MI >0.4 and up to 1-1.9, depending on the frequency), MBs are completely 
destroyed [86]. Acoustic pressure depends on the diameter of the shell and its material, for 
example, thin lipid monolayered bubbles are flexible and vibrate in response to low-pressure US 
(e.g., MI = 0.06) [71], whereas, thick-shelled polymer bubbles don’t crack unless at critical 
pressure, or vibrate resulting in low acoustic echo response [100].  
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Agitated Gas Microbubbles (First Generation) 
 First generation MBs were prepared at patient bedside with two syringes connected via a 
stopcock valve that contained air and saline [101]. When liquid and gas are rapidly transferred 
from one medium to another the resulting high shear flow causes air bubbles to form of varying 
sizes [71]. These bubbles produced by agitation are called agitated-saline and are both large and 
unstable [71, 72]. The surface tension between the gas core and surrounding liquid causes the gas 
to diffuse into the surrounding liquid decreasing the size of the bubble [71]. MB requires a 
stabilizer shell to prolong its circulation time. The rate can be calculated using the equation by 
Epstein and Plesset [102] and Chen et al. [103] that an air bubble with a diameter of 5μm in air-
saturated water disappears in approximately 125 ms and an air bubble with a diameter of 3 μm 
disappears in approximately 32 ms at room temperature and ambient pressure [72].  
 There are several limitations in using these bubbles such as the size of bubble, circulation 
time and gas core. These bubbles are effectively removed by the lungs [72]. Additionally, these 
bubbles have a size greater than 10μm and are unable to traverse the pulmonary circulation [68]. 
MBs larger than 6-8µm are trapped in the lung capillaries and bubbles smaller than 1µm are less 
stable and less ultrasound responsive [81]. These bubbles need to be administered by 
intracoronary or aortic root injection to visualize the left cardiac chambers [72]. Additionally, 
because it takes at least 12 sec for a contrast agent to pass from a peripheral vein (i.e., the site of 
injection) to the end-organ [104], to be useful these bubbles need to persist for several minutes 
[72]. In 1984, Feinstein et al. introduced the use of sonication to create MBs that were stable and 
small enough to transit through the pulmonary microcirculation from right to left heart [77].   
 Since the introduction of saline MBs, other agitated contrast agents (hydrogen peroxide, 
dextrose, indocyanine green dye, iodinated contrast) have been used [68]. 
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Coated Microbubbles filled with Air (Second Generation) 
 The biggest dilemma facing scientists was the circulation time of bubbles. It was found 
empirically that a small admixture of the patient’s blood to the saline improves the stability and 
effectiveness of the agitated saline as a contrast agent [105]. Surfactants from the blood form a 
coating around the gas core and promote the lifetime of the MB by greatly reducing the surface 
tension at the interface [72]. The first stable MB marketed was Albunex (Table 1). Albunex had 
a short shelf-life after intravenous injection (tens of seconds) [71]. 
 An encapsulating shell is necessary to sustain the gas cavity and to reduce both the 
diffusion of gas leaving the core and the surface tension [81]. The encapsulating shell increases 
the shelf-life (days to months) of the bubbles. The albumin coating forms an elastic solid shell 
around the gas core and is relatively stiff. Coating enhances the bubble’s stability by supporting a 
strain to counter the effect of the surface tension [72]. The transpulmonary passage of contrast 
particles became possible only after the addition of a MB shell, i.e., a surfactant (lipid, protein, 
e.g. denatured albumin or polymer, e.g. poly-butyl-cyanoacrylate [69]) coat, which stabilized the 
bubbles so that they did not attach to the extensive surface of lung endothelium capillaries [71, 
106]. Bubble size is a critical parameter that must be controlled in the range of 1-7µm preferably 
around 3µm [81]. At that point, intravenous administration of contrast became a feasible option 
for delivering contrast to left heart chambers [106], with some contrast reaching the myocardium 
vasculature. To circulate freely and avoid entrapment in the microvasculature, MB particles need 
to be smaller than red blood cells (typically <4.5µm in mean diameter) [71]. 
  The compressibility of gaseous particles is many orders of magnitude higher than that of 
liquids and solids. As a result, the scattering efficiency from gaseous particles is many orders of 
magnitude higher than that from other objects. According to Rayleigh Scattering the intensity of 
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MB increases as the fourth power of frequency [81]. For such small MBs, the surface-to-volume 
ratio is high, and air can easily escape and dissolve in the surrounding medium (as a result, 
ultrasound contrast is lost). Therefore, transpulmonary air-filled MBs with these first-generation 
shells did not circulate long after intravenous injection (tens of seconds) [71]. Air consists mostly 
of nitrogen that is able to move easily out of the thin-shelled bubbles, especially in cases of 
oxygen inhalation that had reduced blood levels of dissolved nitrogen [107, 108]. In 
physiological conditions, the blood is saturated with air under atmospheric pressure, whereas the 
air pressure inside the bubbles is larger than atmospheric pressure due to Laplace pressure. When 
air-filled MBs are infused intravenously they dissolve spontaneously [99]. Surfactants such as 
lipid (~3nm thick), protein (15-150nm thick) or polymeric shell (200-500nm thick) eliminates 
the driving force for dissolution of MBs in saturated media as the elastic response of the interface 
arrests the shrinkage of the gas core [99, 109]. To improve MBs’ stability, currently used 
strategy is to fill them with a sparingly water soluble gas (perfluorocarbons act as osmotic agent) 
instead of air [110]. 
 At present Levovist (Table 1) is the most widely studied MB contrast agent and the only 
one commercially available in several countries. Levovist (Table 1), like its forerunner Echovist 
(Table 1) (also by Schering), is made of galactose microcrystals generating air in the vial [74]. 
Adding water to the galactose powder forms a suspension in which air MBs adhere to the fine 
irregularities of the surface of the microcrystals remaining in the solid state, which dissolve after 
injection, releasing the gas MBs into the blood. Levovist and Sonovue (Table 1) have half-lives 
of 78 seconds and 5 minutes, respectively [81]. 
 MBs are manufactured by two general techniques: self-assembly stabilization of 
dispersed gas particles, and double-emulsion preparation with core extraction. The first 
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technique is for lipid or protein-based bubbles. Gases (air or fluorinated gas with low solubility) 
are dispersed in the aqueous medium that contains a lipid or surfactant micellar mixture or a 
protein that is denatured by sonication. Those components are deposited on the gas-liquid 
interface and stabilize the MB. Some preparations are stable on storage in the aqueous phase for 
many months. Alternatively, MBs can be rapidly frozen and lyophilized for extended storage in 
dry state. The addition of water results in a reformation of the MB aqueous dispersion 
immediately before use [72]. 
Table 1: Comparison of Commercially Available Contrast Agents 
Agent Bubble Size mean 
(range) 
Gas Shell Composition 
Albunex 4.5µm (1-10µm) Air Albumin 
Levovist 2-3µm (2-8µm) Air Galactose/ palmitic acid  
Echovist - Air D-galactose 
EchoGen 2-5µm (1-30µm) Dodecafluoropentane Stabilized surfactant 
Sonogen 2-5µm (1-30µm) Perfluoropentane Anionically charged surfactant 
Optison 4.7µm(1-10µm) Octafluoropropane Albumin N-acetyltrytophan, 
Caprylic acid 
Definity 1.5µm(1-10µm) Octafluoropropane Lipids: DPPA, DPPC, 
MPEG5000 DPPE 
Imagent 6µm Perfluorohexane Lipid: DMPC 
Sonozoid 2.4-3.6 µm (3.4µm) Perfluorobutane Phospholipids 
Sonovist 1-2 µm Air Cyanoacrylate (polymer) 
Sonovue 2.5µm(1-10µm) Sulfur hexafluoride Lipids: Macrogol 4000, DSPC, 
DPPG, Palmitric acid 
Sonidel MB101 2.7 µm Perfluorocarbon Stabilized Lipid 
BG1135 2.9µm(1-8µm) Air Polymer 
BR14 2.5-3 µm Perfluorobutane Lipid 
BR38 <10µm Perfluorobutane Phospholipids 
PB 127 4.0µm(3-5µm) Nitrogen Biodegradable polymer bilayer 
PESDA 4.7 µm Perfluorocarbon Albumin 
Artenga 2.5 µm Variable Lipid 
AI-700 2µm Perfluorocarbon Poly-L-lactide co glycolide 
Cardiosphere/
Bisphere 
4µm Nitrogen Polylactide/Albumin 
Targeson 2.5 µm Perfluorocarbon Surface-modified Lipid 
Adapted from Liu, Y. et al. 2006 [69], Alzaraa, A. et al. 2012 [111] and Nomikou, N. and 
McHale, A.P. 2010 [112]) 
30 
Coated Microbubbles filled with Inert Gases (Third Generation) 
 Since 1997, contrast agents have been further stabilized by replacing the air core with 
high-molecular-weight inert gases or water soluble fluorinated gases [71] such as 
perfluorocarbons [72] and sulfur hexafluoride [68] which have a lower solubility and diffusivity 
in aqueous liquids compared with air [104]. Perflurocarbons act as osmotic agents and would 
dilute the other gases inside the bubbles thereby also reducing their partial pressure [81, 113]. 
This effect counterbalances the Laplace pressure and blood pressure [81]. 
 The gas core is generally surrounded by a protein (albumin), lipid, surfactant, or 
biocompatible polymer surfactant with a diameter ranging from 2 to 500nm. This shell improves 
stability against gas loss, dissolution, and MB coalescence, and produces a more standard size 
distribution [68]. The gases such as perfluorocarbons are exhaled through the lungs. Examples of 
this kind of agent are Optison (GE Healthcare, Chalfont St Giles, UK), which contains 
octafluoropropane and an albumin shell; SonoVue (Bracco, Milan, Italy), which has a sulfur 
hexafluoride core and a phospholipid coating [72]; Definity/Luminity (C3F8), Imagent (C6H14) 
and Sonazoid (C4F10) which possess a lipid stabilizer shell [71] (Table 1).  
 
Different types of Coated Microbubbles 
 Shell coating is critical for stabilizing MBs because the configuration and conformation 
of the shell material determines its stiffness which increases its  resistance to rupture by US as 
well as its clearance efficiency by the reticuloendothelial system [68]. The shell can be stiff with 
albumin, lysozyme and polymers or more flexible with lipid or phospholipid. Its thickness can 
vary from 10 to 600nm [81]. Surface tension, shell viscoelasticity and permeability, surface 
charge density, biodegradability, ligand density and payload capacity are properties that largely 
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depend on the choice of the surface-active agent, i.e. lipid, protein or synthetic polymer. MBs’ 
surface properties and size play a crucial role in prolonging the circulation life of MBs as 
phagocytic uptake depends on surface opsonization [114] and particle size. The larger sized MBs 
are eliminated more rapidly. Dendritic cells and macrophages are assigned to the clearance of 
MBs in the bloodstream [99]. The study of MBs’ biodistribution carried out by Tartis et al.[115] 
using Positron emission tomography (PET) showed that MB shell material accumulates in the 
spleen through size dependent filtration mechanisms. Immunogenicity, targeting efficiency, 
availability, potential for imaging and drug release upon ultrasound irradiation are functional 
properties consequently correlated with MBs’ structural features [99].
 
Figure 5. Schematic representation of different coated microbubbles. A) Polymer coated 
microbubbles. B) Phospholipid coated microbubbles. C) Protein coated microbubbles. 
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Interaction of Ultrasound and Microbubbles 
 Acoustic signals from MBs is dependent on the compressibility of the gas, bubble size, 
shell thickness, shell viscosity, shell density, properties of the surrounding medium, US 
frequency and power of the applied ultrasound [116, 117].  
 MBs owe their functionality to the gas core, which can compress and expand easily in 
response to the acoustic pressure change (Fig. 8) [72]. This change can result in 100-fold volume 
change and 4-5 fold diameter change [71]. Thus, when exposed to an ultrasound field, a gas 
bubble will undergo volumetric oscillations in response to the varying pressure (Fig. 8) [74, 
118]. The MB oscillations also results in a high backscattering of the ultrasound wave. The 
amplitude of these oscillations will be much larger than those of a very weakly compressible 
body such as a red blood cell [79]. Thus, despite their similarity in size, the MB will produce 
much stronger US echoes [74, 118]. Moreover, the MBs can act as resonant systems with 
resonant frequencies within the same range as medical ultrasound frequencies [72]. 
 Eventually with increasing pressure from the US the MBs will undergo violent collapse, 
releasing a shock wave and often fragmenting into smaller bubbles (Fig. 6, 7 & 8B) [119]. This 
process is variously referred to as inertial, unstable, or transient cavitation (Fig. 8B). Transient 
and unstable are both slightly misleading terms since a bubble can collapse repeatedly [120] 
without fragmenting, but inertial cavitation means the collapse of a gas cavity with significant 
amounts of energy being released (Fig. 8B) [72]. Broadband emissions are generated during 
inertial cavitation where bubbles undergo large radial oscillations that are dominated by the 
inertia of the surrounding liquid [121]. During compression of MB there is a rise in pressure and 
temperature within the bubble, but during an inertial collapse the temperature may reach several 
thousand degrees centigrade or more [122]. These extreme conditions are confined to the center 
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of the bubble; however, the bubble will have expanded again before any significant heat transfer 
can occur. Highly reactive chemical species may be produced such as free radicals and toxic 
chemicals such as hydrogen peroxide (H2O2) [123] at relatively high intensities [124].   
 
 
Figure 6. Optical frame images and streak image of ultrasound contrast agents. Optical frame 
images and streak image corresponding to the oscillation and fragmentation of a contrast agent 
microbubble, where fragmentation occurs during compression. The bubble has an initial 
diameter of 3 μm, shown in A. The streak image in h shows the diameter of the bubble as a 
function of time, and dashed lines indicate the times at which the two-dimensional frame images 
in A–G were acquired relative to the streak image. (Adapted from Chomas et al. American 
Institute of Physics, 2000 [125].) 
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Figure 7. Schematic representation of lipid (left column) and polymer (right column) 
microbubble interaction with ultrasound of increasing intensity (top to bottom). (Adapted from 
Hernot and Klibanov, Advanced Drug Delivery Reviews, 2008 [68]). 
 In addition to a temperature rise, “streaming” currents may also be set up as ultrasound 
propagates through a liquid as a result of momentum transfer [126]. A similar effect can occur on 
a correspondingly smaller scale around MBs undergoing stable oscillations (Fig. 8A) [127]. If 
the bubble is sufficiently close to a surface, such as a cell membrane, these circulating flows may 
give rise to shearing stresses which have been hypothesized as the means by which uptake of 
therapeutic components is enhanced [128]. Micro-streaming (Fig. 8A) will also contribute to 
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circulating material in the target region, which is extremely important in the context of 
therapeutic applications [129]. At higher amplitudes of oscillation, microstreaming can cause 
significant damage to cells and produce mechanical erosion [79, 130, 131]. In addition when a 
bubble rapidly collapses near a boundary, this collapse is asymmetrical. A high-speed liquid jet 
may form projecting through the bubble towards the boundary. This phenomenon is known as 
microjetting (Fig. 8C) [81]. Microstreaming and microjetting generate moderate shear stress on 
inducing hyperpolarization of the cell membrane by modifying the electrophysiologic cell 
activities and enhancing the cell’s permeability (Fig. 8) [132]. For drug-loaded MBs, 
microjetting would be the ideal release mechanism (Fig. 8C), since it effectively produces small 
holes within a cell membrane (sonoporation) which facilitates the drug uptake [133]. The rupture 
size is large enough to allow the passage of non-deformable particles up to 0.5µm in diameter, 
that depends on several parameters including the MB size, shell composition, acoustic pressure, 
and intravascular pressure [81]. 
 MBs and ultrasonic waves undergo a scattering interaction by absorbing the acoustic 
energy [81]. MBs in a liquid are forced to oscillate with only a relatively small to moderate 
increase and decrease of radius. The mechanical biological effect is estimated by certain 
ultrasound parameters and is called mechanical index (MI).  At low MI<0.1, MBs undergo 
alternate equal expansion and contractions symmetrically and in a linear manner [81]. At a 
slightly higher MI of 0.1 to 0.3, the bubble becomes somewhat resistant to compression than to 
expansion which results in stable or non-inertial cavitation (Fig. 8A & B) and leads to non-linear 
oscillations and backscatter at a variety of frequencies (harmonics, sub-harmonics and ultra-
harmonics) [68, 80]. When the bubbles are collapsing the kinetic energy of the bubble surpasses 
its surface energy and fragments into a number of smaller bubbles. Fragmentation (Fig. 6, 7 & 
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8B) has been exclusively observed with contrast agents with thin, elastic shells [134]. At even 
higher acoustic pressures (MI 0.3–0.6), MBs undergo forced expansion and compression that 
lead to its destruction by different methods such as outward diffusion of the gas during the 
compression phase, diffusion via large shell defects, or complete fragmentation of the shell and 
the gas core (Fig. 6, 7 & 8B)[125, 135]. MBs’ fragmentation can instead produce violent effects 
which causes cell membrane permeability [136] and lysis [133](Fig. 8B). Acoustical experiments 
are performed on a population of MBs, therefore they do not show how individual MBs respond 
in an acoustic field. Experimental evidence is obtained with high-speed camera microscopy of 
insonated bubbles [68]. These optical frame or streak images show the oscillating and 
fragmentation changes of a 3μm MB (Fig. 6) [125].   
 
Figure 8. Schematic representation of ultrasound causing microbubbles to behave in different 
ways that leads to endothelial pore formation and increase vascular permeability. A) Stable 
cavitation leads to expansion and contraction of microbubble that generates shear stress known 
as microstreaming. B) Inertial cavitations lead to implosion of the microbubbles that allow for 
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the release of the bubble contents or fragment into smaller microbubbles. C) Bubbles generate 
microjets when the resonance diameter is larger than the blood vessels that damage the 
endothelial lining. 
 
 Coated MBs undergo damping as dissipation of viscous energy. Damping reduces the 
amplitude of the bubble oscillations and it widens the resonance curve of the bubble [72].  MB 
shell material and stiffness also play a major role in determining the type of explosion or 
implosion that may occur when exposed to acoustic energy. Lipid or protein MBs and polymer 
MBs behave differently and depend on the amplitude of ultrasound to which they are exposed 
[68, 134].  The regime of phospholipid coated MBs depends on bubble radius and the 
concentration of phospholipid molecules. Phospholipid MBs exist in buckled, elastic and 
ruptured regime. The bubble is compressed when the coating is condensed which leads to 
buckling, and with the bubble coating in such a tensionless state, the resulting surface tension is 
zero (Fig. 6D) [72]. When the bubble is expanded (Fig. 6B), the coating may be ruptured and the 
gas core will be exposed to the surrounding liquid, changing the surface tension of the gas–liquid 
interface. In the intermediate elastic regime, the coating is assumed to behave elastically where it 
is relatively stiff. During the elastic regime, its resonance frequency is high and it will not easily 
oscillate when driven below resonance [137]. An increasing acoustic pressure can modify the 
concentration of lipid molecules on the bubble’s surface, forcing the bubble into the buckling 
regime, which suddenly reduces its stiffness [72]. 
 An oscillating phospholipid MB would most likely lead to stable or non-inertial 
cavitation (Fig. 8A & B). For MBs with a thin shell such as Optison (albumin shelled MBs) 
fragmentation is the major mechanism for bubble destruction [116]. Microjets (Fig. 8C) are also 
generated during cavitation of thin-shelled MBs [91] which produce vessel wall ruptures in vivo 
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and extravasation of nanoparticles into the interstitial space. Polymeric shells are stiff and will 
not oscillate actively at low US intensity (Fig. 7). The shell cracks as US pressure is increased 
above  the threshold value resulting in the escape of the encapsulated gas (Fig. 7) [68]. This type 
of MB destruction is called sonic cracking (Fig. 7). However, thick shelled rigid albumin MBs 
also undergo sonic cracking [116, 138]. For bubbles containing drugs in the gas phase (anesthetic 
gases, nitric oxide, oxygen) [139, 140], sonic cracking is a suitable mechanism. Fragmentation 
(Fig. 7), microjetting (Fig. 8) and sonic cracking (Fig. 7) can be effective mechanisms in drug 
delivery and therefore their occurrence should be finely predicted and tuned [81, 141]. 
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Bio-Effects 
 US assisted drug delivery is a very complex process that relies on biochemical and 
mechanical processes that occur during sonoporation which is defined as mechanical disruption 
of the plasma membrane [80, 81] (Fig. 9).  
 
Figure 9. Ultrasound interacts with the microbubble, causing oscillation and eventual 
destruction, leading to the release of genetic material. The accompanying cavitation produces a 
local shockwave that increases cellular permeability, allowing transcapillary passage of 
macromolecules through small endothelial perforations. (Image courtesy of C.R. Merritt, MD, 
Thomas Jefferson University Hospital, Philadelphia, PA.) (Adapted from Howard, Applied 
Radiology, 2004, [142].) 
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US energy can penetrate or “push” materials into skin, blood clots or other tissues [143]. Shear 
stress can be generated on the membrane of an endothelial cell through the  destruction of MBs 
that causes high-energy microstreams and microjets which increases the permeability of blood 
vessels promoting the extravasation (Fig. 10) of high molecular weight drugs [99]. This increase 
in permeability is probably due to transient holes in the plasma membrane and possibly the 
nuclear membrane [69]. Thus, acoustic cavitation is a pre-requisite in promoting the physical or 
chemical release of drugs from carriers (MBs), or in promoting the transport of drugs into cells 
(Fig. 10). US-induced passage of materials from the luminal to the adventitial side of vascular 
tissue (Fig. 9 & 10) have been proposed in the literature such as paracellular widening of inter-
endothelial clefts and tight junctions, free passage through injured endothelial lining and 
transcytosis via fenestration and channel formation [94] (Fig. 11).  
 
Figure 10. Enhanced drug and gene delivery achieved with the combination of particles and 
ultrasound. Insonation of circulating microbubbles in the chorioallantoic membrane model 
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results in small vascular defects, through which a fluorescent dye is transported, reproduced with 
permission from (27). (a)–(f) are a sequence of images acquired from 1.00-MHz center 
frequency insonation at a peak negative pressure of 1.3 MPa. (a) was acquired before insonation, 
(b)–(f) were acquired 0.06, 0.12, 1.24, 2.24 and 3.24 seconds after insonation began, 
respectively, demonstrating the transport of the fluorescent probe from the vasculature to the 
tissue interstitium.(Adapted from Ferrara et al., American Chemical Research, 2009[144].) 
 
Figure 11. Ultrasound mediated drug delivery through different means of transport. 
Sonoporation allows for the mechanical disruption of the endothelial cell membrane. 
Intracellular trasnsport allows for the uptake of microbubbles through endocytosis that transports 
the microbubble through to the interstitium. Paracellular transport allows for the opening of the 
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tight junctions or separation of bonds that hold the endothelial cells together which causes pore 
formation in the blood vessel wall.  
 In vivo studies suggest that a MI of 0.4 has been shown to be detrimental to the plasma 
membrane and microvasculature [145]. However, low intensity stable cavitation may not be 
adequately effective in triggering the drug delivery [81]. Reported bio-effects in vivo include 
hemolysis, damage to the microvasculature, opening of the blood brain barrier, effects on cardiac 
rhythm and thrombolysis [146]. The vessel wall structure has also been found to influence the 
degree of rupture [147]. The fore mentioned mechanisms have been proposed for the blood brain 
barrier (BBB)[148], but are also supported by studies in other tissue beds, including renal [149], 
prostate [150] and skeletal muscle [147] tissues. 
 
Sonoporation 
 Sonoporation refers to the localized, mechanical disruption of plasma membrane (Fig. 
11) [80]. Van Wamel et al., [151] using high speed imaging, showed transport of propidium 
iodide (PI) against endothelial cells as a direct correlation between cell deformation and resulting 
cell membrane permeability with in vitro studies. According to van Wamel et al. [93] poration is 
a transition of hydrophobic to hydrophilic pores. This transition creates cylindrical pores when a 
rotation of the polar heads brings a hydrophilic surface to the pore (Fig. 12). When US is applied, 
the adhered MBs on the transmembrane generate a critical ‘shear’ force, which leads to 
formation of pores once the membrane breakdown force is exceeded. Rapidly oscillating MBs 
undergo rapid expansion and compression (Fig.12) due to changes in the volume of the gases 
inside the bubble. The oscillating MBs generates fluid flow over the cell surface and is termed as 
microstreaming (Fig.13), which is responsible for the disruption of cell membrane by tearing the 
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lipid bilayer membrane open [130]. Cells can withstand compression better than elongation, 
which may act as the main component that determines pore formation. Scanning electron 
microscopy studies have already shown that membrane poration occurs after US and MBs 
treatment [152]. Mehier-Humbert et al. [152] showed an efficient delivery of FITC-dextran (77-
164 KDa) or particles of 25nm. They showed cell membranes with a pore size distribution up to 
75nm with ~60% of cells being positive for delivery of the particle. Pore formation allows for 
direct transfer of molecules into the cytoplasm. Van Wamel et al. [151] have also shown that PI 
does not enter a cell 1 min after the US exposure. These results support the general idea that the 
pores reseal quickly upon termination of US. Mehier-Humbert et al. [152] showed that almost all 
the routes of entry had closed 5 seconds after termination of US. The action of MBs on cells is a 
mechanical one and can be as important as chemical stimuli in determining vascular fate or 
pathological state. The most important biomedical application of the sonoporation technique is 
that it allows the introduction of membrane-impermeable xenomolecules (synthetic molecules) 
such as dyes, hormones, proteins, plasmids, etc. into living cells [93]. 
 
Figure 12. Proposed model of the oscillating microbubble enforced pore formation in the cell 
membrane. The pushing and pulling behavior of the microbubble causes rupture of the cell 
membrane creating a hydrophilic pore allowing trans-membrane flux of fluid and 
macromolecules. (Adapted from van Wamel et al., Journal of Control Release 2006 [93]). 
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Paracellular transport 
 Drugs can be delivered by paracellular transport between functional endothelial cells with 
MBs. Transport by low-frequency US is strongly supported in the literature [153]. When a sound 
wave is propagated through a liquid medium, steady currents (Fig. 13) are set up in the direction 
of beam as a result of momentum transfer [126]. This acoustic streaming (Fig. 13) occurs around 
MBs undergoing stable bubble oscillations (Fig. 13) within the US field growing in size via 
rectified diffusion [154]. These eddying flows may, in turn, impose shear stresses on nearby 
surfaces, such as cell membranes, and it is thought that this may promote the uptake of 
therapeutic components [130, 155]. When a MB oscillates near a vessel wall (Fig. 13), its shell is 
estimated to travel at speeds on the order of 250 m/s [156], either by directly perturbing nearby 
structures or by causing local fluid convection [157]. The acoustic radiation forces cause bubbles 
to move in the direction of the wave propagation by bringing them in contact with vessel 
endothelium [158]. Radiation pressure may be involved in Focused US + MBs-based blood brain 
barrier opening through activating the stretch-sensitive or mechanosensitive (MS) ion channels 
in the vascular endothelium [159]. MS channels are now known to be implicated in many basic 
cell functions [160]. During localized elongation of cell membranes the MS channels are 
activated by the conformational changes [161, 162]. The resulting openings are reversible [163].   
 Endothelial cell morphology can vary significantly between normal and diseased organs. 
The tissue microenvironment surrounding blood vessels seems to control the endothelial cell 
phenotype in vivo [164]. Thus the blood vessels or microvasculature in the brain differs from 
other organs. BBB is known to restrict the paracellular translocation of large hydrophilic 
macromolecules and toxic compounds into the brain via specific membrane located transport 
systems [165]. When MB oscillations occur in the cerebral microcirculation, the BBB is 
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disrupted, causing drug extravasation due to breakdown of transmembrane tight junction proteins 
that regulate the paracellular permeability of the endothelial cell layer [166].  
 
 
Figure 13. Possible mechanisms for blood–brain barrier disruption via ultrasound + 
microbubbles. Assuming that the effect is not due to bubble collapse (inertial cavitation), 
possible effects include stimulation of the endothelial cells via radiation force on the bubbles, 
bubble oscillation or from microstreaming of the fluid around the bubbles. (Adapted from 
Vykhodtseva et al, Ultrasonics, 2008 [159].) 
 
Transcytosis/Intracellular transport 
 MB cavitation can also provoke drug transport through a vascular endothelial cell. 
Transcytosis or intracellular transport (Fig. 11), in the context of drug delivery, consists of the 
drug being endocytosed at the luminal surface of the endothelial cell membrane [80]. 
Transcytosis can be achieved through either a receptor-mediated fashion [167] or by invagination 
caused by cavitation with US [168]. Ghitescu et al. [167] showed specific adsorptive binding of 
albumin complexes to plasmalemmal vesicles and clustering in uncoated pits. Plasmalemmal 
vesicles allow endothelial cells to transport molecules, such as proteins, from the blood that are 
too large to diffuse through cell junctions or fenestrae, and this transport takes place both by 
vectorial transcytosis (vesicles) and by connective transcytosis (channels) (Fig. 11). Ghitescu et 
al [167], also demonstrated that albumin can stimulate endocytosis and transcytosis (Fig.11) in 
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mouse pulmonary and myocardial endothelium. Thus, albumin coated MBs could potentially 
undergo endocytosis through similar process. Subsequent transportation through several 
intracellular compartments and secretion from the cell at the basolateral aspect [169] results in 
delivery to vascular tissue. MBs could undergo endocytosis via caveolar, an alternative pathway 
for targeted drug delivery [170]. Endocytosis through caveolar is a receptor-mediated process via 
receptor-targeted drug vesicles [80, 171]. 
 According to Chen et al. [168], invagination occurs when bubbles collapsed near the 
vessel wall that results in the vessel wall being pulled inward toward the lumen. Invagination 
causes higher strain on the vessel wall than distention resulting in vessel rupture [168]. This 
localized mechanical destruction of the endothelial membrane results in endocytosis and 
subsequent transcytosis (Fig.12). Cavitating MBs near the cell membrane can create a pore for 
increased membrane permeability to macromolecules, genes such as wt-p53 (plasmid vector) 
[172] and extracellular ions such as Ca+2 [173], which is repaired by cellular mechanisms within 
seconds [174]. Meijering et al. [95] demonstrated that endocytosis plays a key role in UMTD of 
macromolecules sized between 4 and 500 kDa. Dextran molecules of 155 and 500 kDa were 
mainly localized in vesicle-like structures after UTMD as a result of macropinocytosis, clathrin-
mediated and caveolin-mediated endocytosis. MBs also showed increased membrane 
permeability to extracellular ions is upregulated by endocytosis due to the calcium flux into the 
cell [95]. The types of MB oscillations required to observe these effects have also been 
investigated. Inertially cavitating MBs near the cell membrane form 1 - 200 nm pores due to 
localized tensions [175]. These pores are capable of resealing bifunctionally by either rapid 
phospholipid rearrangement or gradual, exocytosis-mediated membrane tension changes, which 
restore membrane integrity [173]. Thus, US enhanced endocytosis is an important pathway for 
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targeting drug delivery by UTMD [80]. 
 
Enhanced Permeability and Retention Effect 
 UCAs are typically used to study the vasculature in animals and humans, thus employing 
them to study the aberrant tumor vasculature due to angiogenesis is a natural transition. 
Perfluoropentane filled silica nanoshells and microshells have been used to selectively image a 
tumor in a mouse ovarian tumor model [176]. Tumor angiogenesis is characterized by branching 
vessels with irregular diameters ranging from 10 to 200μm [177] and a lack of defining 
structures such as arterioles, capillaries, or venules [178]. Tumors induce angiogenesis to 
increase their nutrient and oxygen supply. The particular property of angiogenic vessels is their 
rapid growth from established vessels renders them “leaky” and defective. According to 
Pasqualini et al. [179] and Li [177], the tumor microvasculature has a vascular pore cutoff size 
from as low as 380nm up to 780nm, and the endothelial cells are misaligned or have large 
fenestrations. This phenomenon, which is generally referred to as the Enhanced Permeability and 
Retention (EPR) effect, can achieve high local concentrations of nano-encapsulated drugs at a 
tumor site (10- to 50- fold higher than in normal tissue) [99]. US exposure can enhance the size 
of these leaky vascular pores allowing for micron sized bubbles to collect at the tumor site. At 
the breast cancer (SK-BR-3) tumor site Zhao et al. [180], with phospholipid MBs, showed 
membrane pore diameter of 1-2µm with US exposure of 30 sec, diameter of 2-3µm with US 
exposure of 60 seconds and diameter of 3-5µm with US exposure greater than 60 seconds. Thus 
the EPR effect seen in tumors can be extremely beneficial in treating cancer.   
 Submicron bubbles could show higher intracellular uptake than microsized bubbles, 
allowing drug-release in different cellular compartments such as cytoplasm and nucleus [99]. 
The ability to synthesize nanobubbles has opened up further opportunities to deliver therapeutic 
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agents which require targeted extravasation into the tissues as micrometer sized MBs are 
typically too large to exit the vasculature. A prerequisite for this process is that the nanocarrier 
stays in the blood long enough to slowly accumulate in the tissue of interest with affected and 
leaky vasculature [99]. Nanometer sized bubbles can potentially exhibit an improved circulating 
lifetime [178]. The radiation force generated by insonofication [181] with the medical 
ultrasonography equipment can force the nanobubbles or MBs towards pores in these vessels and 
induce penetration of nanobubbles or MBs through the pores. The penetration of MBs results in a 
higher concentration of contrast in the tumor, a better visualization of the acoustic imaging and a 
targeted delivery of drug payload. In addition, the drug containing nanobubbles can be made 
slowly biodegradable, thus delivering their payload at a controlled rate [99]. These properties of 
the micro- or nano- bubbles make them an efficient drug delivery system for treating cancer. The 
most successful nano-bubble system consists of liquid paclitaxel loaded into perfluorocarbon 
emulsions that become echogenic when accumulated at the site of interest such as ovarian, breast 
and pancreatic cancer [182, 183]. 
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Uses of Microbubbles 
 Cavitation of MBs and its subsequent bio-effects on the vasculature and tissue cells 
shows the potential of using MBs as delivery vehicles. The chemical, physical and structural 
properties of the MBs also enhance the notion of using them to deliver therapeutic agents. Drugs 
can be incorporated into the MBs in a number of different ways, including binding of the drug to 
the MB shell and attachment of site-specific ligands. Drugs can also be imbedded in the 
membrane or loaded internally with the therapeutic agents and gas (Fig. 14).  
 
 
Figure 14. Manipulation of the microbubble shell for gene and/or drug delivery. (A) Drugs (red 
diamonds) may be attached to the surrounding microbubble membrane. (B) Materials may be 
imbedded in the membrane. (C) Bubbles may be loaded internally with the therapeutic agents 
and gas. (D) Hydrophobic drugs may be incorporated into an oily emulsion that forms a film 
around the bubble, which is then surrounded by a stabilizing membrane. (Adapted from Unger et 
al., European Journal of Radiology, 2002 [184].) 
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Subsequently, hydrophobic drugs may be incorporated into an oily emulsion that forms a film 
around the bubble, which is then surrounded by a stabilizing membrane (Fig. 14). 
Perfluorocarbon-filled MBs act as carriers of these agents until the site of interest is reached as 
they are sufficiently stable for circulating in the vasculature as blood pool agents [185]. 
Ultrasound applied over the skin surface can then be used to burst the MBs at this site, causing 
localized release of the drug [172, 186-188]. The use of US and MBs lowers the concentrations 
and reduces the systemic side effects of hazardous drugs like cytotoxic agents thereby improving 
the therapeutic index [185]. Thus, there is an increasing interest in developing noninvasive 
delivery methods for gene therapy and chemotherapeutics. 
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CHAPTER III : ULTRASOUND TARGETED MICROBUBBLE DELIVERY IN 
PROSTATE CANCER CELLS 
 
ABSTRACT 
Background 
The use of human adenoviruses (hu-Ads) in gene transfer studies is limited because of their 
immunogenic nature. To circumvent this limitation we have developed a novel approach 
constituted of hu-Ads encapsulated inside microbubbles (MBs). The melanoma-differentiation-
associated-gene-7 or interleukin-24 (mda-7/IL-24) is a tumor suppressor with pro-apoptotic 
activity against several cancers. However, to translate the site-specific gene transfer of Ad.mda-7 
complexes by ultrasound-targeted microbubble destruction (UTMD) from the bench to the 
bedside, studies involving the use of immune-deficient animal and immune-competent mice 
models are required. 
 
Hypothesis 
It has been shown that transfer of genes to mouse cells using hu-Ads is dependent on the 
expression of Coxsackie and Adenovirus Receptor (CAR) and certain integrins, which mediate 
hu-Ad attachment and internalization. Our hypotheses are that the murine derived prostate cancer 
cells will express CAR and/or a,ß integrins and will be transduced by hu-Ads. Microbubbles will 
protect the viruses from inactivating substances such as complement. UTMD will enhance gene 
transfer in both DU145 and murine PC cells regardless of complement rich FBS media.  
 
Methods 
We investigated the expression of CAR and a,ß integrins in murine and control human DU145  
PC cells by flow cytometry analysis. We tested the infectivity of Ad.GFP (green fluorescent 
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protein) and Ad.mda-7/IL-24 on both murine and DU145 prostate cancer cells. Viral burst assay 
was carried out on murine and DU145 PC cells with the CTV.Mda-7 oncolytic adenovirus to 
measure viral replication. We also tested the microbubble delivery of Ads with ultrasound in cell 
culture. Western blot analysis confirmed mda-7 protein expression following Ad-transduction. 
Annexin-V studies assessed the pro-apoptotic effect of the Ad.mda-7/IL-24.  
 
Results 
Our studies showed that cells express CAR receptor, a,ß integrins and that Ad.GFP and Ad.mda-
7/IL-24 transferred their transgene in the murine and human DU145 prostate carcinoma cells. 
Murine PC cells were unable to replicate the CTV oncolytic virus. Additionally, mda-7/IL-24 
significantly increased the apoptotic rate of the murine and DU145 transduced cells. 
Microbubble delivery of Ads with ultrasound in cell culture enhances gene transfer into the cells 
regardless of the complement rich FBS media.  
 
Conclusion 
Our study demonstrated the feasibility of using human DU145 prostate adenocarcinoma cells and 
TRAMP-C2 cells derived from a murine model of prostate cancer to translate the ultrasound-
mediated microbubble Adenovirus delivery system that we have developed. 
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INTRODUCTION 
 For more than four decades, human adenoviruses have served as an excellent model 
system to study molecular mechanisms controlling cell cycle progression and cell death. More 
than 60 types of HAdV have currently been identified and divided into eight species, designated 
A, B1, B2, C, D, E, F and G. Members of the different species use different receptors for virus–
host interactions and some are currently characterized as potential viral vectors in cancer gene 
therapy. HAdV show strict host specificity. Murine cells lack some of the receptors needed for 
HAdV infection such as the Coxsackie and Adenovirus Receptor (CAR), thus, murine cells are 
generally refractory (non-permissive) for HAdV infection and replication, although a very low 
level of HAdV infection and replication has been described in some mouse cells [189, 190]. 
 Melanoma differentiation associated gene-7 also called interleukin-24 (mda-7/IL-24) is 
well-known for its pro-apoptotic, anti-angiogenic, radio-sensitizing, immune-stimulatory 
properties and bystander activity on distant tumors [53, 191-197]. Mda-7/IL-24 is a 
multifunctional suppressor gene belonging to the IL-10 family of cytokines [198, 199]. When 
delivered by HAdV vector, mda-7/IL-24 induces apoptosis selectively in almost all cancer cells 
while leaving normal cells unharmed [195]. Mda-7/IL-24 can be expressed and secreted from 
naïve normal and cancer cells thereby enhancing its apoptotic activity against primary and 
metastatic cancer [194]. Thus, HAdV expressing mda-7 should provide both tumor selectivity 
and adequate induction of newly synthesized mda-7/IL-24 [53]. 
 Gene therapy by adenoviral vectors has shown promising results in treating locally 
advanced cancers; however, due to their immunogenicity they trigger both adaptive and innate 
immune responses. The antigenic nature of Ads leads to their rapid inactivation by neutralization 
antibodies and clearance by the immune system. Ad vectors elicit an innate immune response 
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through the myeloid differentiating factor 88 (MyD88)/Toll-like receptor (TLR)-9 resulting in 
the production of type I interferons (IFNs), interleukin (IL)-6 and IL-12 inflammatory cytokines 
[200, 201]. Additionally, unmodified viruses are generally non-specific in their action and this 
limits their use to direct target tumor or organ injection [53]. To circumvent these limitations we 
developed a novel approach wherein Ads are encapsulated inside the shell of acoustically active, 
lyophilized, lipid-encapsulated, perfluorocarbon microbubbles (MBs) (ultrasound (US) contrast 
agents), which act as delivery vehicles for a site-specific gene transfer system. MBs protect the 
viral payload from detection and rapid degradation by the hosts’ immune system allowing for an 
intravenous (IV) injection rather than intratumoral (IT) injection [53, 202]. US breaks open the 
MB/Ads complexes by inducing cavitation, which allows Ads to transfer their transgene only to 
the sonoporated region. Cavitation of the MBs creates small shockwaves that increase cell 
permeability by forming temporary micropores on the cell surface bypassing the receptor-
mediated dependence of HAdV. Our novel viral delivery technique mediated by MB and US 
brings new hope to the frontier of gene therapy and its use in clinical settings. 
 In order to facilitate the translation of this technology into human application, we 
envision testing an adenovirus carrying mda-7 (INGN 241) that is already in phase-I and -II 
clinical trials in patients with multiple solid tumors (none of which is of prostate origin) in 
treating PC cells [203]. In vivo studies involving the use of immune-deficient and immune-
competent PC mice models are required. Thus, we studied the capacity of human Ad.mda-7/IL-
24 to infect mouse PC cells (TRAMP-C2) derived from immune-competent mice and compared 
it to human PC (DU145). We also studied the effect of Ad.mda-7/IL-24 to increase the apoptotic 
rate of TRAMP-C2 and DU145 prostate cancer cells following mda-7 gene transfer. Lastly, we 
tested US guided MB assisted gene delivery of reporter Ad.GFP in both murine and human PC.   
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MATERIALS AND METHODS 
Cell Lines and Cell Culture 
The DU145 (human prostate adenocarcinoma), TRAMP-C2 (mice prostate 
adenocarcinoma) and human kidney embryonic 293 cell lines were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD). DU145 cells were grown in RPMI 1640 
(Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, 
Waltham, MA), and 100 units/mL penicillin supplemented with 1 mg/mL streptomycin (both 
from Hyclone, Waltham, MA). The 293 cells were grown with Dulbecco’s modified Eagle’s 
medium (Hyclone, Waltham, MA) supplemented with 10% FBS (Hyclone, Waltham, MA). 
TRAMP-C2 cells were grown with Dulbecco’s modified Eagle’s medium (Hyclone, Waltham, 
MA) supplemented with 5% FBS (Hyclone, Waltham, MA), and 100 units/mL penicillin 
supplemented with 1 mg/mL streptomycin (both from Hyclone, Waltham, MA). All cells were 
grown at 37ᴼC, in a 5% CO2/95% atmosphere incubator. 
 
Cytological Observations 
 The cells were examined under an inverted Olympus IX70 microscope (Olympus 
America, Inc. Melville, NY). Fluorescence images were captured with Sensicam QE camera 
(Cooke Co., Auburn Hills, MI) and managed with the SlideBook 3.0 software (Intelligent 
Imaging Innovations Inc., Denver, CO). 
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Adenoviral Production and Purification 
 Ad-GFP, which expresses the green fluorescence protein gene under the strong 
cytomegalovirus (CMV) constitutive promoter was generated using the AdEasy system 
(Carlsbad, CA); the conditionally replication competent cancer terminator virus CTV.Mda-7 
(Ad.PEG-E1A-mda-7) [18, 204, 205] and Ad.mda-7 [206] were amplified and purified with the 
BD Adeno-X virus purification kit (BD Biosciences, Mountain View, CA) following 
manufacturer’s directions. Viral titers were determined by a plaque assay and the titer was 
adjusted to 1.2x1012 plaque-forming units (pfu)/mL as described [206]. CTV.Mda-7 (Ad.PEG-
E1A-mda-7) and Ad.mda-7/IL-24 were provided by Dr. Paul Fisher (Virginia Commonwealth 
University, Richmond VA). Each viral stock was propagated and purified from 293 cell cultures. 
Cells were harvested 24-36 hours after infection, pelleted and re-suspended in heat-inactivated 
media. 293 cells were lysed by a three-freeze/thaw cycle method. Cell debris was removed. 
Viruses were purified by chromatography followed by dialysis. Viruses are aliquoted and stored 
at -80°C. Viral titers were determined by a plaque assay. Ad transductions were performed using 
10, 25, 50 MOI Ads, in RPMI-1640 media with 2% Fetaclone-III heat-inactivated FBS 
(Hyclone, Thermo Scientific, Waltham, MA) and in with DMEM media with 2% Fetaclone-III 
heat-inactivated FBS (Hyclone, Thermo Scientific, Waltham, MA). Cells were collected after 
24- or 48-hours.  
 
Viral Burst Assay 
 HEK 293 cells were used as control. HEK 293 cells, DU145 cells, TRAMP-C2 cells were 
infected with replicative HAdV (CTV.Mda-7) at 100 pfu/mL and 1,000 pfu/mL. Filtered 
transfection supernatants and viral particles present in the cells were collected at both 24 and 48 
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hours post-transfection. Cells were harvested 24- and 48- hours after infection, pelleted and re-
suspended in heat-inactivated media. 293 cells were lysed by a three-freeze/thaw cycle method. 
Cell debris was removed. Viruses are aliquoted and stored at -80ᴼC. The collective viral particles 
were tittered and determined by a plaque assay. 
 
Antibodies 
 The following primary antibodies were used in Western Blot studies: mouse monoclonal 
anti-Mda-7/IL-24 k101 (GenHunter Corporation) (1:2,000 incubation for overnight), GFP 
cat#632377 (1:500) (BD Bioscience) and β-actin cat#A3853 (1:1,500) (Sigma Aldrich) as a 
control. The following are used in the flow cytometry studies: Rabbit Anti-Coxsackie 
Adenovirus Receptor Polyclonal Antibody, Alexa Fluor® 488 Conjugated bs-2389R-A488, 
Rabbit Anti-Integrin Alpha V + Beta 5 Polyclonal Antibody, Alexa Fluor® 647 Conjugated bs-
1356R-A647 and Rabbit Anti-Integrin Alpha V + Beta 3 (CD51+CD61) Polyclonal Antibody, 
Alexa Fluor® 488 Conjugated bs-1310R-A488 from Bioss Inc. 
 
Western Blot Analysis 
 DU145 and TRAMP-C2 cells were transduced with 10, 25, 50 multiplicity of infection 
(MOI) of Ad.GFP and Ad.mda-7. Western blot analysis was conducted as previously described 
[53]. Cells were lysed on ice for 1hr with lysis buffer. Fifty μg of total protein plus loading 
buffer were loaded in each well for western blot analyses. SDS-PAGE was run using 8-12% bis-
acrylamide gel at room temperature. Samples were blotted onto a nitrocellulose membrane. To 
detect proteins the membranes was blocked with 5%Milk-TBST overnight at 4ᴼC and reacted to 
primary antibodies for 2hr at room temperature with constant motion on an orbital shaker. The 
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membranes were washed with TBST to remove excess primary antibodies. Incubation for 45 
minutes with appropriate secondary antibodies followed. Immunodetection was performed using 
the enhanced chemiluminescence (ECL) system (Amersham, IL) according to the manufacturer’s 
instructions. Western blot analyses with antibodies against the targeted proteins were performed 
to validate successful viral transfection of the cells.  
  
Flow Cytometry Assay 
 DU145 and TRAMP-C2 cells were checked for different surface Ad receptors such as 
CAR (coxsackie adenovirus receptor) and integrins αVβ3/5. Each was compared against IgG 
control. 10µL of Boss primary conjugated antibody was added for 30 mins at  4ᴼC, aashed 
several times with 2mL 1X PBS and resuspended in 100µL of 1X PBS. Samples were analyzed 
on BD Accuri C6 Flow Cytometery. 
  Adenoviral transduced DU145 and TRAMP-C2 cells were trypsinized and collected. 
Cells were centrifuged at 5000 rpm, washed and suspended in 1% FCS-PBS. This step was 
repeated three times. Samples were prepared and run by a BD Accuri C6 Flow Cytometer (BD 
Bioscience, San Jose, CA). Single cells population was gated and an FL1 & FL4 area histogram 
was drawn and formatted to show only the events inside the single cell region. 
 
Annexin-V Assay 
 Apoptotic cells were analyzed with fluorescein isothiocyanate (FITC) conjugated to 
Annexin-V antibody and Propidium Iodide (PI) from the Annexin-V/FITC Kit (Bender 
MedSystems, Burlingame, CA) following manufacturer's instructions. Cells were trypsinized and 
washed with PBS. Cells were centrifuged and re-suspended in binding buffer. The samples were 
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analyzed with BD Accuri C6 Flow Cytometer (BD Bioscience, San Jose, CA). Annexin-V assay 
experiment was repeated three times and was run as triplicate of technical repeats. Statistical 
analysis was performed with GraphPad Prism 6 statistical software. 
 
UTMD for Prostate Cancer Cells. 
 Human DU145 and murine TRAMP-C2 prostate cancer cells were grown in both Fetal 
Bovine Serum (FBS) rich media and Heat-inactivated FBS media. Targeson (Targeson, Inc. San 
Diego, CA) custom synthesis US contrast agent (perfluorocarbon microbubbles, encapsulated by 
a lipid monolayer and polyethylene glycol stabilizer) were prepared following manufacturer’s 
instructions [53]. Cells were infected with Ad.GFP with 10MOI or with Ad.GFP complexed with 
microbubbles (Targeson) at 10MOI. US exposure was achieved with a Micro-Maxx SonoSite 
(SonoSite, Bothell, WA) US machine equipped with the transducer L25 set at 0.7 Mechanical 
Index (MI), 1.8 MPa for 1 min [53].   
 
Statistical Analysis 
 Statistical analysis was performed using the GraphPad Prism 6 statistical software. 
Comparison of cell death by Annexin-V on adenoviral transduced groups was conducted using 
an ANOVA test with post hoc test Tukey’s multiple comparison test. P-values of less than 0.05 
were considered statistically significant.  
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RESULTS 
Cytological Observations after Adenoviral Gene Transfer 
 The murine TRAMP-C2 and human DU145 prostate cancer cells were transduced with 
an Ad carrying the green fluorescence protein (GFP) (Ad.GFP) (Fig.15) with increasing doses of 
10, 25 and 50 MOI (multiplicity of infection). TRAMP-C2 cells and DU145 cells infected with 
various doses of Ad.GFP showed a dose dependent increase of fluorescence. However, DU145 
cells showed a higher transduction of GFP in comparison to TRAMP-C2 cells at each 
multiplicity of infection.  
 
 
Figure 15. Fluorescence microscopy images of Ad.GFP (10, 25, 50 MOI) transduced TRAMP-
C2 and DU145 cells. We effectively infected TRAMP-C2 cells with Ad.GFP and observed a 
dose-dependent expression of GFP, which was correlated to the increasing amount of Adenoviral 
MOI used.   
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Quantification of the Ad.GFP Viral Uptake 
 Ad.GFP uptake was determined for murine TRAMP-C2 and human DU145 prostate 
cancer cells by using FACS analysis after infecting the cells with 10, 25 and 50 MOI. A 
discrepancy is observed for TRAMP-C2 cells when infected with 10MOI, showing only a 90% 
uptake of Ad.GFP. A dose dependent increase in uptake of Ad.GFP is observed in TRAMP-C2 
cells as the MOI is increased. DU145 cells on the contrary showed a 100% uptake regardless of 
MOI (Fig. 16).    
 
Figure 16. In vitro assessment of Ad.GFP uptake in murine and human carcinoma cell lines. 
Cells were infected at 10, 25 and 50 particles/cells (ppc) of Ad.GFP and harvested at 24 hours 
post-infection to determine the infectivity by FACS analysis.   
 
Quantification of Ad Receptors Present on the Surface of the Cells 
 Surface Ad receptors were determined by Accuri C6 flow cytometry for the percentage of 
expression of Coxsackie Adenovirus Receptor (CAR), integrin αVβ5 and αVβ3 that are known 
to be responsible for the attachment of Ad5 to mammalian cells (Table 2). Both human DU145 
and murine prostate cancer cells showed a similar expression profile for CAR and integrins 
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αVβ3/5. 
Table 2. Determination of the expression of surface Adenoviral receptors by flow cytometry. 
 
 
 
 
 
Verification of Protein Expression by Western Blots 
 The TRAMP-C2 cell line is generated from prostate tumors harvested from a 32-week 
TRAMP mouse.  We carried out infection studies with Ad5 carrying mda-7 or GFP at different 
multiplicities of infection (MOI). Figure 17 shows dose dependent expression of GFP and mda-7 
protein by western blot analysis (Fig. 17). The results show that we effectively transferred to 
murine PC cells a transgene (GFP or mda-7) with Ad5 viruses.  
 
Figure 17. Western blot analysis of TRAMP-C2 and DU145 cells infected with different MOIs 
of Ad.GFP or Ad.mda-7/IL-24. Cell lysates were run on SDS-PAGE and reacted with 
appropriate specific primary and secondary HRP-conjugated antibodies.  Beta actin was used as 
a loading control. 
Cells CAR αVβ5 αVβ3 
DU145 90.08±1.71 95.98±0.17 28.58±1.13 
TRAMP-C2 96.60±0.22 93.9±1.38 32.70±1.97 
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Viral Burst Assay to Assess the Capacity of Replicative HAd5 to Produce Viral Particles 
 The control HEK 293 embryonic kidney cells and human DU145 prostate cancer cells 
showed an increase in viral count at both 24 and 48 hours post infection of 100 pfu/mL and 
1,000 pfu/mL replicative competent HAd5 (CTV). Thus, DU145 and HEK 293 are permissive 
for the replication of HAd5 and would make good animal models for testing the replicative and 
transfection ability of HAd5. However, TRAMP-C2 cells showed a decrease in viral count from 
24 to 48 hours for both pfu of HAd5 indicating a lack of viral replication (Fig. 18). Thus 
TRAMP-C2 cells are non-permissive for replication of HAd5 and would make a good animal 
model only for the transfection ability of HAd5. 
 
Figure 18.  Subconfluent murine and human cell lines were infected with replicative competent 
HAdV at 100 pfu/mL and 1,000 pfu/mL and harvested 24- and 48-hours later.   
 
Annexin-V Staining for Cell Death 
 The apoptotic rate of the transduced cells was quantified by assessing Annexin-V 
expression. The analyzed cells were allocated in a quadrant diagram according to their DNA 
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content and the presence of Annexin-V on the extracellular cell membrane during apoptosis. 
Statistical analysis was run on Annexin-V triplicates using Graphpad Prism 6 software for an 
ANOVA on dead cells with a post hoc test of Tukey’s multiple comparison test (Fig. 19 and 
Table 3). TRAMP-C2 and DU145 cells were undergoing apoptosis and necrosis, collectively 
called as dead cells. Non-transduced cells were compared to Ad.mda-7/IL-24 transduced cells. 
Mean and standard deviation from Annexin-V experiment was calculated for each adenoviral 
treated group. There was an increase in the significance and percentage of cell death that was 
concentration dependent compared to the control. A significant percentage of cell death for 
TRAMP-C2 cells infected with 50MOI was observed in comparison to 10MOI of Ads (Fig. 19 
and Table 3). Cell death observed for TRAMP-C2 cells infected with 10MOI and 25MOI did not 
show any significant difference in comparison to DU145 cells infected with 10MOI. However, 
overall DU145 cells showed more cell death with Ad.mda-7 at 25MOI and 50MOI in 
comparison to TRAMP-C2 cells infected with the same MOI.   
 
Figure 19. Annexin-V/PI staining of TRAMP-C2 and DU145 cells infected with Ad.mda-7/IL-
24.  TRAMP-C2 cells were transduced with Ad.mda-7/IL-24 at 10, 25 & 50 multiplicity of 
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infection (MOI) and harvested at 96 hours post infection and determined by FACS analysis. Bar 
graph represents sum of apoptotic and necrotic cells. 
 
Table 3. ANOVA (Analysis of Variance) significance table with a Post Hoc Tukey’s multiple 
comparison test for Annexin-V assay between TRAMP-C2 and DU145 cells transduced with 
Ad.mda-7/IL-24. * The mean difference is significant at the 0.05 level. 
Comparison between groups Significant? 
TRAMP-C2:Control TRAMP-C2:10MOI Yes 
TRAMP-C2:Control TRAMP-C2:25MOI Yes 
TRAMP-C2:Control TRAMP-C2:50MOI Yes 
TRAMP-C2:Control DU145:Control No 
TRAMP-C2:Control DU145:10MOI Yes 
TRAMP-C2:Control DU145:25MOI Yes 
TRAMP-C2:Control DU145:50MOI Yes 
TRAMP-C2:10MOI TRAMP-C2:25MOI Yes 
TRAMP-C2:10MOI TRAMP-C2:50MOI Yes 
TRAMP-C2:10MOI DU145:Control Yes 
TRAMP-C2:10MOI DU145:10MOI No 
TRAMP-C2:10MOI DU145:25MOI Yes 
TRAMP-C2:10MOI DU145:50MOI Yes 
TRAMP-C2:25MOI TRAMP-C2:50MOI Yes 
TRAMP-C2:25MOI DU145:Control Yes 
TRAMP-C2:25MOI DU145:10MOI No 
TRAMP-C2:25MOI DU145:25MOI Yes 
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TRAMP-C2:25MOI DU145:50MOI Yes 
TRAMP-C2:50MOI DU145:Control Yes 
TRAMP-C2:50MOI DU145:10MOI Yes 
TRAMP-C2:50MOI DU145:25MOI No 
TRAMP-C2:50MOI DU145:50MOI Yes 
DU145:Control DU145:10MOI Yes 
DU145:Control DU145:25MOI Yes 
DU145:Control DU145:50MOI Yes 
DU145:10MOI DU145:25MOI Yes 
DU145:10MOI DU145:50MOI Yes 
DU145:25MOI DU145:50MOI Yes 
 
UTMD for Prostate Cancer Cells. 
 Human DU145 and murine prostate cancer cells were infected either with Ad.GFP or 
complexed Ad.GFP/MB at 10MOI and after 24hours images were taken with fluorescent 
microscopy. US application increased the expression of GFP in comparison to the control or 
Ad.GFP alone group for both DU145 and TRAMP-C2 cells (Fig. 20 and 22). US also allowed 
for the transfection of Ad.GFP in complement rich FBS media for both DU145 and TRAMP-C2 
cells (Fig. 20 and 22).  
 MBs also facilitated the transfection of Ad.GFP in both FBS rich and Heat Inactivated-
complement depleted FBS media (Fig. 21 and 23). Transfection increased further when Ad.GFP 
was complexed with a MB (Ad.GFP/MBs) and US was applied to both DU145 and TRAMP-C2 
cells (Fig. 21 and 23). Similar GFP expression was observed for DU145 when complexed 
Ad.GFP/MBs were incubated with FBS and US was applied regardless of media being used (Fig. 
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21) because FBS contains a complement, which binds to the free Ads on the surface of the 
bubble thereby inactivating the Ads. Similar observation was also recorded for TRAMP-C2 cells 
(Fig. 23). Lastly, unclean complexed Ad.GFP/MBs showed similar GFP expression compared to 
cleaned (FBS incubated) complexed Ad.GFP/MBs in complement rich FBS media (Regular 
media). Highest transfection was observed for DU145 cells that received the unclean (FBS 
untreated) Ad.GFP/MBs and US (Fig. 21).        
 
Figure 20. DU145 cells infected with Ad.GFP at 10MOI and Ultrasound application. 
*Flo:Florescence, HI:heat inactivated, US: Ultrasound, Regular media: contains fetal bovine 
serum (FBS). 
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Figure 21. DU145 Cells infected with Ad.GFP/MBs at 10MOI and Ultrasound application. In 
second column MBs rehydrated with PBS was added separately with Ad.GFP at 10MOI. In the 
third column Ad.GFP/MBs were complexed but not cleaned with FBS before adding it to the 
cells. In the fourth column Ad.GFP/MBs were complexed and cleaned with FBS before adding it 
to the cells.  *Flo:Florescence, HI:heat inactivated, US:Ultrasound, Regular media: contains fetal 
bovine serum (FBS).
 
Figure 22. TRAMP-C2 cells infected with Ad.GFP at 10MOI and Ultrasound application. 
69 
*Flo:Florescence, HI:heat inactivated, US: Ultrasound, , Regular media: contains fetal bovine 
serum (FBS). 
  
Figure 23. TRAMP-C2 cells infected with Ad.GFP/MBs at 10MOI and Ultrasound application. 
In second column MBs rehydrated with PBS was added separately with Ad.GFP at 10MOI. In 
the third column Ad.GFP/MBs were complexed but not cleaned with FBS before adding it to the 
cells. In the fourth column Ad.GFP/MBs were complexed and cleaned with FBS before adding it 
to the cells.  *Flo:Florescence, HI:heat inactivated, US: Ultrasound, Regular media: contains 
fetal bovine serum (FBS). 
.  
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DISCUSSION 
 There are many obstacles to successful virotherapy that have become apparent from 
clinical studies, including problems associated with the use of replicating human Ads that are 
species-specific as the non-human (animal) model systems rarely predict the outcome seen in 
humans. For example, human tumor xenografts in nude mice can provide a ‘permissive’ 
preclinical model for Ads but nude mice are by definition immune-compromised [190], thus the 
immune responses due to Ads cannot be fully studied in this pre-clinical model. Additionally, 
due to species specificity, Ads do not replicate in normal mouse tissues thereby preventing any 
relevant off-target effects in such systems. Lastly, immune-compromised mice have a deficient 
immune system thus making it difficult to observe the effects of immune modulatory viruses 
[56], thus more suitable animal models need to be selected for the desired effect to be observed. 
 In this study, the ability of both replicating (CTV.mda-7) and non-replicating (Ad.GFP 
and Ad.mda-7/IL-24) human Ad5 was tested by infecting human DU145 and murine prostate 
cancer cells. The goal of this study was to tested if human DU145 PC cells that are radio-
resistant, androgen receptor ablated, p53 mutated cells and isolated from a brain metastasis 
would make a good pre-clinical model for the use of microbubble assisted gene delivery with 
US. This delivery system has several components that needed to be test to ensure successful 
translation from bench to bedside. The infection studies on DU145 cells with Ad.GFP, Ad.mda-7 
and CTV.mda-7 showed successful transduction with different MOI of replication permissive 
HAd5 and demonstrated a therapeutic response to gene therapy with mda-7. Lastly, US greatly 
enhanced the transgene expression of GFP when delivered with complexed Ad.GFP/MBs 
regardless of the presence of FBS, thus ensuring a proper penetration of the encapsulated Ads 
into the cell. FBS acted as a complement protein system inactivating the Ads from infecting 
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DU145 cells. US and MBs cause temporary pore formation on the plasma membranes and 
increase the permeability of the membrane to allow an increased Ad uptake. These factors make 
DU145 xenograts an attractive immune-compromised animal model to test the delivery of 
microbubble assisted gene delivery with US.   
 Similarly, TRAMP-C2 PC cells that are radio-resistant, possessing wild-type (wt) p53, 
isolated from 32-week old C57BL6 immune-competent mice with poorly differentiated prostate 
carcinoma were tested for the delivery of MB assisted gene therapy with US to verify if they 
would make a good pre-clinical immune-competent model. Similar results to DU145 studies 
were observed using TRAMP-C2 cells except that infection studies using TRAMP-C2 cells 
showed a reduced GFP expression in comparison to the transfected DU145 cells. However, a 
dose dependent increase in transgene expression was observed as the MOI were increased. The 
transgene expression could not be explained by the Ads surface receptor expression in TRAMP-
C2 cells, as they are similar to DU145. Also, a reduced therapeutic response was observed for 
Ad.mda-7 transfected cells in comparison to DU145 cells, however still statistically significant in 
comparison to the control. Thus, murine immune-competent TRAMP-C2 prostate cells that can 
be syngeneically implanted into immune-competent C57BL6 would make an attractive model to 
study the immune-modulating, immune-responses due to the Ads and the therapeutic benefit of 
microbubble assisted US guided gene transfer. Additionally, the TRAMP mouse model of 
prostate cancer can be used to demonstrate the validity of UTMD mda-7 gene delivery approach 
in immune competent animals. 
 Successful completion of the immune competent animal studies will open the possibility 
to translate from the bench to the bedside the targeted mda-7 gene delivery method by 
performing clinical studies on metastatic prostate cancer patients.         
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CHAPTER IV: ERADICATION OF THERAPY-RESISTANT HUMAN PROSTATE 
TUMORS USING AN ULTRASOUND-GUIDED SITE-SPECIFIC CANCER 
TERMINATOR VIRUS DELIVERY APPROACH 
This is a revised version of a manuscript published in Molecular Therapy (2010) 295-306. 
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ABSTRACT 
 Intratumoral injections of a replication-incompetent adenovirus (Ad) expressing 
melanoma differentiation–associated gene-7/interleukin-24 (Ad.mda-7), a secreted cytokine 
displaying cancer-selective, apoptosis-inducing properties, profoundly inhibits prostate cancer 
(PC) growth in immune-incompetent animals. In contrast, Ad.mda-7 is ineffective in PCs 
overexpressing antiapoptotic proteins such as Bcl-2 or Bcl-xL. However, intratumoral injections 
of a conditionally replication-competent Ad (CRCA) in which expression of the adenoviral E1A 
gene is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and 
which simultaneously expresses mda-7/interleukin (IL)-24 in the E3 region of the Ad (Ad.PEG-
E1A-mda-7), a cancer terminator virus (CTV), is highly active in these cells. A major challenge 
for gene therapy is systemic delivery of nucleic acids directly into an affected tissue. Ultrasound 
(US) contrast agents (microbubbles—MBs) are viable candidates for gene delivery/therapy. 
Here, we show that MB/Ad.mda-7 complexes targeted to DU145 cells using US dramatically 
reduced tumor burden in xenografted nude mice. Additionally, US-guided MB/CTV delivery 
completely eradicated not only targeted DU145/Bcl-xL-therapy-resistant tumors, but also 
nontargeted distant tumors (established in the opposite flank), thereby implementing a cure. 
These findings highlight potential therapeutic applications of this novel image-guided gene 
therapy technology for advanced PC patients with metastatic disease. 
 
Key Words: CTV; mda-7/IL-24; bystander anti-tumor activity; systemic targeted viral gene 
delivery; apoptosis induction 
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INTRODUCTION 
 Prostate cancer (PC) is the most common cancer and the second leading cause of cancer-
related deaths in men in the United States [1].  At present, no effective therapy is available for 
metastatic PC [207]. Advanced PC is refractory to conventional anticancer treatments because of 
frequent overexpression of antiapoptotic proteins Bcl-2 and/or Bcl-xL [208, 209]. The 
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), is a secreted cytokine 
having broad-spectrum, cancer-selective, apoptosis-inducing properties that profoundly inhibits 
prostate cancer cell growth [210]. Adenovirus (Ad)-mediated delivery of mda-7/IL-24 (Ad.mda-
7) has shown dramatic anti-tumor effects in animal models and in clinical trials [195, 196, 211, 
212].  However, forced overexpression of Bcl-2 or Bcl-xL renders prostate cancer cells resistant 
to Ad.mda-7 [209].  In contrast, a conditionally replication-competent adenovirus (CRCA) (a 
cancer terminator virus- CTV), which expresses mda-7/IL-24 (Ad.PEG-E1A-mda-7) can 
abrogate acquired resistance of prostate cancer cells mediated through Bcl-2 and/or Bcl-xL 
overexpresion causing growth arrest and apoptosis and selectively replicating in prostate cancer 
xenografted cells in athymic nude mice. Moreover, the CTV completely eradicates not only 
primary tumors but also distant tumors following repeated intratumoral injections into the 
primary tumor site [18, 213].   
 A major challenge for effective gene therapy is the ability to specifically deliver nucleic 
acids and potentially toxic gene products directly into diseased tissue. Progress in gene therapy 
has been hampered by concerns over the safety and practicality of viral vectors, particularly for 
intravenous delivery, and the inefficiency of currently available non-viral transfection techniques 
[214]. Viruses are appealing delivery vectors because of their ability to efficiently transfer genes 
with sustained and robust expression. Recombinant Ads are one of the most common gene 
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transfer vectors utilized in human clinical trials, but systemic administration of this virus is 
thwarted by host innate and adaptive antiviral immune responses which can limit and/or preclude 
repetitive treatment regiments [215].   
 The quest for novel, safe and more efficient systemic gene delivery systems has recently 
highlighted ultrasound (US) contrast agents (microbubbles) as a potential candidate for 
enhancing delivery of molecules to target tissue [136, 216-218].  Currently used US contrast 
agents (microbubbles) contain high-molecular weight gasses with less solubility and diffusivity, 
which improves microbubble persistence and allows passage through the microcirculation. 
Microbubbles (MB) can be injected in peripheral veins, because the more robust bubbles can re-
circulate through the systemic circulation numerous times, surviving for several minutes within 
the bloodstream [218, 219]. The ideal MB diameter most likely is between 2.5 to 4 µm. MB is 
small enough to prevent entrapment within the pulmonary capillary bed (ranging from 5 to 8 µm 
in diameter), but big enough to entrap and protect viral vectors such as Ad from the environment. 
 We previously demonstrated the feasibility of site-specific gene delivery mediated by 
diagnostic US using Ad-GFP encapsulated in commercially available US contrast agents in vitro 
and in vivo [214]. An additional goal of our previous study was to determine if incubation of the 
microbubbles with complement could improve specificity of viral transgene transduction to the 
target tissue/organ allowing a simplified approach to encapsulation of the viral vectors with 
commercially available contrast agents. In the current investigation we tested a US contrast agent 
provided by Targeson, Inc (San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound 
platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear array transducer. Targeson’s 
agents are lipid-encapsulated perfluorocarbon microbubbles with a mean diameter of 2.5 µm that 
can be used in a wide variety of animal models, and are compatible with virtually all ultrasound 
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scanners. The gas-filled microspheres effectively lower the energy threshold for non-thermal 
cavitation, thus allowing diagnostic transducers operating within the energy levels mandated by 
the FDA to be used for drug/gene delivery. Ultrasound-targeted microbubble destruction 
(UTMD) enables focal release of entrapped materials as well as the creation of small shock 
waves that increase cellular permeability [220]. In addition, the microbubbles protect the viruses 
from rapid degradation by the immune system, thus allowing for intravenous (IV) injection 
rather than direct target organ delivery by catheter-based approaches or operative bed injection 
[214, 218]. The IV injection is particularly important in cancer gene therapy of potentially 
inaccessible tumors because the microbubbles may also limit the amount of inflammatory 
response to the viruses and may allow repeated injections.  
 The ultimate goal of our research programs is to develop efficacious therapies for cancer. 
A primary focus is to engineer effective and safe delivery systems for viruses, chemotherapeutic 
agents and small molecule drugs. In the present study, we provide proof-of-principle for two 
essential components of this process, a site-specific gene delivery approach mediated by 
diagnostic US generated by a portable platform that works efficiently in vivo in combination with 
Ads delivering a highly effective, broad-based cancer gene therapeutic mda-7/IL-24. Evidence is 
provided that this combination has profound effects in animal models containing therapy-
resistant human prostate cancer cells.  
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MATERIALS AND METHODS 
Cell Lines, Cell Culture and Adenovirus Production 
 The DU145 (human prostate adenocarcinoma), cell line was obtained from the American 
Type Culture Collection (ATCC, Rockville, MD) and the DU-Bcl-xL cell line, which 
constitutively expresses elevated levels of Bcl-xL has been described previously [209]. The cell 
lines were grown at 37 °C, in a 5% CO2/95% atmosphere, in Dulbecco’s modified Eagle’s 
medium (Mediatech Inc., Herndon, VA) supplemented with 10% fetal bovine serum (FBS) from 
Hyclone, Inc., (Logan, UT). Ad-GFP, which expresses the green fluorescence protein gene under 
the strong cytomegalovirus (CMV) constitutive promoter was generated using the AdEasy 
system (Carlsbad, CA); the conditionally replication competent cancer terminator virus CTV 
(Ad.PEG-E1A-mda-7) [18, 204, 205] and Ad.mda-7 [206] were amplified and purified with the 
BD Adeno-X virus purification kit (BD Biosciences, Mountain View, CA) following 
manufacturer’s directions. Viral titers were determined by a plaque assay and the titer was 
adjusted to 1.2x1012 plaque-forming units (pfu)/mL as described [206].   
 
Preparation of Microbubbles and Ultrasound Platform 
 Targeson (Targeson, Inc. San Diego, CA) custom synthesis US contrast agent 
(perfluorocarbon microbubbles, encapsulated by a lipid monolayer and polyethylene glycol 
stabilizer) were prepared following manufacturer’s instructions. Microbubbles were reconstituted 
in the presence or absence of 1 mL of 1.2x1012 pfu of Ads and unenclosed, surface associated 
Ads were inactivated as previously described [214]. For in vivo experiments US exposure was 
achieved with a Micro-Maxx SonoSite (SonoSite, Bothell, WA) US machine equipped with the 
transducer L25 set at 0.7 Mechanical Index (MI), 1.8 MPa for 10 min.   
79 
Antibodies and Western Blot Analysis 
 DU145 cells were transduced with 50 MOI of Ad.mda-7 or Ad-CMV as a control and 24 
or 48-hr post transduction 50 µg of total cell extracts were subjected to Western blot analysis 
using a mouse monoclonal anti-MDA-7/IL-24 (GenHunter, Inc, Nashville, TN) (1:2,000 
incubation for 1 hr) or the mouse monoclonal anti-GAPDH sc-0411 (1:5,000 incubation for 1 hr) 
(SantaCruz, Santa Cruz, CA), as control. Western blot analysis was also conducted on protein 
extracts from microbubble/US assisted in vivo transfer of Ad-GFP or mda-7/IL-24 using 
antibodies that specifically recognized GFP sc-53882 (SantaCruz, Santa Cruz, CA), MDA-7/IL-
24 (GenHunter, Nashville, TN), and β-actin sc-47778 (SantaCruz, Santa Cruz, CA). Briefly, 96 
hr following targeted microbubble/US assisted in vivo transfer of Ad-GFP, mice were sacrificed 
and fresh tumor (right and left flank), heart, lung, liver, and kidney tissues were harvested and 
snap frozen in liquid nitrogen. Mice receiving mda-7/IL-24 gene-microbubble US guided therapy 
were sacrificed at the endpoint of the study (5-6 wks after gene therapy injections). Tissues were 
homogenized and equal amounts of proteins were run on a SDS-PAGE and transferred to a 
nitrocellulose membrane. The membrane was then incubated with the monoclonal anti-GFP 
1:2,000 for 1 hr at room temperature and then washed three times in TBS-T. Monoclonal anti-
MDA-7/IL-24 (GenHunter, Inc, Nashville, TN) was incubated 1:2,000 for 1 hr at room 
temperature and then washed three times in TBST. Monoclonal anti β-actin (1:5,000) was 
incubated 1 hr at room temperature and then washed three times in TBST. Appropriate 
secondary HRP-conjugated antibodies 1:20,000 were incubated 45 min at room temperature and 
washed three times with TBS-T. Signals were developed on an X-ray film after reaction with an 
Electrogenerated Chemiluminescence (ECL) Supersignal kit (Pierce, Rockford, IL). 
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Animal Study and Ultrasonic Bubble Destruction 
 Animal studies were performed in accordance with NIH recommendations and the 
approval of the institutional animal research committee. Animal care and humane use and 
treatment of mice were in strict compliance with (1) institutional guidelines, (2) the Guide for the 
Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC, 1996), 
and (3) the Association for Assessment and Accreditation of Laboratory Animal Care 
International (Rockville, MD, 1997). All the animals used in these studies were 8- to 12-week-
old female/male congenitally athymic BALB/c nude mice, homozygous for the nu/nu allele, bred 
in our laboratory. The colony of the mice was developed from breeding stock obtained from 
Charles Rivers Laboratories, Wilmington, MA. The mice were maintained in isolation in 
autoclaved cages with polyester fiber filter covers, under germ-free conditions; all food, water, 
and bedding were sterilized. A total of about 420 nude mice (n=10 each experimental point) were 
implanted with the human prostate adenocarcinoma cell lines (DU145 or DU-Bcl-xL) as a 
xenograft model (injecting 1.5 X 106 or 2.5 x 106 cancer cells on each flank of the animal). After 
~30-days, mice were sedated in an IMPAQ6 anesthesia apparatus (VetEquip Inc, Pleasanton, 
CA) that was saturated with 3-5% Isofluorane and 10-15% oxygen with the aid of a precision 
vaporizer (VetEquip Inc, Pleasanton, CA) to deliver the appropriate amount of anesthetic and to 
induce anesthesia. The mice were placed on a warmed mat with 37°C circulating water for the 
entire procedure. A27-gauge needle with a heparin lock was placed within a lateral tail vein for 
administration of contrast material. The nude mice received injections of 100 µL of 
microbubbles with/without Ads through the tail vein for 5 wks/once a wk. The mice were split 
into two control groups (one control group receiving 100 µL of microbubbles and US, and 
another control group receiving both microbubbles/Ad-GFP and US) and eight active groups of 
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10 mice each (all receiving microbubbles and Ad.mda-7 or CTV and US). Six additional control 
groups were set up which received direct i.v. injections of 100µL of the Ads (Ad-GFP, Ad.mda-
7/IL-24, or CTV) in the presence or not of US. Grayscale US imaging was performed with a 
SonoSite scanner (SonoSite, Bothell, WA) equipped with the transducer L25 set at 0.7 
Mechanical Index (MI), 1.8 MPa for 10 min. Ultrasound images were recorded as digital clips.  
In every experiment, 10 animals for each treatment or control group were used to study tumor 
regression. Every experiment was repeated at least twice. Tumor volumes were determined by 
measuring the tumors twice a wk with either a caliper or by ultrasound measurements of the 
tumor axes. Tumor volumes were determined using the following formula: V = (π / 8) a Χ b2, 
where V is the tumor volume, a is the maximum tumor diameter, and b is the diameter at 90° to 
a [221]. The mice were humanely sacrificed by placing them in a CO2 gas jar placed in a 
ventilated fume hood. The tumors (right and left flank), heart, lungs, kidneys, and liver were 
harvested. Tissues to be sectioned were dry snap frozen or placed either in OCT (Sakura Finetek 
USA, Inc., Torrance, CA), frozen in liquid nitrogen, and stored at -80°C or were preserved in 
neutral buffered formalin at 4°C prior to embedding in paraffin for immunohistochemical 
analysis. 
Statistical Analysis 
 All statistical analyses were performed by using SAS version 9.1. Comparisons of tumor 
volumes were done separately three times: before the treatment, two weeks after the treatment, 
and at the end of the study. Statistical analyses for comparisons of different types of treatments 
were done using one-way ANOVA followed by Tukey-Kramer multiple adjusted pair wise tests. 
P-value < 0.05 was considered significant.  
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RESULTS 
Targeson Microbubbles and a SonoSite Portable Micro-Maxx Ultrasound (US) Platform 
Efficiently Targets Ad-GFP Viruses to Tumors 
 We previously documented the feasibility of in vivo gene delivery mediated by diagnostic 
US using Ad-GFP encapsulated in a series of commercially available US contrast agents [214]. 
In the current investigation, we tested a different US contrast agent available from Targeson, Inc 
(San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound platform (SonoSite, Inc., 
Bothell, WA) equipped with a L25 linear array transducer. Targeson’s agents are lipid-
encapsulated perfluorocarbon microbubbles with a mean diameter of 2.5 µm that can be used in 
a wide variety of animal models, and are compatible with virtually all ultrasound scanners [222].  
Targeson agents are normally sold as already reconstituted contrast agents that are stable for 
three months from arrival, and for this study we obtained a custom made freeze-dried Targeson 
contrast agent (perfluorocarbon microbubbles, encapsulated by a lipid monolayer and 
polyethylene glycol stabilizer) to be reconstituted with the viruses as previously described [214]. 
 To confirm the ability of the lyophilized Targeson US contrast agent to deliver viruses 
efficiently and specifically to defined sites in vivo, we performed a pilot study in which tumor 
xenografts were established in both flanks of athymic nude mice by injecting each site with 2 x 
106 DU145 human prostate carcinoma cells (Figure 24A). The DU145 tumor-bearing nude mice 
(n=10) were then injected in their tail vein with 100 µL of US contrast agent that was 
reconstituted with Ad-GFP or water as control. A portable SonoSite Micro-Maxx ultrasound 
platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear array transducer set at 0.7 
Mechanical Index (MI), 1.8 MPa for 10 min was used to sonoporate only the tumor implanted on 
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the right side (Figure 24A). Mice were sacrificed 96 hr after treatment and tumors (right and left 
side), lung, heart, liver and kidney were harvested and snap frozen. Figure 24B shows the 
specific delivery to the right tumor as evidenced by expression of the green fluorescence protein 
(GFP) in an immunoblot in which total protein extracts were run on a 10% SDS-PAGE. As a 
GFP control, we ran a GST-GFP fusion protein. Protein gel loading was normalized using β-
actin as a control. US-targeted microbubble destruction (UTMD) enables focal release of 
entrapped materials as well as the creation of small shock waves that are visualized as an 
enhancement of the image on the US scanner. Figure 24, panel C depicts the B-mode US 
imaging of a sonoporated tumor before injection with the microbubble/Ad-GFP complex contrast 
agent. Figure 24, panel D shows the B-mode ultrasound imaging of the same sonoporated tumor 
following microbubble/Ad-GFP complex injection. The image enhancement of the targeted 
tumor from cavitation of the microbubbles within the US field of view is clearly discernable 
indicating that the US settings are efficient in targeting microbubble destruction.  
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Figure 24. (a) Schematic representation of the microbubble delivery of Ad-GFP complexes and 
ultrasound (US) release in a tumor target site of the mouse. (b) Western blot analysis of Ad-
GFP/microbubble–transduced DU145 tumor xenografts. Immunoblot showing the expression 
levels of green fluorescent protein (GFP) in DU145 cells following ultrasound-targeted 
microbubble/Ad transduction of GFP at 96 hours. Only the tumor on the right flank was 
sonoporated for 10 minutes resulting in the delivery and expression of GFP. The left tumor, 
heart, lung, liver, and kidney were negative for GFP expression. Purified glutathione-S-
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transferase–GFP was used as a positive control. Protein gel loading was normalized using β-actin 
as a control. (c) Ultrasound imaging and US contrast enhancement of in vivo transduced DU145 
tumor xenografts. B-mode US imaging of a tumor before MB contrast agent injection. (d) B-
mode US imaging of the same tumor depicted in c following injection of microbubbles/Ad-GFP 
complexes. MBs cavitation within the targeted tumor dramatically enhances the tumor image 
within the US field of view. Ad, adenovirus. 
 
Microbubble Assisted Ad.mda-7 Gene Delivery Inhibits DU145 Human Prostate Cancer 
Growth In Vivo 
 In vitro and in vivo Ad-mediated gene transfer of the human mda-7/IL-24 gene (Ad.mda-
7) potently suppresses the growth of human cancer cells with no apparent toxicity to normal cells 
[195, 203, 206, 211, 212, 223-230]. Repeated intratumoral administration of Ad.mda-7 to tumor 
xenografts of various histological origin results in growth suppression via induction of apoptosis 
and anti-angiogenic mechanisms [195, 196, 209-212, 226, 228, 231]. Additionally, mda-7/IL-24 
induces a profound “bystander” antitumor effect resulting in tumor growth suppression not only 
in the treated tumors, but also in untreated distant tumors [18, 194, 195, 197, 205, 211-213, 223, 
224, 226, 227, 232, 233]. Although these results have been encouraging, this approach is limited 
since systemic delivery of Ad for treatment of disseminated cancer has not shown significant 
efficacy. 
 We have employed a novel systemic delivery approach to target Ad release in a site-
specific manner that consists of Ad incorporated in microbubbles combined with diagnostic US 
[214]. Proof-of-principle for this strategy comes from studies using Ad to systemically deliver 
the GFP gene in a tissue specific manner [214]. Because mda-7/IL-24 has shown significant 
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potential as a selective and effective anticancer agent in multiple animal model studies and in a 
Phase I intratumoral gene therapy trial in patients with advanced solid cancers [195, 196, 203, 
211, 212, 223, 224, 228], we tested the capacity of this approach to deliver Ad expressing this 
novel cytokine in prostate adenocarcinoma nude mouse xenograft models. For these studies, we 
used DU145 human prostate carcinoma cells and DU145 cells genetically engineered to express 
elevated levels of Bcl-xL (DU-Bcl-xL) [209], which is a common event in advanced prostate 
cancer and provokes resistance to multiple chemotherapeutic agents and to mda-7/IL-24 [207-
210]. The therapeutic arm of this work included two different viral constructs to deliver mda-
7/IL-24, Ad.mda-7, a nonreplicating Ad similar to the one used in Phase I clinical trials [206], 
and the CTV, a conditionally replication competent Ad capable of expressing mda-7/IL-24 that 
has been previously shown to completely eradicate not only primary breast, prostate and 
melanoma tumors but also distant tumors by intratumoral injections in a nude mouse model [18, 
197, 204, 205]. 
 To test this new therapeutic approach for tumor delivery, DU145 or DU-Bcl-xL tumor 
xenografts were established on both flanks of nude mice by injecting 2 x 106 cells in each side of 
the animals. DU145 and DU-Bcl-xL tumor bearing nude mice (n=10 each group) were then 
injected in their tail vein with 100 µL of US contrast agent that was reconstituted with Ad-GFP 
or water as control. Additional DU145 and DU-Bcl-xL tumor control nude mice (n=10 each 
group) were injected in the tail vein with 100 µL of Ad.mda-7 or the CTV (Ad.PEG-E1A-mda-7) 
without US contrast agent. Alternatively, tumor-bearing animals were injected in their tail vein 
with 100 µL of US contrast agent that was reconstituted with Ad.mda-7 or the CTV. A portable 
SonoSite Micro-Maxx US platform (SonoSite, Inc., Bothell, WA) equipped with a L25 linear 
array transducer set at 0.7 Mechanical Index (MI), 1.8 MPa for 10 min was used to sonoporate 
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the tumor implanted on the right side. In this study, gene therapy treatments were started ten 
weeks after the injection of the cell lines, when tumors reached an approximate volume of 150-
200 mm3.  Mice were injected once a week for four weeks for a total of four treatments. Mice 
were sacrificed two weeks after the end of the treatments to determine whether tumor 
suppression was reversible or irreversible. At the end of the study tumors (right and left flank), 
lung, heart, liver and kidney were harvested and snap frozen using liquid nitrogen. 
 US of Ad-GFP microbubble complexes in the right side tumor resulted in progressive 
growth of the tumors on both flanks (Figures 25A and E). The results shown in Figure 25 
represent the average tumor volumes measured in a minimum of 7 mice for each mda-7/IL-24 
group and a minimum of 5 mice for each control GFP group. All the mice were injected in the 
tail vein with the microbubble/Ad complexes and only the tumor on the right flank was 
sonoporated. Interestingly, we observed that microbubble-mediated Ad.mda-7 gene therapy 
inhibited the growth of DU145 prostate tumor xenografts during the treatment regimen (Figure 
25B), while the CTV microbubble-mediated gene therapy resulted in a steady progressive tumor 
regression that lasted an additional two weeks post-treatment (Figure 25C). 
 As predicted from previous studies [18, 209, 210], Ad.mda-7 was ineffective in causing a 
therapeutic response in tumor xenografts on either flank developed from DU-Bcl-xL cells 
(Figure 25F). In contrast, the conditionally replication competent CTV (Ad.PEG-Prom-mda-7) 
elicited a sustained growth inhibition of the therapy resistant DU-Bcl-xL tumor xenografts 
(Figure 25G). A Western blot analysis of total protein extracts from the harvested tumors showed 
expression of MDA-7/IL-24 protein in both the tumor samples implanted on the right and left 
flank (Figures 25D and H) validating the “bystander” effects of MDA-7/IL-24 previously 
reported [18, 194, 197, 204, 233]. In the case of the CTV, this amplified expression of MDA-
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7/IL-24 in the non-injected left tumor may also reflect secondary viral infection by the CRCA 
[18]. GAPDH expression was used to confirm equal loading of the gel. No tumor regression was 
observed in mice bearing DU145 and DU-Bcl-xL control tumors when injected intravenously 
with comparable doses of unprotected Ad.mda-7 and CTV viruses (Figures 27 and 28). 
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Figure 25. Growth curves and western blot analysis of large DU145 and DU-Bcl-xL tumor 
90 
xenografts treated with microbubble encapsulated Ad-GFP, Ad.mda-7, or cancer terminator virus 
(CTV) (Ad.PEG-E1A-mda-7) and treated with ultrasound (US) in the right tumor. Subcutaneous 
tumor xenografts from DU145 and DU-Bcl-xL were established in athymic nude mice in both 
right and left flanks and only tumors on the right side were sonoporated following tail-vein 
injection of the indicated microbubble/Ad complexes during a course of 4 weeks. Tumor 
treatments were initiated when tumors reached a size of 250–350 mm3. Arrows point at tumors 
and asterisks point at treatment times. (a) Measurement of green fluorescent protein (GFP)-
treated DU145 tumor volumes. The data represent mean ± SD with at least 5 mice in each group. 
(b) Measurement of Ad.mda-7-treated DU145 tumor volumes. The data represent mean ± SD 
with at least 7 mice in each group. (c) Measurement of CTV-treated DU145 tumor volumes. The 
data represent mean ± SD with at least 7 mice in each group. (d) Western blot analysis of protein 
extracts from representative DU145 tumor samples treated with Ad.mda-7 or CTV. The 
immunoblot was reacted with anti-MDA-7/IL-24. Arrowheads point at the various glycosylated 
forms of MDA-7/IL-24. Protein gel loading was normalized using anti-GAPDH as a control. (e) 
Measurement of GFP-treated DU-Bcl-xL tumor volumes. The data represent mean ± SD with at 
least 5 mice in each group. (f) Measurement of Ad.mda-7-treated DU-Bcl-xL tumor volumes. 
The data represent mean ± SD with at least 7 mice in each group. (g) Measurement of CTV-
treated DU-Bcl-xL tumor volumes. The data represent mean ± SD with at least 7 mice in each 
group. (h) Western blot analysis of protein extracts from representative DU-Bcl-xL tumor 
samples treated with Ad.mda-7 or CTV. The immunoblot was reacted with anti-MDA-7/IL-24. 
Arrowheads point at the various glycosylated forms of MDA-7/IL-24. Protein gel loading was 
normalized using anti-GAPDH as a control. Ad, adenovirus; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase.  
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Microbubble Assisted CTV Gene Delivery Eradicates Prostate Cancer growth In Vivo 
 In our study, the size of the tumor was measured twice a week by caliper as well as by B-
mode ultrasound scanning. Figure 26A shows the ultrasound image and measurements of a 
DU145 tumor before treatment with Ad.mda-7-microbubble complexes. Panels B and C 
demonstrate the volume reduction in the same tumor after 2 and 4 weeks of treatments with 
Ad.mda-7-microbubble complexes and US. Figure 26D shows the B-mode scan image and 
measurements of a DU-Bcl-xL tumor before treatment with CTV-microbubble complexes. 
Panels E and F emphasize the dramatic volume reduction in the same tumor after 2 and 4 wks of 
treatments with CTV-microbubble complexes and US leading to the eradication of the tumor 
xenograft. Additionally, no tumor regrowth in the primary or distant sites was evident CTV-
microbubble complex and US-treated DU-Bcl-xL animals after an additional three weeks post-
treatment. To investigate if the tumor would reappear after a longer period of time following the 
last treatment, three out of ten animals initially treated with CTV-microbubble complexes were 
not sacrificed at the endpoint of the study and were maintained for an additional 3 months. The 
mice were then sacrificed and dissected to look for potential tumor recurrence and/or eventual 
tumor spread. We did not observe any local tumor reappearance or distant metastasis in the lungs 
or liver in these mice that were treated with CTV-microbubble complexes and US indicating that 
this therapeutic approach could be suitable to target conditionally replication-competent 
adenoviruses (CRCA) to prostate tumors causing the eradication of localized as well as distant 
metastatic tumors. Future studies testing this approach in immune competent tumor bearing and 
transgenic animals would provide definitive support for exploring this strategy in the context of a 
Phase I clinical trial. 
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Figure 26. B-mode ultrasound (US) imaging of DU145 tumor xenografts treated with 
microbubble/US-guided Ad.mda-7 and therapy resistant DU-Bcl-xL tumor xenografts treated 
with microbubble/US-guided cancer terminator virus (CTV).  
Subcutaneous tumor xenografts from DU145 and DU-Bcl-xL cells were established in athymic 
nude mice in both right and left flanks and only tumors on the right side were sonoporated 
following tail-vein injection of the indicated microbubble/Ad complexes during a course of 4 
weeks. Tumor volumes were determined by measuring twice a week the tumors with either a 
caliper or by US measurements of the tumor axes.  
(a) Ultrasound image and measurement of a DU145 tumor before treatment with Ad.mda-
7/microbubble complexes and US.  
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(b) US image and measurement of the same DU145 tumor 2 weeks following treatments with 
Ad.mda-7/microbubble complexes and US.  
(c) US image and measurement of the same DU145 tumor 4 weeks following treatments with 
Ad.mda-7/microbubble complexes and US.  
(d) US image and measurement of a DU-Bcl-xL tumor before treatment with CTV/microbubble 
complexes and US.  
(e) US image and measurement of the same DU-Bcl-xL tumor 2 weeks following treatments 
with the CTV/microbubble complexes and US.  
(f) US image and measurement of the same DU-Bcl-xL tumor 4 weeks following treatments with 
CTV/microbubble complexes and US. 
 Complete eradication of the DU-Bcl-xL tumor occurs 4 weeks after initiating the therapeutic 
treatment protocol. Ad, adenovirus; GFP, green fluorescent protein. 
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Figure 27. Growth curves of control DU145 tumor xenografts injected i.v. using unprotected 
Ad-GFP, Ad.mda‐7, or CTV (Ad.PEG-E1A-mda‐7) and treated or not with US. Subcutaneous 
tumor xenografts from DU145 were established in athymic nude mice in both right and left 
flanks and only tumors on the right side were sonoporated following tail vein injection of the 
indicated Ads during a course of 4 wks. Tumor treatments were initiated when tumors reached a 
size of 150 – 200 mm3. Asterisks point at treatment times. 
A) Measurement of CTV-injected and sonoporated DU145 tumor volumes. The data represent 
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mean ± s.d. with at least 5 mice in each group. 
B) Measurement of CTV-injected, but not sonoporated DU145 tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
C) Measurement of Ad.mda-7-injected and sonoporated DU145 tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
D) Measurement of Ad.mda-7-injected, but not sonoporated DU145 tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
E) Measurement of Ad.GFP-injected and sonoporated DU145 tumor volumes. The data represent 
mean ± s.d. with at least 5 mice in each group. 
F) Measurement of Ad.GFP-injected, but not sonoporated DU145 tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
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Figure 28. Growth curves of control DU-Bcl-xL tumor xenografts injected i.v. using unprotected 
Ad-GFP, Ad.mda‐7, or CTV (Ad.PEG-E1A-mda‐7) and treated or not with US. Subcutaneous 
tumor xenografts from DU-Bcl-xL were established in athymic nude mice in both right and left 
flanks and only tumors on the right side were sonoporated following tail vein injection of the 
indicated Ads during a course of 4 wks. Tumor treatments were initiated when tumors reached a 
size of 150 – 200 mm3. Asterisks point at treatment times. 
A) Measurement of CTV-injected and sonoporated DU-Bcl-xL tumor volumes. The data 
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represent mean ± s.d. with at least 5 mice in each group. 
B) Measurement of CTV-injected, but not sonoporated DU-Bcl-xL tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
C) Measurement of Ad.mda-7-injected and sonoporated DU-Bcl-xL tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
D) Measurement of Ad.mda-7-injected, but not sonoporated DU-Bcl-xL tumor volumes. The 
data represent mean ± s.d. with at least 5 mice in each group. 
E) Measurement of Ad.GFP-injected and sonoporated DU-Bcl-xL tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group. 
F) Measurement of Ad.GFP-injected, but not sonoporated DU-Bcl-xL tumor volumes. The data 
represent mean ± s.d. with at least 5 mice in each group.  
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DISCUSSION 
 Microbubbles have been used to protect viruses from rapid degradation by the immune 
system, thus allowing intravenous injection rather than direct target organ delivery by catheter-
based approaches or operative bed injection [234]. However, variable levels of non-targeted gene 
expression have been noted in other organs such as the liver and lungs [234]. We have recently 
shown that US imaging and US contrast agents can increase target specificity of Ads to tumors, 
achieving transient transgene expression with strict image-guided site specificity by selecting 
microbubbles which completely enclosed the Ads in their gas filled core [214]. In our prior 
experience, US-mediated microbubble destruction improved the efficacy and reduced the non-
specific expression of gene therapy vectors providing a useful tool for manipulating gene 
expression in the living animal. 
 Genetic therapies for prostate cancer represent promising strategies for the treatment of 
this neoplasm. The prostate gland is accessible by US, and potential therapeutic genes can be 
directed to this organ using portable diagnostic US platforms such as the SonoSite MicroMaxx 
(SonoSite, Inc., Bothell, WA) after a simple intravenous injection. Importantly, because prostate 
cancer is commonly a relatively slow-growing disease, it may be necessary to use repeated gene 
therapy applications, with single or multiple genes, over the life span of the patient. In these 
contexts, gene therapy protocols that delimit virus exposure to the immune system and can be 
administered multiple times during a patient’s lifetime are appealing. This possibility will need 
to be explored in the future using tumor-bearing immune competent animals. In the current work, 
we explored the ability of US-mediated microbubble destruction to specifically deliver in 
prostate adenocarcinoma xenografts the mda-7/IL-24 gene [235, 236], that has been successfully 
employed in a Phase I clinical trial in patients with advanced solid tumors [195, 196, 203, 211, 
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212, 223, 224, 228]. 
 Potentially useful approaches for treating prostate and other cancers involve the use of a 
replication incompetent adenovirus (Ad.mda-7) or a conditionally replication competent Ad 
(Ad.PEG-E1A-mda-7; CTV) to administer the therapeutic cytokine mda-7/IL-24 to induce 
targeted therapy of tumors [18, 195-197, 204, 205, 211, 212, 237]. Although very effective in 
prostate cancer cell lines, no therapeutic benefit is observed with Ad.mda-7 in the context of 
prostate cancer cells displaying elevated expression of Bcl-2 and/or Bcl-xL [18, 209]. In contrast, 
administration of the CTV by direct intratumoral delivery in nude mice containing xenografted 
Bcl-xL overexpressing DU145 cells implanted on both flanks of the animal results in tumor 
eradication in both the primary injected tumor and the distant untreated tumor [18]. 
Conditionally replication competent Ads (CRCA), which induce oncolysis by cancer-specific 
replication, have been evaluated in several prostate cancer clinical trials [238, 239]. Most 
currently employed CRCA are based on the ONYX-015 backbone, which is dependent on the 
p53 status of the cancer cells and have shown only minimal objective clinical responses, thus 
limiting their universal applicability for the treatment of prostate or other cancers [240]. To this 
end, the novel CTV CRCA that employs the progression elevated gene-3 (PEG-3) promoter that 
functions in all types of cancer cells [18, 204, 205, 241, 242], irrespective of their p53 or 
Rb/retinoblastoma gene status, with very limited to no activity in normal cells has been 
constructed. In the cancer terminator virus (CTV), Ad replication through the E1A gene is driven 
by the cancer-specific promoter of progression elevated gene-3 (PEG-3) [243], which results in 
concomitant production of mda-7/IL-24 from the E3 region of the Ad. This CTV generates large 
quantities of MDA-7/IL-24 as a function of Ad replication uniquely in cancer cells that not only 
have cancer-selective apoptosis-inducing properties but also display a plethora of indirect 
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antitumor ‘‘bystander’’ activities, including distant tumor growth suppression and apoptosis, 
immune modulation and anti-angiogenesis [195, 196, 204, 211, 212, 223, 232, 233, 237]. 
 A limiting factor in effective gene therapy when employing intravenous viral delivery 
and when using CRCA is the effect of the immune system in neutralizing Ads [215]. In this 
context, a means of shielding the initial viral delivery vector using microbubbles in principle 
permits enhanced delivery of the viral payload to tumors when coupled with US [214]. In the 
present study, we have employed this strategy using CTV-microbubble complexes coupled with 
US to treat both DU145 and therapy resistant DU-Bcl-xL established tumor xenografts on both 
flanks in nude mice. Systemic administration of the CTV-microbubble with US on the 
established right-side tumor resulted in robust transgene expression and apoptosis induction with 
complete eradication of both the injected right side primary and distant (opposite flank; 
potentially representative of metastasis) human prostate cancers. However, no tumor regression 
was observed instead in mice bearing DU145 and DU-Bcl-xL control tumors when injected 
intravenously with unprotected Ad.mda-7 and CTV viruses (see Figures 27 and 28), indicating 
that comparable doses of untargeted, unprotected viruses injected directly i.v. failed to elicit an 
antitumoral response. An exciting finding was that this protocol resulted in the indication of an 
enduring response in which no tumor regrowth occurred 3 months after cessation of the therapy 
protocol in the treated or untreated tumor site and additionally these animals had no signs of 
metastatic spread to the lungs or liver. Previous studies have indicated that the CTV when 
injected intratumorally will enter into the circulation, replicate and generate MDA-7/IL-24 
protein in the primary and distant tumors in the nude mouse, predicting induction of a potential 
immune response [18, 204, 205, 237, 241]. Further studies are planned in the context of immune 
competent animals, which would be an important step toward developing clinical trials with the 
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CTV-microbubble approach and US.   
 Obvious questions are why mda-7/IL-24 serves as such an effective anti-tumor agent and 
why the CTV is superior to Ad.mda-7 as a viral-based therapeutic for primary and disseminated 
cancers. A noteworthy reason for the robustness of mda-7/IL-24 is the ability of this secreted 
cytokine to elicit a potent ‘bystander’ anti-cancer effect [195]. Mda-7/IL-24 can directly induce 
apoptosis when expressed inside cancer cells and can also induce growth suppression, apoptosis 
and endogenous MDA-7/IL-24 protein expression and secretion when added as a purified protein 
through interactions with the IL-20R1/IL-20R2 and IL-22R1/IL-20R2 cell surface receptors 
[195, 211, 232, 233]. As a secreted cytokine, MDA-7/IL-24 also induces an array of potent 
immunomodulatory proteins from immune cells, including IL-6, IFN-γ, tumor necrosis factor-α, 
IL-1β, IL-12, and granulocyte macrophage colony-stimulating factor [232]. These cytokines 
secreted by peripheral blood mononuclear cells can activate antigen-presenting cells to present 
tumor antigens, thereby triggering an antitumor immune response [244]. These observations 
have been recapitulated in a Phase I clinical trial involving intratumoral injection of Ad.mda-7 
(INGN 241) in patients with advanced carcinomas and melanomas [203, 211, 228]. In principle, 
the ‘bystander’ effects elicited by MDA-7/IL-24 are concentration dependent [233] and large 
amounts of this cytokine generated by the CTV would be predicted to have an enhanced 
therapeutic impact in the patient. Moreover, the immunomodulatory functions of mda-7/IL-24 
would be particularly significant in a patient with an intact immune system where the generation 
of robust amounts of mda-7/IL-24 by the CTV might result in an amplified immune response 
against the cancer cells. The potent activity of the CTV compared to Ad.mda-7 suggests a need 
for only limited administration of this CRCA [18, 204, 205, 237], which would work extremely 
well in the context of microbubble-Ad complexes. In principle, the microbubble approach would 
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further minimize the activation of the immune system against the Ad that would normally 
promote viral clearance. We presently confirm for the first time that microbubble-assisted 
delivery of the CTV can serve as a valuable therapeutic tool to combat therapy resistant prostate 
cancer. As previously emphasized, the CTV-microbubble injected US treated mice appeared to 
be disease free 3 months after therapy cessation suggesting that a cure was established. We are 
planning to conduct long-term animal studies to verify this provocative observation in both 
immune incompetent and immune competent animals.  
 In summary, the present studies support the proposition that US-directed delivery of 
CTV-microbubble complexes might provide a nontoxic and effective alternative or complement 
to conventional adjuvant treatment modalities for patients with primary and metastatic prostate 
cancer. Based on previous studies of combinatorial therapy preclinical-trials in cell culture and in 
animal models, a combination of CTV-microbubble approach employing US with localized low-
dose radiotherapy might promote an even more profound effect, potentially further enhancing 
mice survival [212, 245]. We are currently studying the effects of chemotherapy and/or radiation 
therapy combined with microbubble-enhanced delivery of the CTV on promoting a cure in a 
preclinical setting of prostate cancer. 
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CHAPTER V: MICROBUBBLE-ASSISTED P53, RB, AND P130 GENE TRANSFER IN 
COMBINATION WITH RADIATION THERAPY IN PROSTATE CANCER 
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ABSTRACT 
 
 Combining radiation therapy and direct intratumoral (IT) injection of adenoviral vectors 
has been explored as a means to enhance the therapeutic potential of gene transfer. A major 
challenge for gene transfer is systemic delivery of nucleic acids directly into an affected tissue. 
Ultrasound (US) contrast agents (microbubbles) are viable candidates to enhance targeted 
delivery of systemically administered genes. 
 Here we show that p53, pRB, and p130 gene transfer mediated by US cavitation of 
microbubbles at the tumor site resulted in targeted gene transduction and increased reduction in 
tumor growth compared to DU145 prostate cancer cell xenografts treated intratumorally with 
adenovirus (Ad) or radiation alone. Microbubble-assisted/US-mediated Ad.p53 and Ad.RB 
treated tumors showed significant reduction in tumor volume compared to Ad.p130 treated 
tumors (p<0.05). Additionally, US mediated microbubble delivery of p53 and RB combined with 
external beam radiation resulted in the most profound tumor reduction in DU145 xenografted 
nude mice (p<0.05) compared to radiation alone. These findings highlight the potential 
therapeutic applications of this novel image-guided gene transfer technology in combination with 
external beam radiation for prostate cancer patients with therapy resistant disease. 
 
 
Keywords: Retinoblastoma, RB, p130, p53, tumor suppressor gene, microbubbles, ultrasound, 
systemic targeted viral gene delivery, radiation, external beam radiation, apoptosis induction, 
prostate cancer. 
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INTRODUCTION 
Current gene transfer clinical trials for prostate carcinoma use adenoviral vectors as 
efficient gene transducing agents but these viral vectors have been shown to elicit an immune 
response [202]. Rapid inactivation of adenoviruses by anti-adenoviral and neutralizing antibodies 
in the blood limits the use of adenoviral gene transfer to intraprostatic injections for site-specific 
delivery. To circumvent this problem we previously demonstrated a unique intravenous site-
specific delivery system for gene transfer both in vivo and in vitro, using adenoviral (Ad) 
mediated delivery of GFP [214] and melanoma differentiation associated gene-7/interleukin-24 
(mda-7) encapsulated in commercially available ultrasound (US) contrast agents (microbubbles) 
[53]. The microbubbles (MBs) are able to entrap and protect viral vectors from the immune 
system and are small enough to flow freely in the pulmonary and liver capillary bed. MBs 
undergo cavitation in the sonification zone, and release their contents. Cavitation also creates 
shockwaves that increase cell permeability allowing for better uptake of the genetic material into 
the targeted cell [53, 68, 214]. 
Radiation therapy (RT) is commonly used in cancer management, with 40% to 60% of all 
cancer patients receiving radiation treatment [246]. RT stimulates death receptors at the cell 
surface, generates reactive oxygen species and activates several cell cycle regulatory proteins 
including p53 [247], pRB [248], and other proteins that trigger senescence, necrosis or apoptosis 
[249]. Additionally, factors such as location, size, and inadequate vascular supply (hypoxia) play 
a role in the lack of responsiveness of neoplasms to ionization radiation [250].  
The human prostate cancer, DU145, displays genetic mutations in key cell cycle 
regulatory proteins, p53 and pRB. DU145 expresses a mutant p53 protein (mt-p53) due to 
mutations at codon 223 and 274 on both alleles [251], which is functionally inactive, stabilized, 
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and temperature sensitive [252]. Therefore, because functional p53 is required for ionizing 
radiation to activate p21cip/waf and to induce a G1-cell cycle arrest, DU145 cells are 
radioresistant [251, 253]. In addition, pRB gene has a biallelic disruption in these cells; one allele 
is deleted while the other produces a truncated product of the RB gene resulting in the loss of 
another G1 cell cycle phase regulator required for apoptosis following irradiation [254]. Studies 
by Sasaki, et al. [255] and Bowen, et al. [256] showed that DU145 cell death following ionizing 
radiation is increased when p53 and pRb are restored.  
Another cell cycle regulator, p130 is frequently altered in several human neoplasms 
including prostatic carcinomas. Previously we observed that p130 was expressed at low levels in 
more aggressive prostate tumors and hypothesized that the lack of p130 expression could be 
involved in the progression of the disease [257]. Additionally, we have examined the role of 
p130 in γ-radiation induced apoptosis by using a hamster tetracycline inducible glioblastoma cell 
line HJC12, and demonstrated that the cell cycle regulator p130 promoted radiation induced 
apoptosis by downregulation of the antiapoptotic BCl-2 gene and upregulation of pro-apoptotic 
transcription factor p73 [258]. These data suggest that cell cycle regulatory proteins play a 
significant role in the radio-sensitivity of prostate cancer cells. 
In 1996, Stevens and colleagues demonstrated that ionizing radiation improves viral gene 
transfer efficiency with greater integration of the transgene into the host cells [259]. In addition, 
combined treatment with adenovirus p53 and radiation has been shown to enhance the proportion 
of apoptotic cells by greatly increasing the number of cells arrested in the G1-phase of the cell 
cycle [255]. We hypothesized that ultrasound guided targeted delivery of adenoviruses 
containing the cell cycle genes p53, RB and p130 in combination with external beam radiation 
can further enhance the incorporation of cell cycle transgenes in prostate cancer cells, resulting 
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in greater ablation of prostate tumors than x-ray radiation alone.   
In the current investigation we used an ultrasound contrast agent provided by Targeson, 
Inc (San Diego, CA) and the portable SonoSite Micro-Maxx ultrasound (US) platform (SonoSite, 
Inc., Bothell, WA) equipped with an L25 linear array transducer. Targeson’s agents are lipid-
encapsulated perfluorocarbon microbubbles (MBs) with a mean diameter of 2.5 µm. The gas-
filled microspheres effectively lower the energy threshold for non-thermal cavitation, thus 
allowing diagnostic transducers operating within the energy levels mandated by the FDA to be 
used for drug/gene delivery. Ultrasound-targeted microbubble destruction (UTMD) enables focal 
release of entrapped materials as well as the creation of small shock waves that increase cellular 
permeability [220]. In addition, the MBs protect viruses from recognition and rapid degradation 
by the immune system, thus allowing for intravenous injection rather than direct target organ 
delivery by catheter-based approaches or operative bed injection [214, 218]. MB protection of 
the viruses may also limit the inflammatory response to the viruses, potentially allowing for 
repeated injections of transgene containing MBs.  
The ultimate goal of this research is to develop efficacious treatment modalities for 
therapy resistant prostate cancer. In the present study, we provide proof-of-principle for a site-
specific gene delivery approach mediated by a standard, portable diagnostic US platform. This 
system worked effectively in vivo to deliver Ads carrying cell cycle regulatory genes (p53, RB, 
and p130). Evidence is offered that the combination of 8 Gy radiation therapy with US targeted 
gene transfer of p53 and RB reduced the tumor size in an animal xenograft model of radiation-
resistant human prostate cancer cells. 
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MATERIALS AND METHODS 
Cell Lines, Cell Culture, and Adenoviral Production. 
The DU145 (human prostate adenocarcinoma), cell line was obtained from the American 
Type Culture Collection (ATCC, Rockville, MD). DU145 cells were grown in RPMI 1640 
(Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (Hyclone, Waltham, MA), 
and 100units/mL penicillin supplemented with 1 mg/mL streptomycin (both from Hyclone, 
Waltham, MA). The human kidney embryonic 293 cells were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD) and grown with Dulbecco’s modified Eagle’s 
medium (Hyclone, Waltham, MA) supplemented with 10% fetal bovine serum (Hyclone, 
Waltham, MA). All cells were grown at 37ᴼC, in a 5% CO2/95% atmosphere incubator. 
The recombinant adenoviruses with wild-type p53, RB, p130 used in this study were 
serotype 5 adenovirus containing a cytomegalovirus (CMV) promoter. Non-coding empty 
Adenoviruses carrying only the CMV promoter were used as vector control. Each viral stock was 
propagated in and purified from 293 cell cultures. Cells were harvested 24-36 hours after 
infection, pelleted, resuspended in heat inactivated media and lysed by three-freeze/thaw cycles. 
Cell debris were removed and the viruses purified by chromatography followed by dialysis. 
Viruses were aliquoted and stored at -80°C. Viral titers were determined by a plaque assay. 
Ad.p53 viruses were generated using the AdEasy system (Carlsbad, CA), as previously described 
[260-263]. The Ad.RB viruses were generously provided by Dr. Juan Fueyo (M.D. Anderson 
Cancer Center, The University of Texas) and Ad.p130 viruses were purchased from Vector 
BioLabs (Philadelphia, PA). All adenovirus transductions were performed using 50 MOI Ads for 
in vitro studies, in RPMI-1640 media with 2% Fetaclone-III heat-inactivated FBS (Hyclone, 
Thermo Scientific, Waltham, MA). 
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Radiation 
 External beam radiation was provided using Varian Medical Systems, Inc. (Palo Alto, 
CA) Model 21EX and Model 6EX linear accelerators (LINAC), each owned and operated by 
Tri-State Regional Cancer Center in Ashland, KY. The machines were approved by the Inspector 
General of the State of Kentucky for irradiations to biological specimens and animals as desired 
by us. These particle accelerators offer a bremsstrahlung x-ray energy of 6 MV, which was used 
in these investigations as well as a rapid dose delivery to the targeted tumor at a rate of 6Gy/MU. 
Here, the number of monitor units (MU) is simply the internal timer of the LINAC. All dosages 
were pre-calculated for in vitro and in vivo  studies as previously described [264].  
 For the in vitro studies, 2 x 10^6 DU145 cells were seeded in 75cm^2 flasks and 
irradiated at 10Gy or 20Gy, at room temperature. For one treatment of 10Gy, 965 MU were 
given at 600 MU/min for a run time of 1 min 37 seconds. For one treatment of 20Gy, 1,930 MU 
were given at 600 MU/min for 3 min 13 seconds. For a combination therapy, 2 x 10^6 DU145 
cells were first radiated at 10Gy and 20Gy following by infection with Ad5CMV-p53 or 
Ad5CMV-RB or Ad5CMV-p130 viruses at 50 multiplicity of infection (MOI) units. The 
sensitivity to x-ray induced apoptosis was evaluated by phase contrast microscopy and flow 
cytometric analysis. Cells were collected at 24, 48, 72 and 96 hours after radiation to carry out 
Flow cytometric analysis and Western Blots. 
 For the in vivo studies, mice received irradiation in pie cages for a one-time dose of 8Gy 
(800 MU given at 600 MU/min for 80 seconds). An approved protocol concerning the Physics 
Policies and Procedures for handling of the mice and disposal of waste was used.  
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Flow Cytometry Analysis 
Irradiated, adenoviral (Ad.p53, Ad.RB and Ad.p130) transduced and combination treated 
DU145 cells were harvested at 24, 48, 72 and 96 hours following treatments, to study the cell 
cycle phase of each group. After three washings in 1mL of 1% fetal calf serum (FCS)-PBS the 
cells were fixed in 70% ethanol and stored at -20ᴼC. Cells were centrifuged, washed and 
resuspended in 1% FCS-PBS. The samples were then incubated at 37ᴼC with propidium iodide 
(PI) and RNAse A for 30 min.  The DNA content was analyzed by a BD Accuri C6 Flow 
Cytometer (BD Bioscience, San Jose, CA). The proportions of G1, S, G2 phase cell cycle were 
determined as previously reported [255]. 
 Apoptosis analysis was done using the Annexin-V assay on the Flow Cytometer. 
Apoptotic cells were analyzed with fluorescein isothiocyanate (FITC) conjugated to Annexin-V 
antibody and Propidium Iodide (PI) from the Annexin-V/FITC Kit (Bender MedSystems, 
Burlingame, CA) following manufacturer's instructions. The samples were analyzed with BD 
Accuri C6 Flow Cytometer (BD Bioscience, San Jose, CA). The Annexin-V assay experiment 
was repeated three times and was run as triplicate of technical repeats. Statistical analyses were 
performed with IBM SPSS statistic software. 
 
Antibodies and Western Blot Analysis 
Western blot analyses with antibodies against the targeted proteins were performed to 
validate successful viral transfection of the cells and of the in vivo tumors. DU145 cells were X-
irradiated, transduced with 50 MOI of Ad.p53, Ad.RB, Ad.p130, or Ad.CMV (control) for 24, 
48, 72 and 96 hrs post-irradiation/transduction. Cells were lysed on ice for 1 hr with lysis buffer. 
Fifty μg of total protein plus loading buffer were loaded in each well for western blot analyses. 
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SDS-PAGE was run using 8-12% bis-acrylamide gel at room temperature. Samples were blotted 
onto a nitrocellulose membrane. To detect proteins, the membranes were blocked with 5%Milk-
TBST overnight at 4ᴼC and reacted with primary antibodies for 2 hr at room temperature with 
constant motion on an orbital shaker. The membranes were washed with TBST to remove excess 
primary antibodies. Incubation for 45 minutes with appropriate secondary antibodies followed. 
Immunodetection was performed using the enhanced chemiluminescence (ECL) system 
(Amersham, IL) according to the manufacturer’s instructions using x-ray films. The following 
primary antibodies were used: mouse monoclonal antibodies against p53 (DO-1) cat#sc-126 
(1:500), pRb cat#sc-102 (1:250) (Santa Cruz Biotechnology, Santa Cruz, CA), β-actin 
cat#A3853 (1:1,500) (Sigma Aldrich) and rabbit polyclonal antibody against RBL2/p130 cat#sc-
317 (1:250). 
 
Preparation of MBs and US Platform. 
Targeson (Targeson) custom synthesis US contrast agent (perfluorocarbon MBs, 
encapsulated by a lipid monolayer and polyethylene glycol) stabilizer were reconstituted as 
previously described [53]. MBs were reconstituted in the presence or absence of 1 ml of 10^12 
plaque-forming units of Ads [53]. Unenclosed, surface-associated Ads were inactivated using 
incubation with FBS as previously described [53, 214]. For in vivo experiments US exposure was 
achieved with a Micro-Maxx SonoSite (SonoSite) ultrasound machine equipped with the 
transducer L25 set at 0.7 Mechanical Index, 1.8 MPa for 10 minutes as previously described [53, 
214]. 
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Animal Study  
Animal studies were performed in accordance with National Institutes of Health 
recommendations and the approval of the institutional animal research committee. DU145, 
human prostate carcinoma cells were xenografted to 8- to 12-week-old female or male athymic 
BALB/c nude mice, homozygous mutant for the nu/nu allele, bred in our laboratory. The colony 
of mice was developed from breeding stock obtained from Charles Rivers Laboratories, 
Wilmington, MA. Mice were sedated in an IMPAQ6 anesthesia apparatus (VetEquip, 
Pleasanton, CA) that was saturated with 3–5% isofluorane and 10–15% oxygen with the aid of a 
precision vaporizer (VetEquip) to deliver the appropriate amount of anesthetic and to induce 
anesthesia. Mice received subcutaneous injections along each of their dorsal flanks (both sides 
per mouse), of 2 x 10^6 DU145 cells in 200µL of PBS using a 22-gauge needle. Tumors were 
measured post-injection in their longest dimension and at 90ᴼ to their longest dimension using 
vernier calipers. Once the tumors reached a volume of approximately 200mm^3 the mice were 
divided into their various treatment groups. Tumor volumes were calculated using the formula 
tumor volume = (long arm x short arm2)/2 [265].  
 Sonoporation:  Gray scale-B-mode US imaging was performed with a SonoSite scanner 
(SonoSite) equipped with the transducer L25 set at 0.7 Mechanical Index, 1.8 MPa for 10 
minutes. US images were recorded as digital clips. Tumors on the right flank were sonoporated 
immediately after the MB encapsulated viral vector intravenous injections using a 27-gauge 
needle. Tumors on the contralateral flank (on the left flank) would serve as internal controls. 
Radiation of 8Gy was given to the appropriate groups followed by four weeks of MB guided 
delivery of Ad.p53, Ad.RB or Ad.p130.  
 Radiation: Radiation treatments were provided to groups of mice, generally 11 mice/pie-
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cage. Groupings were limited by the number of available slots in the Braintree Scientific, Inc. 
(Braintree, MA) Model MPC pie cage. The LINAC was programmed to provide an 8Gy 
radiation. Radiation was given to the appropriate groups followed by four weeks of adenoviral 
treatments.   
The DU145 tumor-bearing mice were directly injected in the tumor (IT) or through the 
dorsal tail vein (IV). Each control group got an IT injection of 100µL of PBS MBs or 100µL of 
un-encapsulated Ad.p53, Ad.RB or Ad.p130 viruses at a concentration of 10^9 pfu/µL.  
Radiation of 8Gy alone constituted an additional control group. Experimental groups were 
injected IV with 100 µL of MB encapsulated Ad.p53, Ad.RB or Ad.p130 at a concentration of 
10^9 pfu/µL. Tumor growth inhibition rate was calculated using the formula (1-(treated 
group/control group))*100%.  
 The animals were sacrificed by CO2 asphyxiation. Tumors, heart, lungs and liver were 
harvested at the end of the treatment course. Tissues used for molecular biological analysis were 
snap frozen in liquid nitrogen and stored at -80°C. Frozen tissues were homogenized and total 
proteins were extracted. Western blot studies allowed determining if the enhanced gene 
expression was specific to microbubble encapsulation and restricted to the US treated tumors 
instead of other tissues. The combination of external beam radiation, ultrasound treatment and 
systemic delivery of MB protected genetic material by viruses was examined for expression of 
the transduced tumor suppressor genes. 
 
In Vivo Bioluminescence Imaging 
 We imaged animals with the IVIS Lumina II (Caliper Life Sciences) at 24hrs and one 
week after MB-assisted gene delivery, to quantify photons emitted by the control animals that 
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received Ad.LUC. For each imaging session mice were injected intraperitoneally with D-
luciferin (150 mg kg−1) under anesthesia using 1.5–2.5% isoflurane/oxygen mixture. Images 
were acquired 10 min after injection of D-luciferin as follows. The anesthetized mice were 
placed in a light-tight chamber, and images were generated over a 1-minute exposure using a 
cryogenically cooled charge-coupling device camera IVIS Lumina II (Caliper Life Sciences) to 
quantify photons spontaneously emitted by the animal. Images were pseudocolored using the 
Xenogen (Caliper Life Sciences, Hopkinton, MA, USA) software and overlayed on a black-and-
white photograph of the animal generated with cabinet lighting. The visual output represents the 
number of photons emitted s_1 cm_2 as a pseudocolor image where the maximum is red and the 
minimum is purple. Image acquisition and BLI data analysis were done using Living Image 
software (Caliper Life Sciences). 
 
Statistical Analyses 
All statistical analyses were performed using IBM SPSS software. Comparisons were 
conducted using an ANOVA test with post hoc test of Dunnett’s T3. P values of less than 0.05 
were considered statistically significant.  
A comparison of tumor volumes was done for week 19 after the treatment at the end of 
the study. Statistical analyses for comparisons of different types of treatments were done using 
one-way analysis of variance using a post hoc test of Dunnett’s T3. P value <0.05 was 
considered significant.  
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RESULTS 
Phase Contrast Microscopic Analysis: Irradiated DU145 Cells that were then Transduced 
with p53, RB, and p130 Genes 
We observed that after 96 hours, radio-resistant DU145 cells, which were x-ray irradiated 
and then transduced with 50 MOIs of Ad.p53, Ad.RB, or Ad.p130 had a higher number of dead 
cells than cells which did not receive the transgenes and that there was an increase in the number 
of apoptotic cells as radiation dose was escalated from 10 to 20Gy (Fig. 29a). Microscopic 
analysis revealed that following radiation induced DNA damage, cells adopted a large flattened 
shape with distorted cell membranes and multiple nuclei typical of senescent cells. We also 
observed that at 96 hours, the RB or p53 gene transfer and radiation therapy resulted in a higher 
increase of cell death than p130 gene transfer (Fig. 29a). Non-irradiated and non-transduced 
control cells exhibited similar percentages of cell death when compared to control non-coding 
CMV-Adenoviruses transduced cells (data not shown). 
Interestingly, cells x-ray irradiated and transduced with Ad.p53, Ad.RB or Ad.p130 
showed an increase in cell death, compared to the control x-irradiated group from 24-72 hours 
(Fig. 29b). Few dead DU145 cells were observed at 24-72 hours following x-ray irradiation 
when compared to the non-transduced control (Fig. 29b). Radiation combined with adenoviral 
transductions increased the number of dead cells regardless of the transduced genes (p53, RB & 
p130) in a time and dose dependent manner (Fig. 29a and b). Taken together, these data suggest 
that gene transfer of RB or p53 resulted in an improvement in the cell death of the radio-resistant 
DU145 cells. 
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Figure 29a. Microscopy image analysis of DU145 cells transduced with Ads carrying tumor 
suppressor genes (p53, RB and p130) ± radiation from 72hrs. Apoptotic cells appear as floating 
in the bright field microscopy image. Top row images are of control DU145 cells and the ones 
that received radiation of 10Gy or 20Gy only. The second row images are DU145 cells that 
received 50MOI adenoviral transduction of p53 alone and those combined with 10Gy and 20Gy 
radiation. The third row images are of DU145 cells that received 50MOI adenoviral transduction 
of pRB alone and those combined with 10Gy and 20Gy radiation. The fourth row images are of 
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DU145 cells that received 50MOI of adenoviral transduction of p130 alone and those combined 
with 10Gy and 20Gy radiation. 
  
Figure 29b. Microscopy images of adenovirally transduced tumor suppressor genes (p53, RB 
and p130) ± radiation from 24-72hrs. Top row images are of DU145 cells that received radiation 
of 10Gy and 20Gy only at 24, 48, and 72 hours, respectively. The second row images are DU145 
cells that received 50MOI of Ad.p53 combined with 10Gy and 20Gy radiation at 24, 48, and 72 
hours, respectively. The third row images of DU145 cells that received 50MOI of Ad.pRB 
combined with 10Gy and 20Gy radiation at 24, 48, and 72 hours, respectively. The bottom row 
images are of DU145 cells that received 50MOI of Ad.p130 combined with 10Gy and 20Gy 
radiation at 24, 48, and 72 hours, respectively.   
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Transgene Expression of p53, pRb, and p130 in Irradiated DU145 Cells 
Western blot studies were done to confirm the adenoviral transduction of DU145 cells by 
adenoviruses carrying genes p53, pRb and p130. Normally, irradiation induced cell death results 
in the accumulation of proteins p53 and hypo-phosphorylated pRb leading to G1 arrest. We 
found that following x-ray irradiation there was no change in the expression of mutant p53 and 
truncated pRb in the control DU145 cells regardless of the irradiation dose (Fig. 30).  Mutant p53 
and truncated pRb are stabilized and non-functional in DU145 cells leading resistance to 
radiation-induced cell death [252, 254]. We also observed an accumulation of p130, which 
occurred in a time dependent manner following x-ray irradiation, regardless of the irradiation 
dose (Fig. 30). Cells transduced with adenoviral Ad.p53, Ad.RB, and Ad.p130 showed increased 
expression of these functional recombinant proteins (Fig. 30). Higher expression levels of all of 
the adenovirally transferred recombinant proteins were observed as the x-ray dose was increased 
from 10Gy to 20Gy.  
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Figure 30. Western Blot analysis of the cell lysates collected at 24, 48, 72 & 96 hours post- 
adenoviral transduction. Treatments and time of collection after radiations are as labeled at the 
top, protein detected are labeled on the right. Anti-beta-actin was used as a loading control. 50μg 
of total lysates were run in SDS polyacrylamide gels. 
Cell Cycle Analysis of DU145 Cells Following X-ray Irradiation and Gene Transduction 
 The replication status of DU145 cells following radiation therapy, adenoviral gene 
transfer of p53, RB, or p130, or combined radiation and adenoviral gene transfer was computed 
as the percentage of cells accumulated in the G1, S or G2 cell cycle phases by a propidium 
iodide staining. The data was plotted on a linear diagram to show points in time where there was 
accumulation or reduction of G1- and G2-phases at 24-96 hours of DU145 cells treated with the 
various adenoviruses and x-ray irradiation (Fig. 31a-f). Control DU145 cells showed a small (8-
11%) fraction of cells in S-phase (Table 4). The cells treated with Ad.p53, Ad.RB, or Ad.p130 
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showed accumulation at the G1-phase with reduction in G2-phase of the cell cycle suggesting a 
block of the G1/S phase transition (Fig. 31a, c and e). Notably, x-ray irradiated DU145 cells 
showed a marked accumulation in the G2-phase with a reduction in the G1-phase of the cell 
cycle suggesting a block at the G2/M transition (Fig. 31a-f). The combined treatment of Ad.p53 
or Ad.RB transduction and x-ray irradiation showed a reduction of the number of cells in the G2-
phase with accumulation of cells in the G1-phase (Fig. 31a,b & c,d). However, combined 
treatment of Ad.p130 transduction and x-ray irradiation showed a G2/M block (Fig. 31e-f), 
suggesting that this cell cycle response was most likely due to the irradiation.  
 
Table 4. The percentage of DU145 cells in G1, S and G2 cell cycle phase with its standard 
deviation that received treatments of adenovirus, radiation and combined (radiation + 
adenovirus) treatment as analyzed by flow cytometry at 24-96 hours. 
 G1 phase 
(Mean ± SD) 
S phase 
(Mean ± SD) 
G2 phase 
(Mean ± SD) 
Groups 24 
hrs 
48 
hrs 
72 
hrs 
96 
hrs 
24 
hrs 
48 
hrs 
72 
hrs 
96 
hrs 
24 
hrs 
48 
hrs 
72 
hrs 
96 
hrs 
Control 40 
± 
18.53 
35.53 
± 
15.65 
39.2 
± 
13.86 
40.9 
± 
12.80 
11.33 
± 
5.28 
10 
± 
1.15 
9 
± 
1.42 
8.87 
± 
1.16 
48.83 
± 
23.25 
49.27 
± 
11.07 
45.93 
± 
19.87 
45.5
3 
± 
20.6
8 
10Gy 
Rad 
70.87 
± 
2.63 
62.3 
± 
1.51 
51.67 
± 
4.29 
40.53 
± 
0.76 
15.63 
± 
1.45 
14.03 
± 
2.20 
19.83 
± 
2.55 
24.17 
± 
1.05 
13.93 
± 
1.67 
23.9 
± 
2.52 
29.4 
± 
0.96 
34.9
7 
± 
1.7 
20Gy 
Rad 
60.93 
± 
3.93 
38.27 
± 
0.75 
33.1 
± 
0.34 
16.77 
± 
3.09 
15.13 
± 
3.8 
22.47 
± 
1.75 
12.67 
± 
1.58 
13.43 
± 
4.22 
25.2 
± 
0.17 
40.1 
± 
1.7 
52.97 
± 
1.31 
67.3
7 
± 
1.62 
Ad.p53 27.33 
± 
4.98 
36.93 
± 
1.59 
49.37 
± 
3.42 
55.8 
± 
2.17 
8.07 
± 
2.89 
10.06 
± 
1.26 
16.87 
± 
3.35 
6.16 
± 
2.39 
65.1 
± 
3.82 
53.63 
± 
1.66 
34.33 
± 
1.53 
36.2
7 
± 
3.42 
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Ad.p53 
+ 10Gy 
Rad 
27.2 
± 
1.61 
36 
± 
1.08 
48.83 
± 
3.27 
59.47 
± 
2.35 
6.07 
± 
0.15 
9.47 
± 
1.94 
14.1 
± 
2.36 
13.07 
± 
2.15 
67.13 
± 
1.53 
53.33 
± 
3.19 
32.63 
± 
3.86 
27.1
7 
± 
1.46 
Ad.p53 
+ 20Gy 
Rad 
39.87 
± 
2.10 
56.1 
± 
1.67 
64.7 
± 
0.72 
74.27 
± 
2.33 
17.87 
± 
2.19 
9.7 
± 
1.21 
11.03 
± 
1.60 
10.77 
± 
1.27 
42.83 
± 
3.5 
34.83 
± 
0.91 
24.7 
± 
1.97 
15.2
7 
± 
3.09 
Ad.pR
B 19.9 
± 
3.74 
30.87 
± 
4.27 
37.33 
± 
2.2 
44.1 
± 
2.36 
11.33 
± 
3.76 
8.3 
± 
3.65 
7.43 
± 
0.59 
12.6 
± 
1.4 
69.03 
± 
1.80 
60.97 
± 
2.18 
55.37 
± 
1.96 
42.9
7 
± 
3.72 
Ad.pR
B + 
10Gy 
Rad 
23.23 
± 
1.93 
31.1 
± 
2.08 
38.77 
± 
4.58 
51.93 
± 
4.68 
8.13 
± 
2.0 
10.23 
± 
0.87 
6.97 
± 
1.47 
11.33 
± 
2.35 
68.9 
± 
1.83 
58.77 
± 
1.69 
54.4 
± 
3.27 
36.4 
± 
2.0 
Ad.pR
B + 
20Gy 
Rad 
26.7 
± 
2.08 
33.6 
± 
2.07 
47.57 
± 
2.42 
68.13 
± 
2.87 
11.4 
± 
5.38 
10.53 
± 
3.89 
13.87 
± 
0.64 
6.93 
± 
3.27 
61.63 
± 
2.83 
54.9 
± 
1.68 
38.53 
± 
2.61 
24.9
3 
± 
3.95 
Adp13
0 
45.43 
± 
3.30 
54.2 
± 
4.33 
58.47 
± 
3.05 
67.2 
± 
3.22 
21.8 
± 
2.26 
19.47 
± 
4.31 
20.9 
± 
3.96 
17.47 
± 
2.40 
32.9 
± 
3.99 
26.23 
± 
1.60 
20.47 
± 
0.67 
15.3 
± 
3.54 
Adp13
0 + 
10Gy 
Rad 
59.73 
± 
1.65 
52.57 
± 
3.13 
43.87 
± 
0.93 
27.73 
± 
7.70 
20.47 
± 
1.50 
19.2 
± 
1.35 
13.23 
± 
3.21 
15.17 
± 
7.41 
19.27 
± 
1.65 
27.8 
± 
2.41 
42.23 
± 
1.70 
56.7 
± 
1.15 
Adp13
0 + 
20Gy 
Rad 
57.9 
± 
1.35 
52.47 
± 
3.86 
34.27 
± 
2.96 
18.73 
± 
4.46 
18.8 
± 
0.82 
14.53 
± 
2.07 
15.33 
± 
1.72 
10.07 
± 
4.79 
24.5 
± 
0.79 
33.33 
± 
5.76 
51.57 
± 
1.53 
70.5 
± 
1.06 
*Ad-adenovirus, *Rad- radiation, *SD- standard deviation 
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Figure 31. The accumulation/reduction of cells in G1- and G2-phase of cell cycle from a 
population of DU145 cells that received adenoviral p53 (panels a and b), RB (panels c and d) 
or p130 (panels e and f) with or without radiation treatments. The days after radiation are 
indicated on the ordinate. The percentage of cells in G1/G2 phase of cell cycle are indicated on 
the abscissa. A best-fit line was drawn on data points collected over four days. 
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External Beam Radiation Followed by Adenoviral p53, pRb, p130 Transduction Increased 
the Apoptotic Rate of DU145 Cells In Vitro 
Apoptotic cell death of Ad.p53, Ad.RB, or Ad.p130 transduced and irradiated DU145 
cells was detected using a fluorescent-labeled Annexin-V antibody (Annexin-V-FITC) in 
combination with propidium iodide (PI) by flow cytometry 24-96 hours after irradiation. We 
observed that the apoptotic rate of DU145 cells transduced with control CMV non-coding 
adenovirus (Ad.CMV) was comparable to the untreated control DU145 cells regardless of time 
point (Fig. 32 & 33). Compared to the control, there was a significant (p<0.05) increase in cell 
death for all treatments (Fig. 32 & Table 5). As radiation was increased from 10Gy 
(14.23%±0.87) to 20Gy (24.67%±2.28) there was a ~10% increase in cell death at 96 hours. A 
trend of increased cell death was also observed in all treated groups as time progressed (Fig. 33). 
The highest percentage of cell death was observed at 96hrs following radiation for all treated 
groups.  
The percentage of cell death increased when adenoviral transduction of p53, RB or p130 
was combined with x-ray irradiation in comparison to the control or to adenoviral transduced 
groups regardless of the time point (Fig. 32 & 33). Compared to the 10 Gy irradiated cells there 
was a significant (p<0.01) increase in cell death for p53 overexpressing cells (Fig. 32 & Table 5).  
Compared to the 10 and 20 Gy irradiated cells there was a significant (p<0.01) increase in cell 
death for pRb overexpressing cells (Fig. 32 & Table 5). The highest percentage (41.17%±1.46) 
of cell death was observed at 96 hours for Ad.RB transduced DU145 cells in combination with x-
ray irradiation (Fig. 32).  
 
 
125 
 
 
 
 
 
Figure 32. Bar graph representation of apoptosis assay with Annexin-V and Propidium Iodide 
staining of adenoviral infected tumor suppressor genes (p53, RB and p130) ± external beam 
radiation at 96hrs analyzed on Accuri C6 flow cytometer. The percentages of dead cells are 
indicated on the ordinate. The control and treatment groups are indicated on the abscissa. * 
indicates statistical significance between control and 10-20 Gy irradiated cells. ** indicates 
statistical significance between irradiated cells and cells that received combination of adenoviral 
gene transfer and external beam radiation. 
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Table 5. Multiple comparison ANOVA (Analysis of Variance) significance table with a 
Dunnett’s T3 test for Annexin-V assay experiment of DU145 cells following radiation and 
adenoviral gene transfer for 96hrs time point. The statistical analysis was run using IBM SPSS 
software.  
 (I) groups (J) groups Mean 
Difference (I-
J) 
Std. Error Sig. 
DU145 CMV -.43 .50 1.0 
Rad 10gy -11.73* .60 .00 
Rad 20gy -22.17* 1.36 .02 
Adp53 -15.00* 1.02 .02 
Adp53+ 10gy -24.60* .96 .00 
Adp53+ 20gy -33.90* 1.92 .02 
AdpRB -18.13* 1.12 .02 
AdpRB+ 10gy -25.93* .54 .00 
AdpRB+ 20gy -38.67* .90 .00 
Adp130 -9.43* .94 .04 
Adp130+ 10gy -14.13* .98 .02 
Adp130+ 20gy -25.67* .87 .00 
 CMV Rad 10gy -11.30* .63 .00 
Rad 20gy -21.73* 1.37 .02 
Ad.p53 -14.57* 1.04 .02 
Ad.p53+ 10gy -24.17* .98 .00 
Ad.p53+ 20gy -33.47* 1.93 .02 
Ad.pRB -17.70* 1.14 .01 
Ad.pRB+ 10gy -25.50* .58 .00 
Ad.pRB+ 20gy -38.23* .92 .00 
Ad.p130 -9.00* .96 .04 
Ad.p130+ 10gy -13.70* 1.0 .02 
Ad.p130+ 20gy -25.23* .90 .00 
 Rad 10Gy Rad 20gy -10.43 1.41 .08 
Ad.p53 -3.27 1.09 .49 
Ad.p53+ 10gy -12.87* 1.03 .01 
Ad.p53+ 20gy -22.17* 1.96 .04 
Ad.pRB -6.40 1.19 .15 
Ad.pRB+ 10gy -14.20* .67 .00 
Ad.pRB+ 20gy -26.93* .98 .00 
Ad.p130 2.30 1.02 .74 
Ad.p130+ 10gy -2.40 1.05 .73 
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Ad.p130+ 20gy -13.93* .95 .01 
 Rad 20Gy Ad.p53 7.17 1.63 .19 
Ad.p53+ 10gy -2.43 1.60 .96 
Ad.p53+ 20gy -11.73 2.31 .13 
Ad.pRB 4.03 1.70 .69 
Ad.pRB+ 10gy -3.77 1.39 .60 
Ad.pRB+ 20gy -16.50* 1.56 .02 
Ad.p130 12.73* 1.59 .03 
Ad.p130+ 10gy 8.03 1.61 .14 
Ad.p130+ 20gy -3.50 1.55 .74 
 Ad.p53 Ad.p53+ 10gy -9.60* 1.32 .03 
Ad.p53+ 20gy -18.90* 2.12 .04 
Ad.pRB -3.13 1.44 .77 
Ad.pRB+ 10gy -10.93* 1.06 .03 
Ad.pRB+ 20gy -23.67* 1.28 .00 
Ad.p130 5.57 1.31 .20 
Ad.p130+ 10gy .87 1.33 1.0 
Ad.p130+ 20gy -10.67* 1.26 .02 
 Ad.p53+10Gy Ad.p53+ 20gy -9.30 2.10 .23 
Ad.pRB 6.47 1.40 .16 
Ad.pRB+ 10gy -1.33 1.00 .98 
Ad.pRB+ 20gy -14.07* 1.23 .01 
Ad.p130 15.17* 1.26 .01 
Ad.p130+ 10gy 10.47* 1.28 .02 
Ad.p130+ 20gy -1.07 1.21 1.0 
 Ad.p53+20Gy Ad.pRB 15.77 2.18 .06 
Ad.pRB+ 10gy 7.97 1.94 .33 
Ad.pRB+ 20gy -4.77 2.07 .72 
Ad.p130 24.47* 2.09 .02 
Ad.p130+ 10gy 19.77* 2.11 .03 
Ad.p130+ 20gy 8.23 2.06 .30 
 Ad.pRB Ad.pRB+ 10gy -7.80 1.16 .1 
Ad.pRB+ 20gy -20.53* 1.37 .00 
Ad.p130 8.7 1.39 .06 
Ad.p130+ 10gy 4.0 1.42 .52 
Ad.p130+ 20gy -7.53 1.35 .09 
 Ad.pRB+10Gy Ad.pRB+ 20gy -12.73* .95 .01 
Ad.p130 16.5* .99 .01 
Ad.p130+ 10gy 11.80* 1.02 .02 
Ad.p130+ 20gy .27 .92 1.0 
 Ad.pRB+20Gy Ad.p130 29.23* 1.22 .00 
Ad.p130+ 10gy 24.53* 1.25 .00 
Ad.p130+ 20gy 13.0* 1.17 .01 
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 Ad.p130 Ad.p130+ 10gy -4.70 1.28 .29 
Ad.p130+ 20gy -16.23* 1.20 .00 
 Ad.p130+10Gy Ad.p130+ 20gy -11.53* 1.23 .01 
 
Microbubble Assisted Adenoviral p53, pRb, and p130 Gene Transfer in Combination with 
External Beam Radiation Enhanced Therapy of Radio-resistant DU145 Tumor Xenografts. 
We have been focusing on developing a safe and effective means of gene delivery in vivo 
to realize the therapeutic potential of the synergistic effects of tumor suppressor gene expression 
and ionizing radiation to combat human malignancy, specifically prostate carcinoma. To follow 
up on our previous studies on the use of microbubble assisted adenoviral gene transfer in radio-
resistant prostate cancer [53], we decided to compare the effects of microbubble assisted 
adenoviral p53, RB, and p130 gene delivery combined with radiation therapy on xenografted 
DU145 tumors in nude mice. 
We have employed here a novel systemic delivery approach to target adenovirus (Ad) 
release in a site-specific manner that consists of Ad incorporated in MBs combined with 
diagnostic US [53, 214]. Proof-of-principle for this strategy comes from studies using Ad to 
systemically deliver the GFP gene or a target gene (Mda-7/IL-24) in a tissue specific manner [53, 
214]. 
 For these current studies, we used DU145 human prostate carcinoma cells. The 
therapeutic arm included three different non-replicating adenoviral constructs to deliver p53, RB, 
and p130 that have been previously shown to increase radiation therapy response or to reduce 
tumor growth in various tumor types [254, 258, 266, 267]. The control arms of the study 
included Adenovirus expressing the green fluorescent protein (GFP) and the firefly luciferase 
gene (LUC). To test the specificity of intravenous injection of Ads complexed MBs for gene 
delivery in vivo we used the reporter firefly luciferase gene (LUC). We showed exclusive 
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bioluminescence in the sonoporated tumor at 24hrs from MB-assisted gene delivery using whole 
animal bioluminescence imaging (BLI) (Fig. 34), which was not extended to other districts of the 
animal even after one week from LUC gene delivery.  
Figure 34. Detection of MB-assisted Firefly Luciferase gene transfer through whole animal 
imaging. Panel a) is the ultrasound image of a tumor xenograft. Panel b) is the image from a 
mouse sonoporated on the tumor xenografted in the left flank showing specific luciferase 
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luminescent signal at 24 hours from the treatment. Panel c) is the image from the same mouse as 
in panel b showing specific luminescent signal at 1 week from the treatment. 
 
To test this new therapeutic approach for targeted tumor delivery of p53, pRb and p130, 
prostate tumor xenografts were established on both flanks of nude mice by injecting 4 x 106 
DU145 cells in the subcutaneous region of each flank of the animals. DU145 tumor bearing nude 
mice (n=5 each group) were then injected in their tail veins with 100 µL of US contrast agent 
that was reconstituted with PBS or Ad.GFP as controls. Additional DU145 tumor control nude 
mice (n=5 each group) were injected intratumorally (IT) with 100 µL of unprotected Ad.p53, 
Ad.RB or Ad.p130. In the treatment arm tumor-bearing animals were injected in their tail vein 
with 100 µL of US contrast agent (Targeson, San Diego, CA) that was reconstituted with 
Ad.p53, Ad.RB or Ad.p130. Tumors implanted on the right-side, were sonoporated as previously 
reported [53]. The treatment schedule is described in figure 4. In this study, gene transfer 
treatments were started twelve weeks after the injection of the cell lines, when tumors reached an 
approximate volume of 200-250 mm3. Mice were irradiated with 8Gy of x-ray irradiation from a 
clinical linear particle accelerator (LINAC) on week 12. Three days after radiation therapy, mice 
were injected once a week for four weeks (wks 13-16) and were again irradiated at week 16 (Fig. 
35). Mice were then injected once a week for three additional weeks (wks 17-19) and were 
sacrificed one week after the end of the treatments because the control tumors reached an 
approximate volume of 1,000 mm3 (Fig. 35). Compared to untreated or to irradiated control, 
tumors transduced with MB-assisted gene transfer using adenoviruses overexpressing p53, pRb, 
and p130 in combination with radiation treatments showed marked reduction of tumor size 
which was statistically significant (p<0.05) (Fig. 36). Tumors treated with ultrasound MB-
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assisted gene transfer of p53, RB, and p130 were smaller in size (Fig. 36) with an inhibition rate 
of 91.24%, 92.27%, and 48.31% respectively, when compared to the final tumor volume of 
control tumors (Table 6). Irradiated tumors were smaller in size than control tumors (Fig. 36) 
with an inhibition rate of 21.98% (Table 6). B-mode US scanned images showed in figure 38 
demonstrate tumor reduction in real time (Fig. 38) as the US images were recorded during the 
course of the treatment. US scanned images for groups that were transduced with p53 or RB 
showed a marked reduction in tumor growth, whereas tumors transduced with p130 exhibited a 
plateaued growth (Fig. 38).  
Compared to untreated or to irradiated control, intratumoral injections (IT) of Ad.p53 or 
Ad.RB significantly reduced tumor size (p<0.05) with an inhibition rate of 81.29% and 85.99%, 
respectively (Fig. 36 and Tables 6 and 7). Compared to radiation only groups, tumor treatment 
with Ad.p53 (p=0.015) and Ad.pRB (p=0.014) significantly decreased tumor growth (Table 7). 
The effect was further significantly enhanced (p<0.05) when gene transfer with Ad.p53 or Ad.RB 
was combined with radiation showing a growth inhibition rate of 88.04% and 87.82% compared 
to radiation control, respectively (Table 6 and 7). We also observed that when IT treatment of 
Ad.p53 or Ad.RB was combined with radiation there was reduction in tumor growth (Fig. 36) 
compared to gene transfer groups alone, although the difference was not statistically significant 
(Table 7). Interestingly, the IT injection with Ad.p130 slowed the growth of the tumors with an 
inhibition rate of 52.70%. However, IT injection of Ad.p130 combined with x-ray irradiation 
improved its efficacy by only about 4% (Table 6).  
The intravenous injection (IV) of MB complexed with Ad.p53 or Ad.RB did not result in 
inhibition of tumor growth when no ultrasound was applied (Fig. 37). Only tumors on the flank 
that received ultrasound (right flank) exhibited tumor growth reduction (Fig. 36 and 37). Tumors 
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on the sonoporated flank (right side) that were transduced with Ad.p53 or Ad.RB (but not 
irradiated) showed a growth inhibition rate of 91.24% and 92.27%, respectively. Tumors treated 
with ultrasound MB-assisted gene transfer of Ad.p53 showed better (but not significant) growth 
inhibition than IT Ad.p53 (p=0.363) or combined x-ray irradiation with IT Ad.p53 (p=0.65). 
This trend was also observed in tumors treated with ultrasound MB-assisted gene transfer of 
Ad.RB versus IT injections of Ad.RB (p=0.630) or combined x-ray irradiation with IT Ad.RB 
(p=0.283) (Table 7). Tumors treated with x-ray irradiation combined with microbubble assisted 
gene transfer of Ad.p130 resulted in 66.0% tumor reduction respect to the radiation control.  
Notably, the greatest tumor reduction was observed in tumors that were treated with x-ray 
irradiation combined with microbubble assisted gene transfer of Ad.p53 or Ad.RB with an 
inhibition rate of 94.44% and 95.95%, respectively (Table 6) (p<0.05).  
 
Table 6. Mean percentage inhibition rate and standard deviation of final tumor volume at week 
19 compared against the control non-treated group.  
Groups Inhibition Rate (%) SD 
Radiation (Control) 21.98 2.92 
IT Ad.p53 81.29 5.71 
IT Ad. p53 + Rad 88.05 2.76 
IT Ad.pRB 85.99 3.13 
IT Ad.pRB + Rad 87.82 0.79 
IT Ad.p130 52.70 4.86 
IT Ad.p130 + Rad 56.12 10.19 
IV MB Ad.p53 US 91.24 0.22 
IV MB Ad.p53 US + Rad 94.44 1.26 
IV MB Ad.pRB US  92.27 2.39 
IV MB Ad.pRB US + Rad 95.95 1.18 
IV MB Ad.p130 US 48.31 2.47 
IV MB Ad.p130 US + Rad 66.02 7.27 
   *SD-standard deviation *Rad-Radiation *% -Percentage 
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Figure 35. In vivo study timeline. Treatments are marked on the line from week 12 to week 19 
(end of the study). Radiation followed by four gene transfer treatments is considered as a cycle. 
In the in vivo study there were two treatment cycles. 
 
Figure 36. Bar graph of DU145 tumor xenografts volumes (± SD) at week 19 after direct 
intratumoral injection (IT) of Ad-GFP, Ad.p53,Ad.pRB, or Ad.p130 with and without radiation. 
Mean tumor volume for intravenous (IV) injections of MBs complexed with Ad.p53, Ad.RB or 
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Ad.p130 of sonoporated tumors (right flank) with or without external beam x-ray radiation was 
also plotted. The mean tumor volumes are indicated on the ordinate. The group is indicated on 
the abscissa. The IT and IV treatments were compared against the non-treated control and 
radiation control to determine the most effective treatment. * indicates statistical significance 
between control and treated cells. 
 
Figure 37. Bar graph representation of mean tumor volume for all groups (left and right flank 
mean tumor volume) with standard deviation error bars. The tumor on the left flanks served as 
internal controls to monitor any additional effect by the adenoviruses or MBs complexed with 
viruses on distant untreated tumors. Only tumors on the right flanks were treated with adenoviral 
vectors or UTMD of Ads/MBs regarding the sonoporated groups. On the ordinate the mean 
tumor volumes are indicated. On the abscissa are indicated the different treatment groups. 
 
136 
Table 7. Multiple comparisons ANOVA (Analysis of Variance) significance table with a post 
hoc Dunnett’s T3 test for the in vivo experiment following radiation and adenoviral gene transfer 
on the treated right tumors at week 19. The statistical analysis was run using IBM SPSS 
software. Mean and standard deviation of final tumor volume obtained at week 19. 
(I) Group (J) Group Mean 
Difference  
(I-J) 
Std. Error Sig. 
Control Rad Control 242.11 70.51 .38 
IT Ad.p53 894.55* 64.95 .02 
IT Ad.p53 + Rad 966.22* 60.59 .02 
IT Ad.pRB 941.38* 64.50 .01 
IT Ad.pRB + Rad 962.28* 60.03 .03 
IT Ad.p130 578.16* 70.36 .04 
IT Ad.p130 + Rad 621.91* 70.97 .03 
IV MB US Ad.p53 999.64* 59.77 .03 
IV MB US Ad.p53 +Rad 1035.58* 59.64 .02 
IV MB US Ad.pRB 1012.58* 60.33 .02 
IV MB US Ad.pRB +Rad 1052.10* 59.72 .02 
IV MB US Ad.p130 530.80 62.32 .07 
IV MB US Ad.p130 +Rad 727.83* 65.38 .03 
Rad Control IT Ad.p53 652.44* 46.05 .01 
IT Ad.p53 + Rad 724.11* 39.66 .01 
IT Ad.pRB 699.28* 45.41 .00 
IT Ad.pRB + Rad 720.18* 38.80 .02 
IT Ad.p130 336.05 53.40 .06 
IT Ad.p130 + Rad 379.80* 54.20 .04 
IV MB US Ad.p53 757.53* 38.40 .02 
IV MB US Ad.p53 + Rad 793.47* 38.18 .02 
IV MB US Ad.pRB 770.48* 39.27 .01 
IV MB US Ad.pRB + Rad 809.99* 38.32 .01 
IV MB US Ad.p130 288.70 42.26 .08 
IV MB US Ad.p130 + 
Rad 485.73
* 46.65 .01 
 IT Ad.p53 IT Ad.p53 + Rad 71.67 28.63 .67 
IT Ad.pRB 46.84 36.18 .99 
IT Ad.pRB + Rad 67.74 27.43 .69 
IT Ad.p130 -316.39 45.81 .06 
IT Ad.p130 + Rad -272.64 46.74 .1 
IV MB US Ad.p53 105.09 26.85 .36 
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IV MB US Ad.p53 + Rad 141.03 26.55 .22 
IV MB US Ad.pRB 118.04 28.08 .29 
IV MB US Ad.pRB + Rad 157.55 26.74 .18 
IV MB US Ad.p130 -363.75* 32.13 .01 
IV MB US Ad.p130 + 
Rad -166.71 37.72 .18 
 IT Ad.p53 + Rad IT Ad.pRB -24.83 27.59 1.0 
IT Ad.pRB + Rad -3.93 14.30 1.0 
IT Ad.p130 -388.06 39.37 .05 
IT Ad.p130 + Rad -344.31 40.46 .07 
IV MB US Ad.p53 33.42 13.16 .66 
IV MB US Ad.p53 + Rad 69.36 12.52 .16 
IV MB US Ad.pRB 46.37 15.52 .49 
IV MB US Ad.pRB + Rad 85.88 12.93 .09 
IV MB US Ad.p130 -435.41* 22.01 .00 
IV MB US Ad.p130 + 
Rad -238.38 29.58 .06 
 IT Ad.pRB IT Ad.pRB + Rad 20.90 26.34 1.0 
IT Ad.p130 -363.22* 45.16 .04 
IT Ad.p130 + Rad -319.48 46.11 .06 
IV MB US Ad.p53 58.26 25.74 .75 
IV MB US Ad.p53 + Rad 94.20 25.42 .40 
IV MB US Ad.pRB 71.20 27.02 .63 
IV MB US Ad.pRB + Rad 110.72 25.63 .31 
IV MB US Ad.p130 -410.58* 31.21 .01 
IV MB US Ad.p130 + 
Rad -213.55 36.94 .08 
 IT Ad.pRB + Rad IT Ad.p130 -384.13 38.51 .06 
IT Ad.p130 + Rad -340.38 39.62 .08 
IV MB US Ad.p53 37.36 10.30 .33 
IV MB US Ad.p53 + Rad 73.30 9.47 .05 
IV MB US Ad.pRB 50.30 13.18 .28 
IV MB US Ad.pRB + Rad 89.82* 10.01 .02 
IV MB US Ad.p130 -431.48* 20.43 .01 
IV MB US Ad.p130 + 
Rad -234.45 28.42 .08 
 IT Ad.p130 IT Ad.p130 + Rad 43.75 54.0 1.0 
IV MB US Ad.p53 421.48 38.10 .05 
IV MB US Ad.p53 + Rad 457.42* 37.89 .05 
IV MB US Ad.pRB 434.42* 38.98 .04 
IV MB US Ad.pRB + Rad 473.94* 38.03 .04 
IV MB US Ad.p130 -47.36 41.99 1.0 
IV MB US Ad.p130 + 
Rad 149.68 46.41 .43 
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 IT Ad.p130 + Rad IV MB US Ad.p53 377.73 39.22 .07 
IV MB US Ad.p53 + Rad 413.67 39.01 .06 
IV MB US Ad.pRB 390.68 40.07 .06 
IV MB US Ad.pRB + Rad 430.19 39.15 .06 
IV MB US Ad.p130 -91.11 43.01 .80 
IV MB US Ad.p130 + 
Rad 105.93 47.33 .76 
 IV MB US Ad.p53 IV MB US Ad.p53 + Rad 35.94 7.64 .17 
IV MB US Ad.pRB 12.94 11.93 1.0 
IV MB US Ad.pRB + Rad 52.46 8.29 .06 
IV MB US Ad.p130 -468.84* 19.65 .01 
IV MB US Ad.p130 + 
Rad 
-271.81 27.86 .06 
 IV MB US Ad.p53 + 
Rad 
IV MB US Ad.pRB -23.0 11.22 .82 
IV MB US Ad.pRB + Rad 16.52 7.24 .75 
IV MB US Ad.p130 -504.78* 19.23 .01 
IV MB US Ad.p130 + 
Rad 
-307.75 27.57 .05 
 IV MB US Ad.pRB 
  
IV MB US Ad.pRB + Rad 39.52 11.68 .41 
IV MB US Ad.p130 -481.78* 21.30 .00 
IV MB US Ad.p130 + 
Rad 
-284.75* 29.05 .04 
 IV MB US Ad.pRB + 
Rad 
IV MB US Ad.p130 -521.30* 19.50 .01 
IV MB US Ad.p130 + 
Rad -324.27
* 27.76 .04 
 IV MB US p130  IV MB US Ad.p130 + 
Rad 197.03 32.98 .09 
*IT – Intratumoral, *IV-Intravenous, *MB-Microbubble, *US-Ultrasound, *Ad-Adenovirus, 
*Rad-Radiation.  
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Microbubble-Assisted p53, pRB, and p130 Gene Transfer Results in Enhanced Protein 
Expression of Targeted Genes. 
Protein expression of p53-, RB-, and p130-transduced genes in tumors that received US 
and x-ray irradiation was analyzed by western blots (Fig. 39). There was no change in expression 
of mutated p53 and pRb in all control tumors with either radiation or ultrasound (Fig. 39a). Only 
endogenous expression of p130 was increased when the tumors were irradiated (Fig. 39 a, d). 
Tumors that received direct intratumoral injection with Ad.p53, Ad.RB, or Ad.p130 showed 
increased expression of the targeted tumor suppressor genes (Fig. 39a-d). Intravenous injection 
of complexed MBs showed high expression of transduced p53, RB and p130 in tumors that were 
sonoporated (Fig. 39a-d). 
 
Figure 39. Western Blot analysis of the tumors collected at week 19 from in vivo study. L and R 
indicate tumors implanted in the left and right flank, respectively. (Panel a) Control (not treated) 
DU145 tumors and treated DU145 tumors, as labeled. PBS+MB = empty MBs; Rad = 8Gy 
radiation; US = Ultrasound. (Panel b) Tumors untreated and treated with Ad.p53 
141 
(Ad.p53+MBs), radiation and ultrasound, as labeled. (Panel c) Tumors untreated and treated 
with Ad.pRB (Ad.pRB+MBs), radiation and ultrasound, as labeled (Panel d). Tumors untreated 
and treated with Ad.p130 (Ad.p130+MBs), radiation and ultrasound, as labeled. Anti-beta-actin 
was used as a loading control. 50μg of total cell lysates were run on SDS polyacrylamide gels. 
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DISCUSSION 
Primary prostate cancer (PC) can be tackled successfully in many cases with standard 
treatments, such as radical prostatectomy, radiation therapy, and hormone therapy, offering long-
term cancer-specific survival for most patients. While surgery and radiation therapy may have 
similar outcomes for early-stage prostate cancer, radiation therapy is the primary option for 
locally advanced prostate cancer. However, over one third of patients who are treated with 
conventional curative therapy will progress to an androgen-independent (castration-resistant) 
prostate cancer. Development of androgen-independent, radio-resistant prostate cancer and 
metastatic progression are key concerns in the management of this disease [268, 269]. The 
strategies used to tackle these issues are the accurate stratification of patients whose early 
prostate cancer is likely to progress to hormone-refractory and metastatic disease, and of course 
improvement and broadening of the available therapeutic choices. Prostate cancer is regarded as 
relatively resistant to radiation [257]. Consistent with this notion, androgen-independent DU145 
human prostate cancer cells manifest resistance to radiation-induced apoptotic death [254, 255]. 
Previous studies using UV- [254] and γ-radiation [270] have been shown to cause a 
G2/M cell cycle-phase block in DU145 cells at 24hrs. In our study, ionizing radiation of 10Gy 
and 20Gy also resulted in G2/M cell cycle-phase block with an increasing number of DU145 
cells accumulated in the G2-phase of the cell cycle when assayed from 24 to 96hrs.  
Interestingly, we observed little apoptotic cell death in the DU145 cells at 24hrs for both 10Gy 
and 20Gy external beam radiation which could be explained by the fact that DU145 cells 
undergo DNA fragmentation as early as 4hrs after irradiation while end-stage DNA 
fragmentation does not peak until 24-36hrs [249]. Additionally, Bromfield et al. demonstrated 
with flow cytometry assays that greater than 70% of DU145 cells were non-proliferating 
following irradiation [251], which provided us with a rationale for investigating modalities to 
143 
increase the sensitivity of prostate cancer to radiation-induced DNA damage using gene transfer 
of key cell-cycle regulators. 
The p53, RB and p130 gene products are key factors that participate in cell-cycle arrest, 
apoptosis and cellular senescence. PCs manifest frequent mutations in tumor suppressor genes 
such as p53 and RB [271], and we have demonstrated in the past an inverse association between 
histological grading in aggressive tumor types of prostate cancer [272] and p130 expression.  
Additionally, p130 has been mapped to the human chromosome 16q12.2, an area in which 
deletions have been found in several human neoplasias including breast, ovarian, hepatic, and 
prostatic cancers [273].   
Our model system, DU145 cells, a human prostate cancer cell line, has a mutant 
nonfunctional temperature sensitive p53, and expresses a truncated pRb protein [254]; however 
the functional status of p130 is undetermined in DU145 prostate cancer cells. P53 and pRb 
overexpression have been shown to play a central role following radiation in PC cell lines [274] 
[256] while RB loss has been linked to radiation resistance in DU145 cells [256].   
We decided to compare and contrast the ability of p53, RB and p130 to radio-sensitize 
prostate cancer cells in vitro and to investigate their efficacy in reducing tumor size following 
targeted gene transfer using a microbubble-assisted gene transfer method that we have perfected 
in our laboratory [53, 214, 218]. This strategy allows for systemic targeted delivery to prostate 
cancer xenografts of therapeutic adenovirus carrying therapeutic genes. 
As expected, DU145 cells transduced with adenovirus carrying wt-p53 showed a shift 
from the G2/M to the G1-phase of the cell cycle regardless of the radiation dose, as previously 
demonstrated [255]. Apoptosis was observed for p53 groups treated with or without radiation. 
Overexpression of p53 in DU145 cells restored irradiation-induced senescence by forming the 
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characteristic heterochromatin structure called senescence-associated heterochromatic foci 
(SAHFs) [275]. SAHFs could account for the relatively low amount of apoptosis at 24 hrs. The 
downstream effectors such as Bax [251] or p21Waf1 that are attenuated/absent in DU145 [276] 
would hamper the cells from undergoing apoptosis. Additionally, the mutant p53 described in the 
DU145 cells has been shown to suppress the ability of wt-p53 to induce cell cycle arrest by 
exerting a dominant negative effect on the DNA binding activity of wt-53 and to reduce the 
trans-activation of target genes [277]. Even by lowering the temperature to 32ᴼC from 37ᴼC and 
activating the temperature sensitive nonfunctional p53 in DU145 cells, Bajgelman and Stauss 
were unable to trans-activate p21Waf1 [252]. However, we observed that adenoviral 
overexpression of wt-p53 restored the sensitivity of the DU145 cells to ionizing radiation 
indicating that gene transfer of wild-type copies of the p53 gene and its overexpression in the 
targeted cells could be a viable therapeutic option for radio-resistant PCs. 
Proteins of the retinoblastoma family (pRb, p107 and p130) are known to exert control 
over the entry into S-phase of the cell cycle [278]. Gamma (γ) and ultraviolet (UV) radiation are 
known to be ineffective on pRb deficient cells. After DNA damage by γ-radiation, pRb is 
hypophosphorylated and induces growth arrest by blocking cell-cycle progression at the G1/S 
phase [279]. G1-phase blockage has been previously observed when cells were transduced with 
pRb in the presence or absence of radiation [254]. Some reports indicate that apoptosis of cells 
which are deficient in pRb protein is inhibited after restoring wt-pRb [280]. In our study, we 
observed that by restoring a wild-type RB in DU145 cells, which have a truncated pRb, we were 
able to facilitate apoptosis similarly to when we restored wt-p53. The highest apoptotic response 
was observed in pRb transduced DU145 cells which received 20Gy irradiation. Interestingly, our 
study showed increased expression of pRb protein when Adenoviral gene transfer treatment was 
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combined with radiation therapy. Similar results have been shown for pRb negative and positive 
esophageal squamous cell carcinoma (ESCC) treated with a combination of adenoviral gene 
delivery of RB94, a truncated more active RB gene product, and radiation therapy [267]. 
Hypophosporylated p130 complexes with E2F transcription factors and has been 
associated with control over the G0/G1 phase of the cell cycle [278]. In our study we observed 
that overexpressed p130 in prostatic DU145 cells led to DNA accumulation at G0/G1 of the cell 
cycle. Interestingly, irradiated or combined irradiated and Ad.p130 gene transfer groups showed 
accumulation of cells in the G2 cell cycle phase suggesting a block at the G2/M transition. In 
several cell lines, the overexpression of p130 has been shown to result in binding to cyclins A 
and B promoter regions, regulating the expression of S- and G2-phase transitions, and 
dominating the p53-p21 DNA damage response pathway leading to senescence [281].   
Our in vitro study confirmed an increase in expression of endogenous or transduced p130 
after exposure to genotoxic stress such as radiation, as previously observed [275, 282].  
Adenoviral overexpression of p130 increased the percentage of apoptotic cells after ionizing 
radiation, but to a lower extent than in groups transduced with p53 or RB.   
It has been shown in the prostatic cancer cell lines C4-2 and LNCap, that ionizing 
radiation exposure results in up-regulation of the transcription factor E2F4 which has been 
shown to complex with p130 and to co-localize in the nucleus regardless of androgen sensitivity, 
resulting in tumor growth suppression and G2 arrest [282]. The authors demonstrated that the 
formation of the E2F4/p130 complex is specifically regulated by IR in prostate cancer cells and 
suggested that the interaction between p130 and its natural partner CDK2 is also affected by IR, 
which may be a result of the increased levels of E2F4 associated with p130, leading to a decrease 
in p130 phosphorylation and decreased cell viability. The inhibition of E2F4 by siRNA in 
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prostate C4-2 cells results in apoptosis and increased sensitivity to radiation [282], thus 
suggesting a partial explanation of the lack of apoptosis and radiation resistance of the DU145 
cells following overexpression of p130. Additionally, p130 induces accumulation of pro-
apoptotic p73, a p53-related gene that alternatively splices and mediates radiation-induced 
apoptosis independent of p53 by interacting with c-Abl tyrosine kinase in glioblastoma cells 
indicating that p130 radiosensitization could be cell type specific [258].   
Adenoviral gene transfer is limited by the ability of Adenovirus serotype 5 (Ad5) to 
transduce target cells and the inability to deliver it intravenously without causing liver 
inflammatory damage or elimination by the immune system [202]. Patients exposed to 
adenoviruses tend to develop neutralizing and anti-adenovirus antibodies [283, 284]. Another 
limitation of using Adenoviruses for gene transfer techniques in cancer is that the efficiency of 
these viruses to transfer genetic materials to cancer cells is dependent upon the availability of 
Coxsackie adenovirus receptor (CAR) on the surface of the targeted cells, which facilitates 
adenoviral entry. These difficulties in the use of Adenoviruses for cancer gene therapy have 
limited their use to direct injections to the tumoral mass, which resulted in partially transduced 
tumors [218, 285]. 
To circumvent the difficulties caused by the use of adenoviruses as vectors for gene 
transfer we used ultrasound contrast agents (microbubbles) to provide protection to the virus 
from the immune system as well as to increase target organ specificity, allowing intravenous 
injection and less aggressive viral administration [214]. Microbubbles (MBs) can be injected into 
peripheral veins, as these robust bubbles can re-circulate through the systemic circulation 
numerous times within the bloodstream [219]. Cavitation also improves the efficiency of viral 
infection by creating small shockwaves that increase cellular permeability [220]. Phase I to III 
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clinical trials have demonstrated that MBs are safe and well tolerated even at higher doses [286].  
 Previous studies of our lab demonstrated that MB complexes with Ad.GFP (Green 
Fluorescent Protein) were able to express GFP specifically localized to sonoporated tumors [53]. 
Our western blot studies on harvested tumors showed high levels of transgene expression at the 
tumor site by more efficient GFP gene transfer into the target cells [53]. 
In earlier studies, therapy resistant prostate cancer cell lines containing wt-p53, mutated 
p53 or p53 null were radio-sensitized by adenoviral mediated p53 gene transfer [274, 287]. As 
expected, in our in vitro study the DU145 cells transduced with p53 were radio-sensitized to 
ionizing radiation resulting in higher apoptotic rates than either irradiation group or adenoviral-
p53 transduced groups. Additionally, reduction of tumor volumes by ultrasound mediated 
microbubble destruction of wt-p53 or wt-pRb resulted in increased ablation of the tumors when 
compared to intra-tumoral injections. Ad.p130 intra-tumoral injection in mice showed slower 
growth rate than the untreated control or irradiated groups. Interestingly, Ultrasound targeted 
microbubble destruction (UTMD) of Ad.p130 MB complexes resulted in slower tumor growth, 
but no tumor reduction was observed (Fig. 36).   
 Clinical studies for combinational therapy of p53 and RB gene transfer and ionizing 
radiation in lung [266], hepatocellular [288], and esophageal carcinomas [267] have been 
successful in eliciting partial and complete remission of tumors. Our study demonstrated that 
combination therapy of radiation and intratumoral injections of Ad.p53, Ad.RB or Ad.p130 
caused an enhanced effect in comparison to adenoviral intratumoral injections (IT) or radiation 
treatment alone. Currently, phase-I clinical studies of combination therapy with IT adenoviral 
p53 gene delivery for prostate cancer are underway at M.D. Anderson Cancer Center, Texas and 
UCLA School of Medicine, California to test its efficacy [289]. Interestingly, we observed more 
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profound response in reducing tumor growth of treated tumors by combining the ultrasound-
targeted destruction of Ad.p53 or Ad.RB MB/complexes with ionizing radiation. As 
demonstrated by western blot analysis, tumor volume reduction in these samples was associated 
with overexpression of the p53 or RB genes (Fig. 39). UTMD of Ad.p130 combined with 
radiation resulted instead in a relatively plateaued tumor growth curve, which was comparable to 
the initial volume of tumors at the beginning of the treatment schedule. Thus p130, in a 
comparative gene transfer study with other known cell cycle regulating proteins such as pRb and 
p53, caused a “tumorstatic” effect that was not significantly enhanced by radiation therapy. On 
the other hand, we showed that the highest decrease in tumor growth was observed when p53 
and RB genes were transferred by ultrasound-targeted destruction of Adenoviral-MB/complexes 
in combination with ionizing radiation.  
 An open question is: What effect would the pooled transfer of the cell cycle regulating 
genes p53, pRb and p130 with or without ionizing radiation have on tumor growth? It is possible 
that combined gene transfer of multiple cell cycle regulatory proteins could result in further 
tumor growth suppression. In fact, tumors are made of a heterogeneous population of cells that 
may contain a variety of genetic dysfunctions and/or changes. Thus exploring the effects of 
pooled transfer of therapeutic genes is needed in order to increase their antitumoral activity while 
possibly decreasing the number of injections needed to realize their radiosensitizing ability. 
Altogether, these findings highlight the translational therapeutic potential of this novel image-
guided gene transfer technology in combination with external beam radiation for prostate cancer 
patients with therapy resistant disease.  
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CHAPTER VI : CONCLUSION AND FUTURE DIRECTIONS 
 In Chapter 1, we reviewed current literature on prostate cancer (PC) and highlighted 
some of the therapeutic options in treating PC. We also reviewed some of the potentials and 
barriers to gene therapy with viral vectors. We chose to study metastatic PC because there are no 
successful treatment modalities available for the disease while treatment options for stage T1/T2 
have decent 5 year survival rates.   
 In Chapter 2 we described the ultrasound targeted destruction of microbubbles as a gene 
delivery system. We reviewed current literature on the different types of available MBs that are 
currently used. We also described the behavior of the MBs when exposed to US and the 
biological changes that are associated with their interactions. Chapter 2 clearly shows that 
together MB and US become a reliable systemic drug delivery system.  
 In Chapter 3, we explored human DU145 and murine TRAMP-C2 PC cells as potential 
animal models for testing the UTMD drug delivery system. Infection studies were carried out to 
establish whether human non-replicative viruses (Ad.GFP and Ad.mda-7/IL-24) and replicative-
competent virus (CTV.mda-7) could be used to determine a therapeutic response in cancer cells. 
We clearly observed that Ad.GFP and Ad.mda-7/IL-24 could infect and transfer their transgene 
in both PC cells, although only CTV.mda-7 could be replicated in DU145 cells. UTMD gene 
delivery system was also tested in an in vitro setting showing an increased enhancement of 
Ad.GFP transgene expression. This clearly showed that US with MBs caused pore formation on 
the plasma membrane thereby increasing the permeability of the membrane to allow increased 
Ad uptake. Thus, animal studies on xenografted DU145 PC studies in immune-compromised 
nude mice and syngeneic model of TRAMP-C2 PC injected in immune-competent mice become 
attractive to test the UTMD gene delivery system. 
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 In Chapter 4, we described our studies of the UTMD gene delivery system for Ad.GFP, 
Ad.mda-7 and CTV.mda-7 in a xenograted DU145 PC model with tumors on both flanks of nude 
mice. Targeson MBs/Ads complexes were injected into the tail vein while only the tumor on the 
right flank was sonoporated. The study was designed to define an improved therapeutic approach 
for delivering Ad.mda-7, which will permit systemic delivery and targeted tumor release by US 
specifically and effectively in the primary tumor. This treatment resulted in a dramatic reduction 
in the size of not only the treated tumor on the right flank, but also of the non-treated tumor on 
the left flank due to mda-7 bystander effect [53]. US-guided focused release of entrapped 
materials from the MBs will increase the delivery specificity and therapeutic efficiency of 
Ad.mda-7 towards PC xenografts. Our findings in combination with the positive results of 
Phase-I Clinical trial with Ad.mda-7 [211] suggest that this cytokine has considerable potential 
as a gene therapy for cancer.  
 In Chapter 5, we described the combined therapy approach of using radiation and UTMD 
for the delivery of Ad.p53, Ad.RB and Ad.p130 in a xenografted DU145 PC model with tumors 
on both flanks of nude mice. Similar to the previous animal study, Targeson MBs/Ads 
complexes were injected into the tail vein while only the tumor on the right flank was 
sonoporated. We demonstrated that combined radiation and UTMD gene therapy enhanced the 
therapeutic benefit of tumor suppressor genes in radiation resistant PC. There was no bystander 
activity that was observed in this study as tumor suppressor genes such as p53, pRb and p130 are 
not secreted proteins. The increased expression of p53, Rb and p130 further proved that UTMD 
targets only the tumor that is sonoporated making it a specific gene delivery therapy system.   
 In addition to the experiments that were performed, we propose to further develop the 
UTMD system using immune-competent animals to facilitate its translation into a clinically 
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feasible technology for the effective delivery of therapeutic genes to treat human PC. Our data 
shows that murine TRAMP-C2 PC cells are efficiently infected by non-replicative Ad.GFP and 
Ad.mda-7/IL-24 using the MB/Adenoviral system cavitated by US, which results in the 
expression of the transduced genes. Additionally, mda-7/IL-24 acts as a pro-apoptotic gene 
resulting in the increased cell death of PC cells. Thus we believe that MBs will effectively shield 
the Ads from immune surveillance in immune-competent mice, and target the delivery of 
Ad.GFP & Ad.mda-7 specifically to PCs. These studies would further establish the efficiency 
and specificity of gene delivery in primary advanced prostate cancer by using an innovative 
system consisting of ultrasound contrast agents, viral vectors and ultrasound waves. 
  In conclusion, our present body of work supports the hypothesis that the UTMD systemic 
gene delivery system we have developed is a promising therapeutic approach for PC that 
deserves further investigation in immune competent organisms to warrant its future translation 
from bench to bedside.  
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